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ABSTRACT 
The development of low toxicity cationic liposome-based gene delivery systems with the 
design capacity for systemic application in vivo is gaining momentum. In this study, 
three untargeted and six ligand-directed cationic liposome-based non-viral delivery 
systems have been optimized for gene transfer in vitro. Thus three novel cationic 
cholesterol derivatives have been prepared and formulated into unilamellar liposomes 
with the helper lipid dioleoylphosphatidylethanolamine (DOPE). Their interaction with 
the luciferase expression plasmid pGL3 affords lipoplexes which have been 
characterized by three separate assays viz. band shift, serum nuclease digestion, 
ethidium displacement and by transmission electron microscopy. All derivatives feature 
a dihydrazide linker in the spacer separating the cationic head groups and the 
cholesteryl moieties. Toxicities and transfection activities were determined in vitro in 
four transformed cell lines. N, N-Dimethylaminopropylaminylsuccinylcholesteryl-
formylhydrazide (MS09), with a tertiary amino head group and a twelve atom 15 A 
spacer, afforded weakly cytotoxic lipoplexes at the optimal liposome:DNA +/-
transfection ratio (0.7) and exceeded LipofectinTM-mediated transgene activity in the 
three human transformed cell lines HeLa (cervix), HepG2 (hepatocyte) and SNO 
(oesophagus). Glycylcholesterylformylhydrazide (MS10) and p-alanylcholesteryl-
formylhydrazide (MS11 )-based lipoplexes also proved to be effective mediators of 
transfection but did not attain the levels reached by MS09, which was selected for 
incorporation into ligand-directed transfecting complexes. 
Consequently, MS09 was formulated into two separate liposome preparations 
containing DOPE and either biotinylcholesterylformylhydrazide (MSB1) or 
aminohexanoylbiotinylcholesterylformylhydrazide (MSB2). The biotinyl appendage was 
used to secure a streptavidin(bi03-transferrin) conjugate to the liposome while the 
cationic component (MS09) interacted with the pGL3 plasmid DNA. The resulting 
ternary complexes, which displayed good stability in 10% foetal bovine serum (FBS), 
achieved high transfection activity in HeLa cells which express the transferrin receptor. 
In the presence of free iron-loaded transferrin (400 I-Ig/ ml), activity was reduced by 60-
v 
70% to levels obtained by untargeted biotinylated lipoplexes therefore strongly 
supporting the notion that complexes entered the cells largely by transferrin receptor-
mediation. Moreover, the presence of 10% FCS in transfection mixtures was virtually 
without effect on transfection activity. 
Furthermore, four cholesteryl glycosides were prepared for inclusion into a cationic 
liposome-based system intended for gene targeting to the asialoglycoprotein receptor 
expressed in HepG2 cells. Hence cholesteryl-u-D-galactopyranoside (MSuGAL), 
cholesteryl-~-D-galactopyranoside (MS~GAL), cholesteryl-u-D-glucopyranoside 
(MSuGLU) and cholesteryl-~-D-glucopyranoside (MS~GLU) were separately formulated 
with MS09, DOPE and pGL3 plasmid DNA into lipoplexes. Competition assays with 
asialofetuin (600 1-191 ml), a cognate ligand for the asialoglycoprotein receptor, reduced 
transfection activity by >90% in all cases to levels of transfection achieved in HeLa cells, 
which are asialoglycoprotein receptor-negative. Although all four lipoplexes promoted 
high levels of luciferase gene expression, interestingly, the MS~GAL system achieved a 
four fold greater activity than its MSuGAL counterpart and an eight fold increase over 
the MSuGLU and MS~GLU lipoplexes. Not only does this demonstrate an anomeric 
preference by the asialoglycoprotein receptor for the MS~GAL lipoplexes but an 
epimeric preference is also apparent with respect to the C-4 position of the hexose, the 
position at which D-galactose and D-glucose differ. The transfection activity displayed 
by MS09 lipoplexes in the cell systems investigated in this study was high, but showed 
significant improvement by the addition of the targeting components discussed. High 
gene expression levels coupled to low toxicity in vitro render these novel liposome 
formulations promising candidates for possible future in vivo studies. 
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1.1. GENE THERAPY 
Malignant transformations leading to an unregulated growth of cells is almost always 
caused by genetic aberrations and often is associated with epigenetic events. Hence in 
the last few decades gene transfer has emerged as an important technique to shed 
some light on this potentially fatal process. Gene therapy was originally envisaged as a 
treatment for inherited monogenic disorders such as cystic fibrosis that could be treated 
by the restoration of the function of a single gene. In 1990 the first gene therapy trial for 
the treatment of adenosine deaminase (ADA) deficiency using retroviral vectors was 
undertaken (Blaese et a/., 1990). It has since been extended to include numerous 
diseases or disorders viz. arthritis (Kang et.a/., 1997; Jorgensen et a/., 2002), 
cardiovascular diseases (Yla-Herttuala and Martin, 2000), cancer, Parkinson's disease 
(Rubanyi, 2001) and the acquired immunodeficiency syndrome (AIDS) (Haynes, 1996; 
Weber, 1996). 
The concept of gene therapy appears simple, i.e. the delivery of a good copy gene or 
DNA that will ultimately correct the defects of a disease arising from a defective gene. 
However execution of this procedure is far from being simple. The Gene Therapy 
Advisory Committee of the United Kingdom defines gene therapy as "the deliberate 
introduction of genetic material into human somatic cells for therapeutic, prophylactic or 
diagnostic purposes". Gene transfer could entail the transfer of new genetic material or 
the manipulation of an existing gene. Gene therapy can also be used to destroy 
unwanted cells such as cancer cells. Genes can be introduced directly into the target 
cells in the body or the target cells can be modified outside the body ex vivo and then 
reimplanted. Major hurdles to successful gene therapy include delivery of the gene, 
vector design, gene regulation and avoidance of immune responses (Romano et a/., 
1998). Hence basic research is still required to answer these pressing issues. 
1 
Genetic material is usually delivered by specific vectors. One hurdle is that most 
existing vectors are far from being ideal. An ideal vector can be described as one that 
will transfer the gene of interest to a specific target cell, bringing about regulated and 
sustained expression of the gene product without being toxic to the cells. Most vectors 
can meet several of these requirements but not necessarily all (Hodgson, 1995). The 
choice of a vector will largely depend on the therapeutic needs of the target disease. 
Among the strategies utilized for introducing genes are viral and non-viral methods that 
possess unique characteristics. 
1.2 VIRAL GENE DELIVERY SYSTEMS 
Viral vectors have been successfully utilized for the delivery of genetic material as they 
contain all the features necessary for efficient gene transfer such as cell adhesion, 
membrane translocation, efficient transcription, and translation (Cristiano, 1998). 
Although viral methods seem to offer high efficiencies in gene delivery and stable 
integration of exogenous genes into host chromosomes in the case of retroviruses, they 
may possess long term risks such as possible recombination with endogenous viruses, 
insertional mutagenesis, immunogenecity and oncogenic effects (Joo and Kim, 2002). 
The recent report on the occurrence of leukemia in children treated with viral gene 
therapy (retroviral based system) against severe combined immunodeficiency (SCID), 
demonstrated the toxicity problems associated with viral gene therapy (Kaiser, 2003). 
Another limitation of viruses is their relatively small packaging capacity of therapeutic 
DNA (Luo and Saltzman, 2000). Viruses commonly used in gene therapy include 
retroviruses, adenoviruses, lentiviruses, poxviruses, Sendai virus (or haemagglutinating 
virus of Japan), vaccinia virus (W), and herpes viruses that carry the therapeutic 
gene in their capsid, thus protecting it from enzyme digestion. 
Retroviruses are RNA viruses that undergo reverse transcription after infecting the cell, 
hence producing double stranded DNA. Retroviral vectors are modified retroviruses in 
which the genes required for replication have been removed and replaced with a 
2 
therapeutic or marker gene. Once they have been "packaged" in a protein coat, they 
operate in their normal manner to infect a cell. They were the first viral system adapted 
for gene therapy. They infect only actively dividing cells, leaving quiescent cells 
unaffected (Miller ef al., 1990). This aids in the selection of neoplastic cells over normal 
cells. Retroviruses have a large cloning capacity of about 10 kb (Trono, 2000). The DNA 
integrates stably, but in a random fashion into the host genome. Hence using this 
method the DNA is permanently integrated into the host genome, thus raising long-term 
safety concerns including possible mutagenesis. Recently an oncoretroviral vector was 
utilized in gene transfer to keratinocytes which revealed the absolute need for 
proliferation in order to achieve efficient gene transfer. The virus itself is difficult to 
produce at high titres. These problems represent a clear limitation of retroviral systems 
(Serrano ef al., 2003). 
Adenoviruses are DNA viruses that infect the eukaryotic cell. They lose their protein 
coat and transfer DNA to the nucleus where it is transcribed . DNA is not integrated into 
the host genome. The average size of the genome is about 36 kb (Zhang Wei-Wei, 
1999) and the vector can accommodate large DNA inserts of approximately 7-8 kb. 
Adenoviral vectors are capable of infecting non-dividing cells and hence will not be able 
to discriminate between neoplastic and normal cells. There are more than 40 different 
human serotypes, which are classified into 6 subgroups (A-F) based on their properties. 
Serotype 2 (Ad2) and 5 (AdS) are the most studied adenoviruses in gene therapy. 
Concerns about the use of adenoviral vectors include pro-inflammatory properties, 
cytotoxic properties and possible immune responses to the vector capsid protein and 
transfected cells in some tissues (Amalfitano and Parks, 2002) and the lack of cell-
specific targeting. Adenoviral vectors have been used in delivery of tumour-suppressor 
genes, antisense oncogenes, suicide I toxin genes, and have shown anticancer 
immunity in different animal models (Addison ef al., 1995). They can be produced in 
high titre (about 1011 Iml). 
Herpesvirus vectors are usually derived from the strains of the Herpes Simplex virus 
type 1 (HSV-1). Herpes Simplex Virus (HSV), one of the human herpesviruses is a 
3 
natural pathogen causing recurrent oropharyngeal cold sores. They are double stranded 
DNA viruses that have the ability to remain latent in tissues and to be reactivated at the 
original site of infection. HSV-1 repl icates within the infected cells and causes cell lysis 
and infection of surrounding cells. They can incorporate large amounts of exogenous 
DNA and can be grown to high titres. Vectors based on the herpes virus seem to be 
attractive possibilities for CNS gene therapy (Parks and Bramson, 1999). The 
disadvantages of these viruses include cytotoxicity that was reported especially in vitro, 
limited duration of transgene expression, and marked inflammatory response in the 
host. 
Lentiviruses belong to the family of retroviruses. Lentiviral vectors ego The human 
immunodeficiency virus type 1 (HIV-1), can replicate in non-mitotic cells similar to the 
adenoviral vector (Trono, 2000). Recent studies have shown that recombinant vectors 
derived from HIV-1 lentivirus can transduce a variety of non-dividing human cells, 
including neurons, liver, muscle, and keratinocytes (Kuhn et al., 2002 ; Serrano et al., 
2003). Gene expression from a lentiviral vector has been shown to be stable for up to 
14 months (Amado and Chen, 1999). Lentiviral vectors have a total insert capacity of 
10 kb (Romano et al., 1998). They seem to be a popular choice for genetic modification 
of retinal cells. HIV vector-mediated gene therapy is often utilized in treatment of 
recessive forms of inherited retinal degeneration (Miyoshi et al., 1997). Despite this, 
lentiviral vectors seem to be very poor in delivering genes in vivo into liver and muscle 
(Trono, 2000). 
Poxviruses are large, enveloped viruses containing a double stranded DNA genome. 
They are predominantly engineered for gene therapy to stimulate the immune system. 
They have a large packaging capacity of up to 25 kb. These viruses have been used 
extensively in humans for vaccine research and clinical vaccine application (Paoletti, 
1996). Vaccinia virus vectors belong to the family of poxviruses. They have a long 
history in medicine as they were the first vectors used for vaccinating humans against 
smallpox. They are double-stranded DNA viruses with a genome of approximately 
200 kb. Vaccinia is a promising vector since the virus infects nearly all mammalian cell 
4 
types (Smutzer, 2000). However the main disadvantage of poxviruses is their high 
immunogenicity and their use is limited to therapy requiring transient expression 
(Paoletti, 1996). 
Adeno-associated viruses (AA V) have been used more often in pre-clinical/clinical 
trials over the past few years. Adeno-associated viruses are non-enveloped 
parvoviruses with a 4.7 kb single-stranded DNA genome (Srivastava et al., 1983). They 
do not seem to be associated with any human disease since no pathology was found to 
be associated with infection with AA V and it is widely believed AA V-2 (human) can 
replicate efficiently in human cells when a helper virus is applied. This is because AAV 
is not a fully functioning virus and cannot replicate in host cells without co-infection with 
a helper virus such as, adenovirus (Atchison et al., 2003), vaccinia virus and herpes 
simplex virus (Schlehofer et al. , 1986 ; Smith-Africa and Bartlett, 2001). The 
mechanisms of AAV integration are still poorly understood. They can target a wide 
range of cells derived from different tissues as well as non-proliferating cells and hence 
have a lower immunogenic property. They have the ability to establish latent infection by 
viral genome integration into the cell genome. High titers of this virus are difficult to 
obtain in the pure form (Romano et al., 1998). However AAV have a relatively small 
transgene capacity of less than 5 kb, low transfection efficiency in non-dividing cells, 
and the possibility of humoral responses occurring (Kootstra and Verma, 2003). 
Lastly, Sendai virus or haemagglutinating virus of Japan (HVJ) is a member of the 
paramyxoviruses. It has been incorporated in several different gene delivery systems, 
ego the Sendai virus has been combined with liposomes to produce a novel gene 
delivery system, called HVJ-liposomes. These viruses are being assessed for gene 
therapy of liver diseases (Nakanishi, et al., 1999). A glycoprotein of the vesicular 
stomatitis virus envelope has also been developed for gene therapy (Schuster et al., 
1999). 
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1.3 NON-VIRAL GENE DELIVERY SYSTEMS 
Non-viral gene delivery systems are techniques designed to introduce a coding DNA 
sequence without the means of q virus. There has been an increase over the years in 
the development and application of non-viral vectors in gene therapy. Non-viral gene 
therapy has a significant clinical potential, although its therapeutic use has been limited 
thus far by extracellular and intracellular barriers. Non-viral vectors can now hope to 
rival the viral vectors in respect of transfection efficiency. Most non-viral gene therapy 
research has focused on the delivery of plasm ids which is an attractive approach for 
gene transfer applications due to flexibility. Plasmids may be engineered to incorporate 
large DNA segments (Ahearn and Malone, 1999). 
Non-viral vectors can be introduced either by physical or chemical methods. Physical 
transfection of genes can be accomplished by electroporation, microinjection, or the use 
of ballistic particles (gene gun method). Chemical transfection introduces DNA by 
calcium phosphate, lipids and / or protein complexes. Some of the current popular 
methods of non-viral gene transfer viz. gene gun method, electroporation, direct gene 
(DNA) transfer, cationic polymers and lipid based delivery systems will be discussed. 
1.3.1 Gene Gun Method 
This method is also referred to as the ballistic method, the particle acceleration method, 
or the micro-projectile method. It involves the penetration of the physical barrier of 
mammalian cells ego the cell membrane and core membrane, by coated gold particles. 
A compressed shock wave of helium gas is created that accelerates the DNA-coated 
gold particles of varying sizes (1-3 I-Im) to a high speed. This force is sufficient to 
penetrate substantial physical barriers such as plant cell walls, cell membranes, and 
the stratum corneum of the mammalian epidermis (Yang et al., 1999). 
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The use of high velocity microprojectiles was initially developed for the delivery of 
nucleic acids into plant (onion) cells and was later extended to microbes and animals 
(Klein et at., 1992). The main limitation of this process is the requirement of accessible 
tissue surface for application. Hence this method has thus far been largely used in gene 
transfer to the skin due to its physical accessibility. This method allows DNA to 
penetrate directly into the cytoplasm or nuclei and to bypass the endosome I lysosome, 
thereby avoiding enzyme degradation (Nishikawa and Huang, 2001). 
A major application of the gene gun method is in genetic vaccination, and may be 
employed in combination with intramuscular injection of DNA or conventional protein 
antigens to achieve an optimal immunization effect (Yang et at., 1999). Gene gun 
transfection was applied to the skin tissue of mice ( Larson et at., 1998), pigs (Macklin et 
at., 1998), rhesus monkey (Fuller et at., 1996), and horses (Lunn et at., 1999), where 
humoral and cellular immune responses were elicited. These responses were seen to 
protect the animals from infection by viruses, bacteria, and parasites. 
1.3.2 Electroporation and Nucleofection 
Electroporation is a commonly applied technique to introduce DNA and other 
macromolecules such as antibodies and restriction nucleases into cells (Meaking et at., 
1995). This approach was pioneered in the 1960's by Coster, and has been used in 
microbiology and eukaryotic cell culture laboratories around the world (Vienken, 1978). 
Electroporation involves the application of brief but intense high voltage electric pulses 
to cells resulting in the formation of nanometer-sized pores in the cell membrane. The 
expression vector (DNA), or other molecules can enter the cytoplasm directly via the 
pores or as a result of redistribution of the membrane components following closure of 
the pores. 
Electroporation depends on the field intensity, pulse duration, number of pulses and the 
direction of the field incident to the cell membrane (Meaking et at., 1995). This is a 
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reproducible and a relatively simple technique, but seems to be restricted to in vitro 
gene delivery. The usage of high voltages can cause a fair amount of cell death, hence 
electronic parameters need to be optimized for each cell type. Electroporation was 
described in the delivery of mRNA encoding tumour ~ntigens into human dendritic cells, 
suggesting an application in future dendritic cell-based tumour vaccines (Van Tendeloo 
et al., 2001). This technique has also been applied to the skin (Titomirov et al., 1991), 
the liver (Heller et al., 1996) and muscle (Aihara and Miyazaki, 1998). From the tissues 
examined, skeletal muscle required mild electrical field strength of 100-400 V/cm while 
the skin and liver required shorter and more intense electrical pulses (Aihara and 
Miyazaki, 1998). The possibility that electroporation could give rise to DNA damage 
was investigated and was found to be partly dependent on the duration for which the 
current is applied (Meaking et al., 1995). 
Nucleofection is a novel transfection technology and a further development of 
electroporation. It is cell type-specific and depends on less harmful electric pulses and 
specific solutions optimized for specific cell types. Nucleofection transports DNA directly 
into the nucleus leading to rapid expression of the delivered gene within as low as forty 
minutes. The use of nucleofection has been reported recently in the delivery of small 
interfering RNA molecules (siRNA) into primary human cells (Chun et al., 2002). 
1.3.3 Direct I "Naked" DNA Delivery 
The use of "naked" DNA is probably the simplist non-viral gene delivery system 
available. It was originally thought that "naked" I purified DNA could not enter eukaryotic 
cells due its large size and high negative surface charge. However it was first reported 
in 1990 that murine skeletal muscle could be transfected by injection of "naked" DNA 
(Wolff et al., 1990). This muscle transfection ability has led to "naked" DNA being 
administered intramuscularly for vaccination purposes, where DNA encoding an antigen 
is administered with the aim of developing a protective immune response to the 
transgene antigenic product (Smith et al., 1998). 
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Besides muscle, "naked" DNA has been applied to the liver (Zhang et al., 1997), solid 
tumours, e.g. melanomas (Yang and Huang, 1996; Vile and Hart, 1993), skin epidermis, 
hair follicles (Yu et al.,1999) and urological organs (Yoo et al., 1999). Although 
expression was achieved in direct cutaneous injection in patients suffering from lamellar 
ichthyosis, a genetic skin condition caused by the loss of expression of the enzyme 
transglutaminase, the pattern of expression was not uniform and failed to correct the 
histological and functional abnormality of the disease (Choate et al., 1997). 
Although direct transfer of DNA is not very efficient and gene expression levels are 
relatively low, immunization effects have been observed, making it sufficient for 
vaccination purposes. The transferred plasmid is usually maintained 
extrachromosomally in a circular form making expression variable. Immune responses 
produced have been shown to protect animals from a variety of live infectious agents, 
leading to a new class of therapeutic agents called "DNA vaccines" (Danko and Wolff, 
1994). The mechanism for naked DNA-mediated gene transfer is not clearly 
understood as yet, but recent studies suggest that naked DNA is taken up by the 
parenchymal cells in vivo by an active, receptor-mediated process (Budker et al., 1996). 
Application of "naked" DNA to the site of pathology and away from the degradative 
elements such as plasma is thus a viable strategy for gene therapy. However, it is 
ineffective if DNA dosing to anatomically inaccessible sites e.g. solid tumours in organs, 
is required (Brown et al., 2001). 
To improve DNA delivery across cellular barriers and to increase its stability of DNA 
against enzymatic degradation, DNA can be associated with or formulated with viral or 
non-viral delivery systems. The gene gun method and electroporation were developed 
to enhance gene transfer via "naked" DNA. These physical approaches also allow the 
DNA to penetrate the cell membrane and bypass the endosome / lysosome, avoiding 
enzymatic degradation. Intramuscular injection of plasmid DNA followed by 
electroporation produced impressive levels of gene expression in mice (Li and Huang, 
2000). Recently, a single injection of a keratinocyte growth factor DNA encoded on a 
plasmid coupled with electroporation was found to improve and accelerate wound 
9 
closure in a delayed wound-healing mouse model (Marti et a/., 2004). The most 
common method to increase transfection efficiency of "naked" DNA involves the use of 
liposomes (Eck, 1999). 
1.3.4 Cationic Polymers 
Polymer based gene delivery systems are actively studied with greater interest focused 
on cationic polymers, although some neutral polymers ego Polyvinyl pyrrolidone (PVP), 
have been utilized to improve gene transfer by direct intramuscular injection (Mumper et 
al., 1996). Polymers bearing cationic groups are protonated at physiological pH and 
have been used most frequently. They have been widely accepted due to their ability to 
condense DNA and interact with cells often better than lipids. The complexes formed 
between cationic polymers and DNA are referred to as "polyplexes" (Feigner et a/., 
1997 ; Ogris et a/., 1999). Cationic polymers complex with DNA and protect it against 
the action of nucleases. The cellular uptake of the plasmid DNA in "polyplexes" occurs 
by non-specific adsorptive endocytosis, similar to that of cationic liposomes (Nishikawa 
and Huang, 2001). 
The cationic polymers produced to date are relatively poor in carrying DNA molecules 
across the membrane (Mansouri et a/., 2004). The most commonly used cationic 
polymers are polyethyleneimine (PEl) (Boussif et a/., 1995 ; Kichler et a/., 1999) (Figure 
1.1) and poly-L-Iysine (PLL) (Wu and Wu, 1987 ; Perales et al., 1994) (Figure 1.2). 
Several novel cationic polymers have been synthesized, viz. gelatin (Leong et a/., 
1998), polybrene (Mumper et al., 1996), chitosan (Corsi et al., 2003), poly (L-histidine)-
graft-poly-L-Iysine (Benns et a/., 2000) and oligoaminosiloxanes, e.g. Poly (alkylamino-
siloxane) (Kichler et a/., 2003). 
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Figure 1.1 : Structure of (a) linear and (b) branched polyethyleneimines. 
Figure 1.2 : Structure of poly-L-Iysine 
Polyethyleneimines exist as both branched and linear polymers (Figure 1.1). PEl is a 
polymer with one of the highest densities of amine functions. It has shown efficient gene 
transfer without the need for endosomolytic or Iysosomotropic agents, such as 
chloroquine, to enhance receptor-mediated endocytosis (Brown et al., 2001). 
Endocytosed PEl, whether administered with or without DNA, undergoes nuclear 
localization in the form of ordered structures (Godbey et al., 1999). The transfection 
efficiency of PEl, depends largely on its molecular weight and isoform (branched or 
linear) (Fischer et al., 1999). The addition of targeting ligands have enhanced activity in 
some cell lines, although some toxicity to cells has been reported (Boussif et al., 1995). 
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Poly-L-Iysine was the first polycation utilized for gene delivery and was conjugated to 
asialoorosomucoid for hepatocellular gene targeting (Wu and Wu, 1987). It has also 
been complexed to ligands such as transferrin (Cotton et al., 1990), and folate (Mislick 
et al., 1995). Gene transfer of poly-L-Iysine polymers without the use of receptor-
mediated strategies is poor unless endosomolytic or Iysosomotropic agents are added 
(Brown et al., 2001). Poly-L-Iysine polymers incorporating poly-L-histidine were also 
used to deliver genes to mammalian cells (Benns et al., 2000). Glycosylated and a-
mannosylated polylysine were synthesized for gene transfer into normal human and 
cystic fibrosis tracheal gland serous cells, with the glycosylated polylysines 
(Uglycofectins") showing greater efficiency than the a-mannosylated derivatives ( Allo et 
al., 2000). 
Chitosan [( 1 ~4 )2-amino-2-deoxy-~-D-glucan)] is obtained by alkaline deacetylation of 
chitin, a polysaccharide found in the exoskeleton of crustaceans and insects. It is a 
copolymer of N-acetyl-D-glucosamine and D-glucosamine. Chitosan is a non-toxic 
biodegradable polycationic polymer with low immunogenicity. DNA-loaded chitosan 
microparticles were also found to be stable during storage. Chitosan was shown to be 
able to enhance the transport of drugs across the cell membrane and has been used in 
the delivery for nasal, ocular and oral drug delivery to prolong contact time and improve 
drug absorption (Mansouri et al., 2004). Ligand modified chitosan for targeting of DNA 
to cell specific receptors has resulted in increased transfection efficiency (Sato et al., 
2001 ). 
Oligoaminosiloxanes are also able to condense DNA and deliver it to cells by adsorptive 
endocytosis. Unlike poly-L-Iysine, the oligoaminosiloxanes are only partially protonated 
at physiological pH. These polymers display a pH- and substitution-dependent structure 
and are hence thought to be useful in controlled release applications (Kichler et al., 
2003). The potential for cationic polymers used for gene therapy to adversely interact 
with host genes exists, and hence presents itself as a concern when using these 
methods to treat human diseases (Godbey et al., 1999). 
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1.3.5 Lipid based Gene Delivery Systems 
Although gene expression can be achieved by direct intra-tissue injection of naked 
DNA, gene transfer via other routes of administration e.g. intravenous injection will 
require the use of a delivery vector or vehicle. Some of the more popular lipid based 
systems developed in the past include liposomes and non-liposomal cationic lipids or 
polymers. 
1.3.5.1 Liposomes 
The most widely used non-viral transfection system for gene therapy applications are 
lipid based artificial macromolecular complexes. These complexes generally involve 
liposomes formed from diverse synthetic and often novel and amphiphilic lipids in 
combination with helper lipids (eg. phosphatidylethanolamine), and sometimes natural 
and synthetic polycations (polylysine, polyethyleneimine) or hydrophobic oligo- and 
polycations (Zhdanov et a/., 2002). 
Liposomes were first described by Bangham et a/., in 1965. It was found that when 
specific extracted lipids from egg yolks were placed in water, the lipids naturally 
organized themselves into microscopic spheres under appropriate conditions. The 
membranes enclosing these spheres resemble in appearance and function the 
biological membranes that enclose cells and constitute their boundary. Due to this 
similarity liposomes were initially used in studies as model membrane systems. They 
have also been used to investigate permeability parameters of various molecules and 
ions across the lipid bilayer. Later, however, the carrier potential of Iiposomes was 
realised. Various peptides and proteins such as insulin, immunoglobulins, and 
enzymes have been incorporated into liposomes and delivered to their target cells 
(Mukherjee et a/., 1978). 
Liposomes have been described as assemblages of phospholipids and other lipids 
sustaining a bimolecular configuration and not requiring mechanical support for their 
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stability (Gregoriadis, 1976). Liposomes are vesicles consisting of one or more 
concentric lipid bilayers alternating with aqueous compartments, within which is 
entrapped a variety of lipid-soluble or water-soluble substances respectively. 
Liposomes can be characterized by their size as: small unilamellar vesicles (SUVs) that 
are up to 200 nm in size, large unilamellar vesicles (LUVs) , that are greater than 500 
nm in size, and large multilamellar liposomes (MLVs) that are very much larger than 
500 nm. However it has been reported that complexation of DNA with multi lamellar 
liposomes of diameter of 300-700 nm mediated a two fold higher gene expression than 
those prepared with small unilamellar vesicles of about 50-100 nm (Feigner et al., 
1994). 
Among the more conventional transfection methods, liposomes have become 
increasingly more popular and acceptable as a convenient and reproducible vehicle for 
DNA-mediated transfection. There are generally four major classes of liposome types 
viz. conventional liposomes (those that are anionic or neutral), cationic, 'stealth' or 
sterically stabilized liposomes (carry polymer coatings to obtain prolonged circulation 
times), and targeted liposomes (Storm and Crommelin, 1998). Most of the early studies 
on liposomes used anionic and neutral liposomes. 
Transfection with anionic liposomes generally requires that the DNA be entrapped in the 
aqueous space of the liposomes. Improvements in liposome technology now permit the 
encapsulation of nucleic acids in liposomes. Liposomes encapsulating RNA and DNA 
can be introduced and genetic material expressed in mammalian cells (Fraley and 
Papahadjopoulos, 1981) and in plant cells (Fraley et al., 1982 ; Gad et al., 1990; 
Rosenberg et al., 1988). This method however has not been widely used for gene 
transfer probably because encapsulation efficiency is variable and the actual process 
very time consuming. Neutral and anionic liposomes however are less toxic and more 
compatible with biological fluids and therefore may be suitable for systemic gene 
delivery (Li and Ma, 2001). 
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Steric stabilization of liposomes not only increases the colloidal stability of the lipid 
dispersion but it also promotes its biological stability. Stabilisation can be achieved by 
grafting or by absorption of a polymer to the liposomal surface. The so called grafting 
method is more commonly used and is achieved by incorporation of poly( ethylene 
glycol)-phospholipids. It was shown that poly(ethylene glycol) (PEG) grafting to 
liposomes hinders protein interaction with the liposome surface, whereas liposome-
grafted dextran (a more rigid polymer) in similar quantities does not affect protein-
liposome interaction (Torchilin et al., 1994). Polymer stabilized liposomes can be 
thought of as structural mimics of red blood cells in which a relatively thick glycocalyx 
layer shields the lipid bilayer membrane (Chisti, 1999). 
These sterically stabilised liposomes help prolong the circulation time of the liposome 
from minutes to days (about one hundred times longer than conventional liposomes) 
(Lasic and Papahadjopoulos, 1995), and also increases their efficiency in drug delivery. 
This is due to the apparent repulsive hydrophilic barrier around the liposomes provided 
by the covalently attached PEG, which prevents liposomes from cell adhesion and from 
being opsonised by proteins (Ou et al., 1997). Grafting of PEG into lipids or liposomes 
leads to the dehydration of the lipid headgroup region and a decrease in bilayer effects 
and enhanced lateral packing of the phospholipid acyl chains. All these factors 
contribute to steric stabilization (Barenholz, 2001). A typical PEG-liposome resembles a 
lipid bilayer with the grafted PEG moieties protruding from the surface and the 
hydrophobic tails of these molecules remaining inserted in the lipid bilayer (Kuhl et al., 
1998) (Figure 1.3). These liposome types will play an important role especially in in 
vivo gene transfer. 
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(a) (b) DSPE-PEG 
Figure 1.3: Schematic representation of a sterically stabilised liposome with PEG (a). 
The common PEG-lipid DSPE( distearoylphoshatidylethanolamine )-PEG 
where n ranges from 17 to 114 in PEG molecular structure (b). 
Another method employed to enhance the stability and circulation time of liposomes in 
vivo is via the use of pH sensitive liposomes. These pH sensitive liposomes help to 
mediate the introduction of highly hydrophobic molecules or macromolecules into the 
cytoplasm and generally contain phosphatidylethanolamine and titratable stabilizing 
amphiphiles. They are stable at pH 7.4 but undergo destabilization and acquire 
fusogenic properties under acidic conditions, leading to the release of their aqueous 
contents in the endocytotic pathway (Simoes et a/., 2004). 
1.3.5.2 Cationic Liposomes and Cationic Lipids 
Cationic liposomes, on the other hand, do not require the DNA to be entrapped. DNA-
liposome complexes can be easily prepared by simply mixing the liposome and DNA 
solutions and incubating the mixtures for a short while (Farhood et a/., 1992). Cationic 
liposomes tend to have favourable interactions with DNA which is bound to the external 
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layer of the liposome membrane due to the strong interactions between the cationic 
head groups of the lipid and the DNA (Behr et al., 1989). Theoretically, there is no strict 
size limitation on DNA and almost 100% of the DNA can be recovered in a complexed 
form (Li and Ma, 2001). There is an extensive lipid rearrangement during complex 
formation, with resulting complexes bearing little resemblance to the starting or original 
liposome. Cationic liposome/DNA complexes have been simply referred to as 
'lipoplexes' (Feigner et al., 1997). 'Lipopolyplexes' can also be produced and are 
defined as being composed of vectors that have a polycation-condensed DNA coated 
with lipid bilayers The resulting net charge of the liposome-DNA complex (lipoplex) 
(positive charge) facilitates fusion with the negatively charged cell membrane (Li and 
Ma, 2001). 
In addition to DNA, cationic liposomes can be used to deliver RNA (Malone et al., 
1989), proteins (Debs et al., 1990), and antisense oligonucleotides (Jaaskelainen et al. , 
2002). Among the non-viral vectors for gene transfer, cationic liposomes have intrinsic 
properties which make them attractive as vehicles for gene delivery. They are synthetic, 
and hence manufacturable to drug standards, biodegradable and seem to have the 
added advantage of low toxicity, higher efficiency, non-immunogenicity, easiness of 
use, and the design capability for cell-specific targeting. Furthermore cationic 
liposomes can interact with DNA to promote its transfection into both replicating and 
non-replicating cells (Birchall et al. , 1999). An understanding of the phospholipid-
cationic lipid interactions is essential for rational development of the potential of cationic 
liposomes for gene /drug delivery. 
Since the pioneering work of Feigner and coworkers in 1987 (Feigner et al., 1987), 
who used a monocationic lipid , N-[1-(2,3-dioleyloxy) propyl]- N,N,N- trimethylammonium 
chloride (DOTMA), (Figure 1.4), in combination with a neutral zwitterionic phospholipid, 
dioleoyl-phosphatidylethanolamine (DOPE), several other related compounds or 
formulations have been reported and have proven to be valuable tools in gene delivery 
(Behr,1994). Many of these cationic lipid formulations are now available commercially. 
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All cationic lipids have four functional domains viz. a positively charged head group(s), a 
spacer of varying length, a linker bond and a hydrophobic anchor (Figure 1.5) 
Figure 1.4: Structure of DOTMA 




lipid I hydrophobic anchor 
Figure 1.5: An example of a cationic cholesterol derivative (CHOL -T) defining the 
four components of a typical cationic lipid. 
The lipid anchor is usually a fatty acid chain or a cholesterol ring . The linker bond 
determines the lipid's stability and biodegradability. The length of the spacer arms 
differs in various lipid preparations and may be as critical as the nature of the head 
groups for transfection activities. The hydrophobic component ensures that the cationic 
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lipids assemble into lipid bilayer vesicles on dispersion in aqueous media, shielding the 
hydrophobic portion of the molecule and exposing the head group to the aqueous 
medium. The head group is the DNA binding moiety of the liposome (Brown et al., 
2001 ). 
Based on the differences in the hydrophobic anchor, cationic lipids can be grouped into 
three different categories: cholesterol-anchored lipids ego 3P[N-(N',N'-
dimethylaminopropane)-carbamoyl]cholesterol (Chol-T) (Figure1.5) (Singh et al., 
2001 b), and 3P[N,N',N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-CHOL), 
(Figure 1.6), (Gao and Huang, 1991); double chain hydrocarbon-anchored lipids 
ego N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulphate, (DOTAP) 
(Figure1. 7), dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide (DMRIE), 
(Harrison et al., 1995), 1 ,3-dioleoyloxy-2 (6-carboxyspermyl) - propylamide (DOSPER), 
(Figure 1.8) (Buchberger et al.,1996), (+)-N-(3-aminopropyl )-N,N-dimethyl-2,3-bis-
(dodecyloxy)-1-propanaminium bromide (GAP-DLRIE), (Figure 1.9), (Wheeler et al., 
1996); and 2,3-dioleyoxy-N-[ 2(sperminecarboxamido) ethyl ]-N,N-dimethyl-1-
propanaminium trifluoroacetate (DOSPA), (Harrison et al., 1995); and single chain 
hydrocarbon anchored lipids, ego dodecyltrimethylammonium bromide (DTAB), 
cetyltrimethylammonium bromide (CTAB), and tetradecyltrimethylammonium bromide 
(TTAB) (Figure1.10) (Li and Ma, 2001). 
Single chain hydrocarbon anchored lipids are commonly known as detergents and 
generally too toxic to be used alone in transfection and are therefore mixed with DOPE, 
a neutral helper lipid, to decrease toxicity (Pinnaduwage et al., 1989). Single chain 
cationic lipids are generally less efficient than double chain cationic lipids and are hence 
not suitable for in vivo gene transfer. The lipids currently under investigation and ones 
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Figure 1.9: Structure of GAP-DLRIE 
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DTAB: R= H 
TT AB : R = CH3CH2 
CTAB: R = CH3(CH2h 
Figure 1.10: Structure of single chain hydrocarbon-anchored lipids 
Two lipopolyamines, dioctadecylamidoglycyl-spermine (DOGS), (Figure 1.11), and 
dipalmitoyl-phosphatidylethanolamido spermine (DPPES), (Figure 1.11), were also 
synthesised for delivery of DNA into eukaryotic cells (8ehr et al., 1989). In these 
polyamines, the headgroups interact strongly with the minor groove of DNA. A 
nucleosome type structure is formed in which the DNA molecule is packaged. DOGS 
has a higher cationic charge number in its headgroup than DOTMA, hence favouring a 
stronger interaction with the negative DNA, resulting in a compact DNA-DOGS complex. 
DOTMA, on the other hand, forms liposomes in aqueous solutions which aggregate 
spontaneously with negatively charged DNA molecules (Fortunati et al., 1996). The 
combination of equimolar quantities of DOPE and DOTMA was widely used in liposome 
formulations for lipofection (Feigner et al., 1994). Liposomes containing DOTMA have 
been formed to facilitate transfection of cultured mammalian cells with recombinant 





Figure 1.11: Structure of lipopolyamines DOGS and DPPES 
23 
Since their introduction in the late 1980's, cationic liposomes such as DOTAP were 
quickly and widely adopted as convenient, reliable and flexible tools for gene transfer 
studies in mammalian cells. DOTAP has been used with varying degrees of success in 
more than fifty different cell types, to introduce DNA, RNA, oligonucleotides and 
peptides into cells. However it was found to have a deleterious effect on erythrocytes 
(Uchegbu et al., 1998) and macro phages (Filion and Phillips, 1998). DOTAP differs 
from DOTMA in that its two oleic acid moieties are in ester linkage to the propyl moiety 
whereas in DOTMA the two oleyl chains are in ether linkage to the propyl backbone. 
The ester bonds are inherent to natural lipids and DOTAP offers high transfection 
efficiency and lower toxicity. This is probably due to the fact that cellular lipases or 
esterases easily degrade this artificial lipid (Buchberger et al., 1996). It has been found 
to exert a potent destabilizing effect on the lipid bilayer physical properties which may 
be important in drug delivery (Campbell et al., 2001). DOTAP-based liposomal carriers 
were found to be more effective in the delivery of antisense oligonucleotides than 
cationic polymer-based systems (Jaaskelainen et al., 2002). 
The use of DOTMA is restricted due to its toxicity to treated cells, and also the cost of 
the reagent. DOSPER, on the other hand, is a polycationic amphiphile with ester bonds 
similar to DOTAP, which can be biodegraded by the target cells. DOSPER, with fatty 
acids connected to the 1 and 3 positions and the polyamine component attached to the 
2 position of the propane backbone, also forms liposomes (Buchberger et al., 1996). 
DMRIE is a polycationic lipid and has been used complexed to DOPE for in vivo gene 
delivery in mice and in clinical trials to deliver genes into cutaneous tumours in late 
stage melanoma patients (Nabel et al., 1993). 
GAP-DLRIE was found to enhance plasmid DNA delivery and expression in mouse lung 
cells (Wheeler et al., 1996). DC-CHOL contains a cationic lipid component which is a 
tertiary amine conjugated to a cholesterol group via a short spacer arm and a carbamoyl 
bond. It is stable at 4°C and has been used in clinical trials for cancer gene therapy. 
F arhood et al. (1992) synthesised four different cationic cholesterol derivatives 
containing tertiary or quaternary amino head groups, with and without succinyl spacer 
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arms. They found that the tertiary amine derivatives showed greater transfection 
activities and were less toxic to the cells than the quaternary ammonium derivatives. 
Most cationic lipid reagents are formulated as liposomes containing two lipid species 
viz. a cationic amphiphile and a neutral lipid such as DOPE which is important in 
facilitating membrane fusion during cationic lipid mediated DNA delivery. The term 
"cytofectins" describes this class of positively charged lipids. Cationic lipids can have 
monocationic head groups ego DOTMA, DOTAP, DC-CHOL, or polycationic head 
groups ego DOSPA and DOGS (Feigner et al., 1994). Multivalent cationic lipids are 
thought to condense DNA more strongly than monovalent cationic lipids in vitro. 
Successful gene transfer is a combination of delivery and expression of the foreign 
gene in the target cell (Gao and Huang, 1993). The cationic lipids discussed usually 
provide non-specific targeting to the negatively charged (sialic acid bearing) 
components of the cell surface. Inclusion of lipids such as DOPE that have a low 
transition temperature are thought to be important for the activity of these cationic lipids 
(Cotten and Wagner, 1993). DOPE is a common helper lipid used in the formation of 
cationic liposomes, except in DOGS-based liposomes. In most cases an equimolar 
mixture of cationic lipid and DOPE ensures optimal transfection efficiency. The liquid-
crystalline nature of the DOPE I lipid bilayer promotes efficient binding and penetration 
of plasma proteins into the liposomal structure (Feigner et al., 1994). 
Although the use of cationic liposomes for in vitro gene transfer has become common-
place, whole organism studies are increasing in number. An early study has shown that 
injected DNA complexed with a cationic liposome (Iipofectin i.e. DOTMA:DOPE) 
mediated transfection in the mouse (Brigham et al., 1989). Cationic liposome-DNA 
complexes were also expressed after intra-arterial administration (Nabel et al., 1990) 
and aerosol inhalation (Stribling et al., 1992). Some liposomal formulations have 
undergone clinical evaluation as vectors for gene therapy in cancer (Nabel et al., 1993), 
and cystic fibrosis (Mclachlan et al., 1996). 
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1.4 CATIONIC LlPOSOME-DNA INTERACTION 
Several techniques have been employed to study the organization of DNA in 
lipoplexes. The cationic liposome DOTAP:DOPE has been commonly utilized in these 
studies. DNA / lipid association is extremely rapid and occurs within one minute after 
mixing (Gershon et al., 1993). The DNA / lipid complex will continue to change over time 
in a maturation process. The lipoplex structure is determined by a number of factors, 
including the structure or type of cationic lipid used, the charge ratio between the 
cationic lipid and the DNA, the concentration of lipid and DNA used, time allowed for 
lipoplex formation, the temperature at which lipoplexes are preformed, the nature of the 
solvent or buffer system employed during sonication or extrusion of liposomes and the 
helper lipid utilized (Bennett et al., 1996). Depending on the pKa of the cationic lipid, 
the pH may also affect the interaction of cationic lipids with DNA and the structure of the 
resulting complex. Incubation of cationic liposomes with DNA usually leads to a 
heterogeneous population of particles (Zabner et al., 1995). 
Studies have shown that lipoplexes generated from SUV's are two phase systems over 
most lipid / DNA charge ratios, but are single phase systems for LUVs and ML Vs over 
a broad range of mixing ratios (Concalves et al., 2004). Small angle X-ray scattering 
(SAXS) has shown the coexistence of lamellae and hexagonal lipid-DNA domains in 
lipoplexes. Atomic force microscopy (AFM) has revealed that even in lipoplexes with an 
excess cationic charge, there still exist regions of DNA not covered by cationic lipid. 
Circular dichroism (CD) was employed to investigate secondary and tertiary DNA 
structures in complexes, and it was found that a highly condensed form of DNA is 
generated known as '¥-DNA, a form which is easily promoted by cationic liposomes 
(Simberg et al., 2001). 
The absolute structure of the DNA within lipoplexes is under discussion. It was 
previously assumed using CD data, that DNA is converted from its B form to the C form 
in complexes (Zuidam et al., 1999 ; Simberg et al., 2001), but recent investigations 
using vibrational spectroscopy have revealed that the DNA maintains its B form 
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conformation, but tends to become dehydrated at the liquid interface. This results in the 
apolar region of the lipid bilayer becoming fluidized upon the binding of DNA 
(Choosakoonkriang et al. , 2001). Furthermore, supercoiled plasmid DNA seems to 
undergo a significant loss of rotational strength upon interaction with a cationic lipid. The 
use of Fourier transform infrared (FTIR) and Raman spectroscopy have shown that 
these changes occur within the B type conformation of DNA and also within short 
stretches of DNA. It appears that lipid / DNA interactions extend far beyond direct 
electrostatic coupling between the lipid headgroup and the phosphate backbone, to 
alteration in base stacking interactions as well as hydrogen bonding (Braun et al., 
2003). 
Almost all aspects of the structure of lipid / DNA complexes and of gene transfer 
mechanisms are connected to electrostatic interactions and the important role of the 
charge i.e bioelectrochemistry, since it is generally accepted that cationic liposomes 
interact with DNA through charge attraction. Electrostatic interaction and hydrophobic 
bonding are proposed as driving forces for complex formation . Hydrophobic forces 
between lipid side chains predominate but upon mixing with DNA, electrostatic 
interactions draw the positive surface of the cationic liposomes together with the 
negative phosphate backbone of the plasmid (Brown et al. , 2001). 
The formation of the liposome-DNA complex involves two processes viz. a fast 
exothermic process attributed to the electrostatic binding of DNA to the liposomal 
surface and a slower endothermic process caused by the fusion of the two components 
and their rearrangement into a new structure. These two processes result in an 
homogeneous and physically stable suspension being formed (Zhdanov et al., 2002). 
The thermodynamic driving force for lipid / DNA association is the entropy increase from 
the release of counterions and bound water associated with the plasmid DNA and the 
lipid surface. A similar result was seen for DNA that occured in the linear form (Kennedy 
et al., 2000). Several models have been proposed for the structure of cationic liposome-
DNA complexes. These will be discussed further in chapter two. 
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1.5 MECHANISM OF LlPOFECTION 
Despite the enormous amount of work using liposomes as drug and gene carriers, the 
actual molecular mechanism of the liposome-cell interactions (lipofection) has not been 
fully elucidated. Lipofection involves formation of the DNA-liposome complex, the entry 
of the complex into the cell , escape of the DNA from the endosomal compartments and 
finally entry into the nucleus (Kennedy et al., 2000). Liposome uptake by different cells 
has a varying dependence on liposome composition, eg small mole percentages of 
negatively charged phospholipids viz. phosphatidylserine (PS), phosphatidylglycerol 
(PG) etc., in the liposome enhanced uptake twenty fold when compared to uncharged 
liposomes in CV 1 cells (Straubinger et al., 1983). The molecules on the cell surface 
that are responsible for interaction with lipoplexes are also not well defined. However 
proteoglycans on the cell membrane appear to play an important role, and cells 
deficient in proteoglycan synthesis are more difficult to transfect (Li and Huang, 2000). 
Various methods have been postulated over the years (Figure 1.12), but recently two 
pathways have emerged as the main route of entry of liposome-DNA complexes viz. 
direct fusion with the cellular membrane (Feigner et al., 1987), and endocytosis with 
subsequent destruction of an endosome within the cell (Zabner et al., 1995 ; Leventis 
and Silvius, 1990). It has been suggested that the hydrophobic moiety of the cationic 
lipid is involved in cell membrane interaction, membrane passage, and escape from the 
endosome (Wetzer et al., 2001). Adhesion of cationic liposome complexes onto the 
negatively charged outer membrane of the cell occurs through electrostatic interactions 
(Hui et al., 1996). It was also proposed that DNA delivery and release from cationic 
liposome complexes occurs via anionic lipid exchange with the cytoplasmic surface of 








FIGURE 1.12: Four different interactions of liposomes and cells: fusion, endocytosis, 
adsorption, and lipid exchange (adapted from Lasic,1997). The methods 
of fusion and endocytosis are the main postulated mechanisms of 
liposome delivery. 
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In an early study by Papahadjopoulos et al., 1973, it was suggested that the liposome 
membrane fuses with the plasma membrane. It was proposed that fusion depended on 
the phospholipid composition of the liposome and also on the phase in which it exists 
ego a liquid crystalline phase produces greater fusion than a gel phase. This mechanism 
postulates that the liposome membrane fuses with the plasma membrane of two 
adjacent cells, hence providing a bridge between the two cells. However lipid mixing 
assays did not reveal much correlation between fusion events of lipoplexes and cellular 
membranes and their transfection efficiency (Zhou and Huang, 1994). 
Although fusion of liposomes with cell membranes is a proposed mechanism of DNA 
delivery by cationic liposomes it is more likely that the liposome-DNA complex enters 
the cell by endocytosis (Pinnaduwage et al., 1989). It was found that most complexes 
are internalized by endocytosis and only 2% of the cells are transfected via direct 
complex membrane fusion (Zhou and Huang, 1994). Plasmid DNA, like all endocytosed 
molecules, travels after internalization in the cell via an endosomal compartment where 
it is degraded. However for a transfected gene to be expressed, the intact DNA 
molecule must cross either the endosomal or lysosomal membrane into the cytosol and 
finally into the nucleus (Wattiaux et al., 2000). Once in the cell, liposomes then 
encounter a low pH compartment (Straubinger et al., 1983). It is generally accepted 
that the liposomes and bound DNA enter the Iysosomes. 
Evidence for endocytosis is based on application of inhibitors ego wortmannin, 
chloroquine, monensin and NH4CI (Simoes et.al., 1999b; Zuhorn et al., 2002). The use 
of inhibitors of endocytosis indicated that fusion occurred primarily at the plasma 
membrane. These inhibitors also inhibited transfection, further indicating that 
endocytosis is the primary route of gene delivery, despite fusion at the plasma 
membrane. However the precise effects of inhibitors are difficult to interpret as both 
increases and reductions in transfection efficiency have been observed (Zuhorn et al., 
2002). Electron microscopic studies of cells incubated with liposomes containing gold 
have revealed that the liposomes are taken up via endocytosis in coated pits 
(Straubinger et al., 1983). This was supported by confocal laser scanning microscopy 
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(CLSM) and atomic force microscopy (AFM). These techniques also revealed that the 
cationic liposome:DNA complexes were transferred to Iysosomes by a microtubule-
mediated pathway and that membrane fusion between cationic liposomes and the 
endosome membrane leads to the displacement of DNA from the cationic liposome 
(Nakanishi , 2003). 
Noguchi et al. (1998), provided evidence that cationic liposome:oligonucleotide 
complexes fused with the endosome and at low pH the oligonucleotide was released 
into the cytoplasm. In addition microtubules were found to be involved in the 
intracellular dynamics of gene transfection (Nakanishi and Noguchi, 2001). The delivery 
mechanism of the liposomes involve the destabilisation of the liposome bilayer in the 
late endosome at acidic (pH 5.0 to 6.3), and destabilisation and fusion of the vesicle 
membrane within the endosome. The intracellular fate of the delivered DNA is still 
poorly understood (Legendre and Szoka, 1992). Furthermore the plasmid DNA must 
dissociate from the cationic liposome complex prior to entry into the nucleus of the cell, 
since cationic lipid:DNA complexes microinjected directly into the nucleus exhibit a low 
transfection efficiency (Zabner et.al., 1995; Alino et al. , 2000). This has led to the 
development of pH-sensitive liposomes that could destabilize and undergo membrane 
fusion at mildly acidic pH and also sufficiently destabilize the endosomes to deliver their 
macromolecules into the cytoplasm. Unfortunately one of the drawbacks of pH-sensitive 
liposomes is their rapid removal from circulation in vivo (Torchilin et al., 1993). 
Various approaches such as the use of fusogenic peptides have been employed to 
facilitate release of DNA into the cytoplasm. These are unusually water soluble at 
physiological pH and are converted to an amphipathic alpha helix at low pH. Upon 
association with the lipid bilayers they trigger pH-dependent fusion of small liposomes. 
When co-delivered with a lipoplex, they disrupt the endosome and improve cytoplasmic 
delivery of DNA (Simoes et.al., 1998; Li and Ma, 2001). In the case of the polycation 
PEl, a proton sponge mechanism has been proposed in which the PEl buffers the 
acidification by sequestration of protons and counterions, resulting in osmotic swelling 
and subsequent rupturing of the endosomes (Boussif et al., 1995). 
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It was recently shown that cholesterol depletion results in the inhibition of clathrin-
mediated endocytosis, whereas non-clathrin mediated endocytosis is much less 
affected. Decrease in clathrin-mediated endocytosis is caused by the disability of the 
coated pits to invaginate and detach from the plasma membrane. A clathrin 
independent pathway, of which caveolae form a part, may also be a delivery route. It is 
a pathway commonly utilised by viruses. Caveolae generally cluster to form vesicles 
called caveosomes. The drugs, filipin III and chlorpromazine have been used to 
distinguish between clathrin-mediated and caveolae-mediated internalization of 
lipoplexes. Filipin III is a sterol-binding pentaene macrolide antibiotic, that inserts into 
lipid membranes containing cholesterol. It inhibits the caveolae invagination by 
formation of cholesterol precipitates, leaving the coated pits unaffected. Chlorpromazine 
on the other hand, is a cationic amphiphilic drug that causes localization and 
accumulation of clathrin in late endosomes, thereby inhibiting coated pit endocytosis. 
Only a fraction of lipoplexes are internalized via caveolae, and eventually lipoplexes 
accumulate into the lysosomal compartment, which is the end of an endocytotic rather 
than a caveolae-mediated internalization. Hence clathrin-mediated endocytosis is the 
major pathway for lipoplex internalization (Simoes et.al., 1999b; Zuhorn et al., 2002). 
Clathrin is involved in two crucial transport steps viz. receptor-mediated and fluid phase 
endocytosis for plasma membrane to early endosomes; and transport from the trans-
Golgi network (TGN) to the endosomes (Marsh and McMahon, 1999). 
1.5.1 Receptor-Mediated Endocytosis 
Liposomes targeted to receptors on the cell surface usually follow the receptor-
mediated endocytotic pathway. Receptor-mediated endocytosis is an effective method 
for gene delivery into target cells. It is a natural process that cells utilise for the uptake 
of proteins or peptides such as asialoglycoproteins, transferrin, epidermal growth factor, 
insulin, low denSity lipoproteins, diptheria toxin and also vitamins such as folic acid, and 
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viruses. One advantage of the receptor-mediated endocytosis of DNA is the ability to 
target DNA to specific cells by coupling the DNA-binding vector to cell specific ligands, 
and thus generating a cell specific DNA-delivery conjugate (Cotten et al., 1990). 
The first step in receptor-mediated endocytosis involves the binding of the ligand to its 
cognate cell surface receptor (Figure 1.13). Subsequently, the receptors undergo a 
conformational change which leads to the clustering of the receptor-ligand complexes in 
coated pits located on the plasma membrane (Wagner et al., 1994). These pits are lined 
on the intracellular surface by a clathrin triskelion structure comprising three polypeptide 
heavy chains (190 kDaltons) and three polypeptide light chains of approximately 25 
kDaltons each. These triskelions oligomerise in vivo and in vitro to produce polygonal 
arrays generally seen under electron microscopy. In cultured cells, the assembly of a 
clathrin coated vesicle during endocytosis, takes about one minute and several hundred 
to a thousand or more can form every minute (Marsh and McMahon, 1999). Receptor 
internalization is actively coupled to the formation of coated pits. The formation of 
clathrin is the driving force behind membrane invagination (Mousavi et al., 2004). 
Movement of the clathrin molecules results in deepening of the pits and the clathrin-
associated membrane being "pinched off' (scission) as a clathrin coated vesicle (CCV). 
This invagination process requires the presence of G-proteins and ATP. Upon the 
removal of the clathrin coat, the vesicles fuse with and become part of the acidic 
endosomal compartments. The endosome is converted into a CURL (compartment of 
uncoupling of receptor and ligand) vesicle. The ligands and the receptors have different 
fates. Receptors can either be destroyed in a degradative pathway, or be brought back 
to the cell surface in a recycling pathway (Cotten et al., 1993). The endosome combines 
with Iysosomes and the ingested material is degraded by the Iysozymes. Degradation 
products may be released into the extracellular fluid by the process of exocytosis. 
Receptor-mediated endocytotic pathways differ according to the type of receptor-ligand 
pair. Low endosomal pH mayor may not trigger dissociation of the receptor and the 
ligand. In the case of transferrin, the iron loaded transferrin releases the iron at low 
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endosomal pH, while the apotransferrin remains bound to the receptor. Other ligands 
and receptors also dissociate under these conditions (Cotten et al., 1990). Endocytotic 
vesicles formed are usually transported to the lysosome, where the contents are 
degraded. The hydrolysis of the vector is a prerequisite for the endocytosed DNA to 
quickly reach the Iysosomes. Such a hydrolysis would take place in the endosomal 
compartment that contains peptidases (Berg et al., 1995). The asialoorosomucoid 
(AOM) endocytotic pathway is ultimately degradative, with the delivery of the ligand to 
the Iysosomes, early in the internalisation process (Tolleshaug et al., 1979). Hence 
effective delivery of DNA into cells via receptor-mediated endocytosis depends upon 
the escape of DNA from the endosome during transport (Lyerly, 1993). It has been 
proposed that pore formation in the endosome may be a possible mechanism of escape 
for the complexes or of free DNA into the cytoplasm (Simoes et al., 1999a). The DNA 
must finally enter the nucleus to ensure gene expression. 
It is presumed that lipoplexes bind non-specifically to cellular receptors that become 
clustered in coated regions and are internalized. Internalisation of ligand-receptor 
complexes are generally rapid (about one minute), but internalization of lipoplexes is a 
relatively slow process. This could be due to possible restraints placed on lipoplexes to 
enter coated vesicles. Hence the rate limiting step includes the rate of association of 
the receptors and the lipoplexes, and the extent to which these receptors can non-
































Figure 1.13: Receptor-mediated endocytosis of hormones, growth factors, ADM, 
transport proteins and low density lipoproteins (LDL). In the case of 
transferrin the iron is released, and both the ligand and the receptor are 
recycled to the cell surface. In the case of insulin, LDL and ADM, the 
ligand is delivered to the lysosome while the receptors are recycled to 
the cell surface. 
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1.5.2 Nuclear Uptake 
Ultimately, the DNA must be delivered to the nucleus for transcription of the transgene 
to take place. The mechanisms of DNA nuclear translocation are not fully understood 
but appear to depend on the type of delivery vehicle employed (Weithoff and Middaugh, 
2003). The efficiency with which the DNA is imported into the nucleus also depends on 
its size and conformation. Linear plasmid DNA seems to be translocated more efficiently 
into the nucleus than other conformations of plasmid DNA (Li and Ma, 2001). The 
nuclear membrane is a barrier that prevents the uptake of most macromolecules greater 
than 70 kDaltons into the nucleus, unless they are able to interact with the nuclear pore 
active transport system. The actual pore size in the nuclear membrane is about 55 A in 
diameter (Li and Ma, 2001). Poor access of plasmid DNA into the nucleus represents a 
major barrier to the success of non-viral gene therapy (Pouton and Seymour, 2001). 
Three possible routes for DNA transport into the nucleus have been proposed. The 
DNA can pass into the nucleus through the nuclear pores, it can become physically 
associated with chromatin during mitosis when the nuclear envelope breaks down, or it 
could traverse the nuclear envelope. The latter mechanism (or "route") seems to be the 
most widely accepted, but there exists little experimental support for this proposed route 
of entry (Weithoff and Midduagh, 2003). It is assumed that the crossing of large 
molecules across the nuclear membrane is facilitated by a nuclear pore complex (NPC), 
which is a supramolecular aggregate of about 124 megaDaltons. The NPC generally 
binds proteins that carry consensus basic amino acid sequences called nuclear 
localization signals (NLS) (Li and Ma, 2001). 
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1.6 TARGETING OF LlPOSOMES 
Of all the colloidal drug / gene carrier systems proposed for site-specific delivery, 
liposomes have attracted the most attention (Lasic, 1998). Liposomal gene delivery 
has often been regarded as being non-specific as liposomes do not posses specific 
receptors for attachment to and subsequent entry into target cells. Antibodies and 
several low molecular weight ligands have been used to target vectors to cell surface 
receptors. Adding a targeting ligand to the cationic lipid / DNA complexes via a covalent 
or non-covalent linkage can improve transfection efficiency. A targeting system may 
contain the liposome / DNA complex together with a ligand or an antibody conjugate, as 
was used by Trubetskoy et.al. (1992) (Figure 1.14). More specifically a monoclonal 
antibody against an epitope expressed on the lung endothelial cells was used. The 
antibody was covalently linked to the positively charged poly-L-Iysine which formed part 
of a ternary complex containing cationic liposomes and DNA (Figure 1.14). 
+ + 
Cationic 
+ liposome + ~l~ Ab-NPLL 
+++ +++ 
-c x • x • :> - DNA -+ 
+++ +++ 
lr+ + + + 
+ 
+ 
Figure 1.14: Ternary complex between antibody(Ab), N-poly-L-Iysine (NPLL), 
DNA and cationic liposomes .The DNA acts as an ionic bridge 
between the two cationic liposomes and modified antibodies. 
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Monoclonal antibodies have been the most widely used molecules for targeting 
liposomes as they have a high affinity and specificity for cell surface antigens against 
which they have been raised. Antibody-targeted liposomes are referred to as 
immunoliposomes, and have been used for selective drug delivery to cancer cells by 
targeting to tumour-associated antigens (Lopes de Menezes et a/., 1998). 
Hence the antibody or ligand can be targeted to a specific tissue, depending on the 
ability of the antibody or ligand to facilitate cell specific docking (Lee and Low, 1994). 
Protein conjugates are recognised by cell surface receptors and antibodies by 
histocompatability antigens (Mack et a/., 1994). By careful selection of the appropriate 
ligand-receptor interaction for liposome targeting, one may be able to enhance 
Iiposomal uptake by target cells. Targeted delivery systems would be of advantage in 
drug delivery and gene transfer as they would permit directed incorporation of selected 
macromolecules into a specific type of cell (Rosenberg et a/., 1987). 
The process of targeted delivery can be roughly divided into two phases viz. a transport 
phase where liposomes travel from the site of administration (in vivo) to the target cells, 
and the effector phase that includes the specific binding of liposomes to the target cells 
and the subsequent delivery of the bound genes or drugs (Mastrobattista et a/. , 1999). 
Selective localization of genes or drugs can be obtained using either "passive" or 
"active" targeting. "Passive" targeting refers to the natural localisation patterns of 
liposomes when introduced into the body. It is a process by which the physical 
properties of the Iiposomes together with the microanatomy of the target tissue 
determine gene or drug selective localization (Barenholz, 2001). Liposomes injected 
intravenously localise mostly in mononuclear phagocytes of the reticuloendothelial 
system in the liver, spleen, bone marrow and in monocytes. Hence liposomes can be 
targeted to these cells passively (Poste et a/., 1984). "Active" targeting on the other 
hand, requires in addition to reaching the diseased site in specific cells, tissues or 
organs, a homing device, such as receptor ligands, antibodies, etc. to be attached to the 
liposome surface so that the liposome may recognize specific 'diseased" cells and bind 
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to them (Barenholz, 2001). Once the DNA-protein-liposome complex reaches the target 
cell, it is internalised. The targeting of liposomes may be carried out in vivo and in vitro. 
Targeting to specific cell types in vitro poses fewer challenges than the more complex 
task of directing vectors to target tissues in vivo, although problems may arise in 
employing cell culture techniques. A mitotic cell population which has the capability to 
expand is a prerequisite (Hodgson, 1995). In vitro targeting provides the convenience of 
working with well characterised cells in culture and Iiposomes can be added directly to 
the desired target cells. These methods can hopefully be utilised eventually to develop 
methods to be used in vivo. 
Various naturally occurring ligands to cell surface receptors such as hormones, vitamins 
(folate), growth factors, transferrin and asialoorosomucoid have been employed. They 
offer some advantages over antibodies such as lack of immunogenicity and low 
preparation costs (Ishii et aI. , 1989). In a non-liposomal approach, asialoorosomucoid-
poly-L-Iysine-DNA conjugates were successfully delivered into asialoglycoprotein 
receptor-positive HepG2 cells (Wu and Wu, 1988). More recently a polycationic lipid 
(DOGS)-asialoorosomucoid-DNA ternary complex was effectively delivered to the same 
human hepatocyte derived cell line (Mack et al., 1994). Furthermore, cationised 
asialoorosomucoid, used in a ternary complex with novel cationic Iiposome 
formulations and DNA showed promising results in gene delivery to HepG2 cells in vitro 
(Singh et al., 2001 b; Singh and Ariatti, 2003). Targeting of 'Iipoplexes' (Tros de I1arduya 
and D(jzg(jne~, 2000), and 'polyplexes' (Ogris et al., 1999) to the transferrin receptor 
has also been attempted. 
Liposomes to which the epidermal growth factor (EGF) was covalently coupled were 
targeted to hepatocytes expressing the EGF receptor. Since many carcinoma cells 
show a high expression of EGF receptors, EGF-targeted liposomes would be useful for 
tumour targeting (Ishii et al., 1989). The folate targeted liposomes were found to bind 
specifically to cells that overexpress folate receptor. The folate receptor has been 
identified as an important surface marker in ovarian carcinomas (Lee and Low, 1995). 
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Folate receptor targeting has been found to enhance intracellular delivery of attached 
proteins, liposomes, viruses, antisense oligonucleotides, gene therapy vectors, 
polymeric drug carriers, imaging compounds, and neutron activation agents (Low and 
Antony, 2004). Targeting of cationic liposomes to specific target cells will be discussed 
in greater detail in chapters 3 and 4. 
1.7 LlPOSOMES AS DRUG CARRIERS 
Liposomes have steadily gained interest as potential carriers of drugs for certain 
diseases, especially for the chemotherapy of neoplastic diseases (Poste et al., 1984). 
The amphiphilic nature of liposomes, with the hydrophobic bilayer and the hydrophilic 
inner core, enable solubilisation or encapsulation of both hydrophobic and hydrophilic 
drugs. They are clinically the most developed of all drug carriers. Association of a drug 
with liposomes markedly alters the drug's distribution in the body and its pharmacology, 
which may be exploited to achieve targeted therapies (Chisti , 1999). Liposomes offer 
several attractive features as carriers for drugs and antigens: 
Solubilisation : Liposomes may solubilise lipophilic drugs that would otherwise be 
difficult to administer intravenously. 
Protection : Liposome-encapsulated drugs are inaccessible to metabolizing enzymes 
and most body components such as erythrocytes or tissues at the injection site are not 
directly exposed to the full dose of the drug. Liposomes can also protect the patient 
against possible side effects of the encapsulated drug. 
Duration of action: Liposomes can prolong drug action by slowly releasing the drug in 
the body. 
Directing potential: Targeting options change the distribution of the drug over the body. 
Intemalisation : Liposomes are generally endocytosed or phagocytosed by cells, 
opening up opportunities to use "Iiposome-dependent drugs'. Lipid based structures 
(non-viral) can also be utilized in this way. 
Amplification: Liposomes can be used as adjuvants in vaccine formulations. 
(Storm and Crommelin, 1998). 
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The main applications of liposomes in drug delivery technology is in passive tumour 
targeting, as vaccine adjuvants, passive targeting to lung endothelium, targeting to 
regional lymph nodes, and targeting to cell surface ligands in various organs or sites of 
pathology (Uchegbu, 1999). Most of the interest in liposomes as drug delivery vehicles 
stems from the potential to target these liposomes to specific cell types or organs by the 
incorporation of ligands into the surface membrane that could selectively bind to cell 
surface determinants on the desired target cells (Poste et al., 1984). This will reduce 
the possibility of harmful side effects due to the minimized distribution of the drug to 
non-targeted tissues. Furthermore they are able to deliver high concentrations of the 
desired drug. Folate receptor-targeting is being exploited for the delivery of drugs for 
the treatment of cancer and some inflammatory diseases (Low and Antony, 2004; Lu et 
al., 2004) such as rheumatoid arthritis where activated macro phages show an elevated 
level of folate receptor expression (Paulos et al., 2004). 
Cationic liposomes themselves can act as antimicrobial agents causing death of 
bacteria and fungi at concentrations that barely affect mammalian cells in culture. In 
addition, they are thought to be excellent solubilisers for hydrophobic drugs. 
Amphotericin B was effectively solubilised by the cationic liposome synthesized from 
dioctadecyldimethylammonium bromide (DODAB) (Carmona-Ribeiro, 2000). Liposomal 
amphotericin B (Ambisome) was the first liposomal preparation to be licensed for clinical 
use in the treatment of systemic fungal infections. Anticancer drugs that usually 
produce toxic side effects have been encapsulated within liposomes for tumour 
targeting. The use of liposomes in drug delivery was originally hampered by the fact 
that they were rapidly cleared from the circulation and mostly taken up by liver and 
spleen macrophages (reticuloendothelial system). The production of liposome surface 
ligands and "stealth" liposomes have reduced the uptake of liposomes by macro phages 
and increased their circulation time (Uchegbu, 1999). 
41 
1.8 OUTLINE OF THESIS 
Currently viral based gene delivery systems are the most widely used in clinical gene 
therapy approaches. Patient safety will be of paramount importance and this is where 
viral systems may be disadvantaged, since they have the problem of immune 
responses of the host against viral proteins. Non-viral methods of gene delivery are 
beginning to emerge as more attractive alternatives since they are considered much 
safer. However, poor delivery and lack of sustained gene expression are generally the 
drawbacks associated with non-viral vectors. This thesis attempts to address the issue 
of delivery of genes in vitro using novel cationic liposome systems that show promise 
and that may be considered for further development. 
The aim of this research is to prepare new and untested cholesteryl derivatives for 
incorporation into liposomes and to determine their transfection capabilities in a variety 
of cell lines. Thus three cationic, two biotinyl and four glycosyl derivatives were 
synthesized for evaluation in various phases of this project. 
Chapter two focuses on the the synthesis and analyses of three cationic cholesterol 
derivatives, their formulation into liposomes, and a study of their effectiveness as gene 
transfer vectors in four cell lines viz. human cervical carcinoma (HeLa) cells, mouse 
fibroblast (NIH-3T3) cells, human esophageal cancer (SNO) cells and hepatocellular 
carcinoma (HepG2) cells. Results obtained were compared with a commercially 
available cationic liposome formulation. The final results obtained were encouraging 
and the most efficient liposome preparation was utilized in the development of the 
targeting systems that are discussed in chapters three and four. 
Chapter three deals with the targeting of biotinylated cationic liposomes to the 
transferrin receptor on HeLa cells using iron-loaded transferrin bound to a biotin-
streptavidin complex. 
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In chapter four the targeting of lipoplexes to the asialoglycoprotein receptor is explored. 
Thus a and ~ anomers of both galactopyranosyl cholesterol and glucopyranosyl 
cholesterol were prepared and separately incorporated into cationic liposomes. 
Glycosylated lipoplexes were then evaluated for receptor-specific uptake into HepG2 
cells in vitro. 
Various aspects of the liposome formulations were studied. These include aspects of 
lipoplex formation and characterisation, liposome toxicity to cells, and finally transfection 
activity. The gene expression levels of the cationic liposome mediated transfections 
were assessed using the luciferase reporter gene assay in a transient expression 
system. The targeting systems designed and examined in vitro during the course of this 
study are of potential interest as transferrin receptor expression is elevated in certain 




PREPARATION OF NOVEL CATIONIC LlPOSOME FORMULATIONS AND THEIR 
EFFICIENCY AS LlPOSOMAL GENE DELIVERY VEHICLES IN VITRO 
2.1 INTRODUCTION 
Most of the cationic compounds intended for liposome preparations are either those that 
possess cholesterol as an anchor lipid ego DC-CHOL and CHOL-T, or those that 
possess double acyl chains of varying lengths and variable hydrocarbon saturation, as 
anchors ego DOTMA and DOSPER (refer to chapter one). The selection of the 
appropriate lipid anchor is of great importance as it was found that headgroups attached 
to cholesterol anchors were generally more active than those linked to diacyl chains 
(Marshall et al., 1999). The liposomes discussed in this chapter are all cholesterol 
anchor based. 
This chapter focuses on the synthesis of three different and untested cationic 
cholesterol derivatives N,N-dimethylaminopropylaminylsuccinylcholesterylformyl-
hydrazide (MS09), glycylcholesterylformylhydrazide (MS 10), p-alanylcholesteryl-
formylhydrazide (MS11) that were formulated to produce three unique cationic 
liposomes. All cationic cholesterol derivatives were analysed and formulated in a 1:1 
ratio with dioleoylphosphatidylethanolamine (DOPE) as the helper lipid. Liposome 
characterization was achieved using transmission electron microscopy (TEM). Lipoplex 
formation was analysed using gel retardation studies, nuclease digestion experiments, 
dye displacement assays and TEM. All three liposomes were assessed for cytotoxicity 
and transfection efficiency on four different cell lines, viz. HeLa, NIH-3T3, SNO, and 
HepG2 cell lines. The pGL3 plasmid DNA was complexed to each cationic liposome in 
different ratios respectively and introduced to the cells. Transfections were assayed 
using the Luciferase assay system. 
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2.1.1 Liposome Composition 
The composition of lipid bilayers can be manipulated to influence the physicochemical 
characteristics of the liposomes, ego surface charge, sensitivity to pH change, and 
bilayer rigidity (Gregoriadis, 1995). Most cationic liposomes are composed of a neutral 
lipid and a cationic lipid. The most frequently used "helper" lipids in cationic 
liposome formulations are the neutral lipids, dioleoylphosphatidylcholine (DOPC), 
dioleoylphosphatidylethanolamine (DOPE) and cholesterol (Figure 2.1). The role of 
"helper" lipids was shown to be critical for gene delivery (Campbell et al., 2001). 
Cholesterol is often added to improve mechanical stability of the bilayer and to 
decrease leakage of any encapsulated material (Lasic, 1997). It was also found to be 
associated with increased stability of cationic lipid:DNA complexes in serum, better than 
DOPE (Crook et al., 1998). Furthermore Sakurai et.al. (2001) observed that complexes 
were stabilized against fusion with red blood cells when administered intravenously. 
Both helper lipids DOPE and cholesterol can significantly increase the resistance of the 
formulated complexes to polyanion mediated disassembly (Wiethoff et al., 2001). Hence 
addition of 'helper' lipids such as DOPE to cationic liposomes tends to destabilize the 
cationic liposome (Farhood et al., 1995), and can further increase their transfection 
efficiency (Smutzer, 2000). It is proposed that in those cases where DOPE improves 
transfection, it may do so by acting as an emulsifier, facilitating the dispersion of the 
lipid so that more of it becomes capable of interacting with the plasmid DNA 
(Rakhmanova et al., 2000). The use of DOPE as the colipid (50 mol %) with cationic 
lipid resulted in a 2-5 fold increase in the transfection activity compared to formulations 
containing the same mole percentage of dioleoylphosphatidylcholine (DOPC) or those 
without any neutral lipid (Feigner et al., 1994). 
The use of PE in liposome preparations facilitates membrane fusion unlike the use of 
phosphatidylcholine (PC) that was found to inhibit fusion (DOzgOne~ and Nir, 1999). PE 
and PC are both zwitterionic phospholipids. Phosphatidylethanolamine (PE) has a 
minimally hydrated and small head group that occupies a lower volume compared to 
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the respective hydrocarbon chains, exhibiting a cone shape which favours strong 
intermolecular interactions between the amine and phosphate groups of the polar 
headgroups (Simoes et al., 2004). PE is unable to form stable bilayer vesicles at 
neutral pH in physiological saline, and it undergoes a phase transition to an inverted 
bilayer hexagonal (Hn) phase (Farhood et al., 1995), above the phase transition 
temperature (TH), which for DOPE is 10°C (Simoes et al., 2004). This phase transition is 
an important factor in cellular delivery of nucleic acids and promotes fusion between 
liposome:plasmid DNA complexes and cell membranes such as the endosomal 
membrane. This also assists in the improved transfer of internalised cationic 
liposome:DNA complexes from the endocytotic cellular compartments into the cell 
cytoplasm (Farhood et al., 1995). 
PC, however, forms stable bilayer vesicles in physiological saline. For DNA transfection 
PC is generally less efficient than PE because of the reduced tendency to undergo the 
structural transition important for DNA delivery. PC liposomes are generally more 
suitable for entrapping and delivering therapeutic agents (Campbell et al., 2001). 
Nevertheless, high levels of stable transfection were achieved in human cervical 
carcinoma cells (HeLa), using unilamellar liposomes prepared from lipids, 
phosphatidylcholine (PC), phosphatidylglycerol (PG), and cholesterol together with a 
cationic cholesterol derivative, N,N-dimethylaminopropylaminylsuccinylcholesterol. 
(Singh et al., 2001a). 
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Figure 2.1: Neutral lipids commonly used as 'helper' lipids in gene transfection. 
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2.1.2 Liposome Preparation 
There are various methods that have been employed over the years in the preparation 
of liposomes. The common step in all these methods entails evaporating the organic 
solvent in which the lipids are generally dissolved and / or stored. Cholesterol and 
charged lipids are often added to the composition of liposomes. Phospholipids are 
characterised by a phase transition temperature (Tc) that permits membrane transition 
from a so-called crystal liquid to a gel state. In the gel state, liposomal membranes 
become fluid as a result of phase transition. Tc increases with increasing acyl chain 
length and is greater for saturated phospholipids. 
Cationic liposomes used for gene delivery generally contain the phospholipid, 
dioleoylphosphatidylethanolamine (DOPE) as the neutral lipid, and a cationic lipid as is 
the case in this study. The dried lipids are then dispersed in an aqueous buffer solution. 
It is predicted that the furthest distance between two opposing lipids in the liposome 
bilayer is about 6 nm, depending on ionic activity of the aqueous solvent (Smith et al., 
1993). The preparation methods for liposomes differ in the way the lipids are dispersed. 
Some of these methods can be classified as follows: 
i) The original hand shaken preparation producing multilamellar vesicles 
(Bangham et al., 1965). 
ii) Small unilamellar vesicles prepared by sonication (Papahadjopoulos and 
Miller, 1967; Chapman, 1984). 
iii) The ethanol injection technique (Batzri and Korn, 1973 ; Campbell, 1995). 
iv) Gel filtration of micelles (Brunner et al., 1976). 
v) Ether infusion technique that produces large unilamellar vesicles 
(Daemer and Bangham, 1976). 
vi) Reverse phase evaporation technique (Szoka and Papahadjopoulos, 1978). 
vii) Thin lipid film hydration (Gao and Huang, 1991). 
The latter method was adapted for the preparation of the cationic liposomes used in this 
study. 
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2.1.3 Preparation of Liposome:DNA Transfection Complexes 
Emerging from the extensive search for versatile DNA carriers, are complexes formed 
between DNA and cationic liposomes, that promise to be viable alternatives to the 
predominantly viral vectors. However little is known about the exact structure and 
properties of such complexes. In this chapter the preparation of three different 
complexes of this type and an evaluation of their transfection capabilities in various cell 
lines is reported. Complexes were prepared with cationic liposomes N,N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide (MS09), glycyl-
cholesterylformylhydrazide (MS1 0), ~-alanylcholesterylformylhydrazide (MS11), and 
pGL3 DNA respectively. The Iiposome:DNA complexes were subjected to gel 
retardation assays to determine optimum binding ratios and their ultrastructure was 
visualized by transmission electron microscopy. 
The exact mechanism of cationic liposome-DNA interaction , and the structure of such 
complexes are still not fully understood. The DNA binds to the surface of cationic 
liposomes, but size and shapes are maintained (Feigner and Ringold, 1989). Complete 
complexation is achieved by simply mixing and incubating the cationic liposomes and 
DNA (Feigner et al., 1987). Liposomes are dynamic in nature, and are able to interact 
or associate in different conformations depending upon size, charge, and conditions of 
formation (Smith et al., 1993). When forming a complex with DNA, a profound structural 
rearrangement of the liposome structure occurs (Birchall et al., 1999). 
The positively charged lipid complex reacts with the negatively charged phosphate 
groups of the DNA resulting in formation of the liposome:DNA complex. It is unlikely that 
all the negative and positive charges are involved in ionic interactions because both the 
supercoiled DNA and the liposomes are bulky enough to produce steric hindrance 
preventing close contact to each other (Farhood et al., 1992). Short alkyl chains of 
Iiposomes and complex polar headgroups with quaternary and primary amino groups, 
could impart physical properties to the DNAliposome complex, resulting in maximum 
DNAliposome interaction, and lipid:DNA packing (Wheeler et al., 1996). It is proposed 
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that the ability of a cationic lipid or liposome to rapidly wrap and condense plasmid 
DNA, in conjunction with the facilitation of DNA release from a lipoplex by DOPE, allows 
for efficient lipoplex-mediated gene transfer (Zuhorn et al. , 2002). 
The use of fluorescence, gel electrophoresis, and electron microscopy techniques have 
helped to elucidate the structural features of the resulting complexes. There are 
currently three models of DNA:liposome interactions which either situate the DNA on 
the external or internal surface of the liposome. These models generally apply to 
unilamellar liposomes but could be extended to multi lamellar liposomes as well. The 
internal model essentially describes the entrapment of DNA within the liposome. The 
other two models viz. the electrostatic model and the coated electrostatic model involve 
cationic liposome:DNA interaction and will be discussed further, since all studies are 
based on cationic liposome:DNA binding. 
The electrostatic model is based on the probability that electrostatic forces underlie the 
successful interaction between cationic lipids and DNA, and also assist the entry of the 
complex into the cell. This type of model has been proposed by Feigner and Ringold in 
1989 for the commercially available liposome formulation, Lipofectin™ [DOTMA:DOPE 
(1:1)]. Their model proposed that the plasmid DNA interacts with the cationic liposome 
such that one plasmid molecule is trapped in the interior of a complex of four liposomes 
(Figure 2.2). 
According to this model the cationic liposomes approach opposite sides of the anionic 
DNA strand and fuse with each other. The final arrangement of the lipoplex involves the 
coating of the DNA strand with a single lipid bilayer. It is assumed that these liposomes 
have an average diameter of 250 nm and would hence each contain 2500 lipid 
molecules, half (1250) of which are positively charged (DOTMA). For a standard 2500 
base pair plasmid, approximately 5000 negative charges will be available. Hence to 
totally neutralize the positive charges on the cationic liposome (1250), requires four 
liposomes . Although four liposomes may interact with one plasmid , very little of the 
evenly distributed lipid charges would be utilised, and the size of the plasmid could bring 
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the four liposomes into close proximity, so that they would repel each other and may 
dissociate from the DNA. This model fails to consider the possibilities of charge 
localization, sharing of charges between inner and outer lipid layers, and the structural 
differences between linear and supercoiled plasmid DNA (Smith et al., 1993). 
+ Cationic liposomes +0 + + + ++ ++ ++~: 
+ 
-c ____ x::-____ :x: ____ X::-____ => - DNA 
+ + 
++0++ ++0+ + + + + + Cationic liposomes 
Figure 2.2 The electrostatic model of lipid-DNA complexes proposed by Feigner 
and Ringold, 1989. 
Boles et al., 1990, proposed that the supercoiled plasmid, assumes a branched 
plectonemic form with a superhelix axis length of about 41 % of the total DNA length 
(Figure 2.3). The four branches of the DNA protrude from the corners of a central core 
branch, and are each of equal length. This structure may be conducive to DNA-
liposome complex formation, consisting of several liposomes clustered like grapes 
around compacted, branched DNA molecules. Such structures have been visualized by 
transmission electron microscopy in studies of the ultrastructure of lipoplexes. 
These structures are common for DNA at both high and low levels of supercoiling. It is 
assumed that for a 2500 base pair plasmid, there exists a structure with four branches 
51 
at an average of 70 nm in length and 5 nm in diameter and a central "trunk" of similar 
length and diameter from which they protrude. 
Cationic 
Liposome 
Figure 2.3 Model depicting interaction between the supercoiled plasmid DNA and 
the cationic liposome as proposed by Boles et al., 1990. 
In the coated electrostatic model, DNA is coated by continuous lipid bilayers due to the 
DNA being entrapped between lipid bilayers during liposome fusion that draws bilayers 
together. An electron microscopy study by Gershon et al., 1993, suggested that cationic 
liposomes are attached like beads on a string, gradually covering the DNA chain until at 
a specific lipid to DNA ratio, a complete lipid coating is reached, composed of a 
multilayer of liposomes. At a critical liposome density two processes occur, viz. DNA 
induced membrane fusion, and liposome induced DNA collapse. The lipid coating 
seems to protect the DNA and this should enhance the uptake by recipient cells. 
Using freeze fracture electron microscopy, it was shown that DNA:liposome structures 
formed often resembled tubular "spaghetti-like" structures. The diameter of these 
tubular structures is approximately 7 nm (Sternberg et al., 1994). The ratio of DNA to 
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cationic liposomes determines the net surface charge on the complex. This will alter the 
interaction of the complex with other ligands, such as asialoorosomucoid and 
transferrin and further alter its ability to bind and enter cells in vivo (Zhu et al., 1993). 
A mixed model can also be proposed where the DNA is bound both on the inside and 
on the outside of the liposomes. In the case of cationic liposomes it is assumed that the 
DNA will prefer those regions of the liposome bilayer that contain the greatest positive 
charge or it will draw these charges together. Since DNA is added after formation of 
cationic liposomes, the continuous lipid bilayer must become transiently discontinuous 
to allow entry of the DNA. This could occur by membrane fusion via the formation of an 
inverted cylinder or inverted micellar intermediate. DNA seems to be capable of acting 
as a fusogenic agent in the presence of cationic liposomes (Smith et al., 1993). 
2.1.4. Tissue Culture and Transfection 
Transfection in eukaryotic cells is a powerful tool in cell biology. A major focus is on the 
improvement of methods for the introduction of DNA into appropriate cells, and also on 
the quality of DNA used which is also significant in transfection efficiency. Gene transfer 
methods include in vitro and in vivo gene delivery. Using in vitro gene transfer, 
appropriate cell lines can be targeted. Transfected cells can be selected and 
expression of the transgene monitored. A limited degree of success has been achieved 
using intra-peritoneal, intra-arterial, intra-hepatic, intra-muscular, and intra-tracheal 
routes using physical or viral methods (Lyerly, 1993 ; Li and Ma, 2001). 
The aim of this study was to develop synthetic gene transfer systems based on cationic 
liposome mediated transfection, that could be subsequently utilized for targeting to a 
specific cell type. Liposome mediated transfection is regarded as being a reliable and 
reproducible technique for gene transfer (Stamatatos et al., 1988). Conventional 
cationic liposomes as prepared in this chapter have no cell-specific targeting 
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properties, and may be elaborated by addition of a targeting component for targeted 
in vivo gene transfer applications. The pGL3 plasmid DNA is used to detect transient 
expression of the luciferase gene (Iuc+) in mammalian cells grown in culture, since 
these cells lack endogenous luciferase activity. The intensity of luciferase activity will be 
a measure of the success with which gene transfer has been effected. 
The use of vectors in transfection allows considerable flexibility in regulating the 
expression of cloned genes. Various plasmid vectors have been constructed and 
contain characteristics which render them amenable for gene cloning. A common 
feature of all plasmid based vectors is the presence of a prokaryotic replication origin 
(replicon) , and a selectable marker gene to permit the recombinant DNA molecule to be 
amplified in E.co/i. Most vectors have in addition a eukaryotic replication origin or a 
eukaryotic selectable marker. This latter feature is required for stable expression. The 
eukaryotic replication origin is usually derived from viruses such as bovine papilloma 
virus (BPV), Simian virus 40 (SV40), or Epstein Barr virus (EBV) (Murray, 1993). 
Transfection of eukaryotic cells with reporter gene constructs have been widely used. 
The reporter gene encodes a reporter enzyme that is used in detection of gene 
expression. The most popular reporter enzymes are chloramphenicol acteyltransferase 
(CAT), B-galactosidase (B-Gal), and luciferase, which accumulate in the cytoplasm 
during experimental gene expression. The detection of luciferase activity is thought to 
be more sensitive than assaying for the chloramphenicol acetyltransferase expression. 
In addition the green fluorescent protein has been used in many gene expression 
studies (Blum et a/., 2004). 
The pGL3 DNA vector, incorporating the firefly luciferase gene, /uc+, was used in this 
study as the expression vector. The luciferase that was isolated from the North 
American firefly Photinus pyra/is is one of the most extensively studied enzymes that 
catalyse light production in bioluminescent organisms. It has a molecular weight of 
approximately 62 000 daltons (Wood et a/., 1985), and it requires luciferin, ATP, and 
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oxygen as substrates. The structure of firefly luciferin (Figure 2.4) has been determined 






Figure 2.4: Structure of firefly D-( -)-Luciferin 
The luciferase gene is a single copy gene in firefly P. pyralis. It is composed of seven 
exons separated by six very short introns ranging from 48 to 58 bases in length. The 
nucleotide sequence of the six introns was also determined from analysis of cDNA and 
genomic clones (De Wet et al., 1987), (Figure 2.5). The structure and restriction map of 
the pGL3 plasmid DNA can be seen in Figure 2.6. 
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INTRON 1 (58 bp) TTGCTTTT GTGAGTATTTCTGTCTGATTTCTTTCGAGTTAACGAAATGTTCTTATGTTTCTTTAG ACAGATGC 
177 10 20 30 40 50 178 
INTRON 2 (51 bp) TAATGAAC GTAAGCACCCTCGCCATCAGACCAAAGGAATGACGTATTTAATTTTTAAG GTGAATTG 
385 10 20 30 40 50 386 
INTRON 3 (48bp) CATGCAAG GTATGTCGTATAACAAGAGATTAAGTAATGTTGCTACACACATTGTAG AGATCCTA 
719 10 20 30 40 720 
INTRON 4 (49bp) GCAAAACG GTGAGTTAAGCGCATTGCTAGTATTTCAAGGCTCTAAAACGGCGCGTAG CTTCCATC 
1040 10 20 30 40 1041 
INTRON 5 (43bp) GATATCAG GTAATGAAGATTTTTACATGCACACACGCTACAATACCTGTAG GTGGCCCC 
1395 10 20 30 40 1396 
INTRON 5 (47bp) CGTCGCCA GTAAATGAATTCGTTTTACGTTACTCGTACTACAATTCTTTTCATAG GTCAAGTA 
1561 10 20 30 40 1562 
Figure 2.5: Structure of the P. pyralis luciferase gene. The luciferase gene exons 
appear as open boxes and the introns as shaded boxes. Restriction 
sites are abbreviated as Ps = Pst 1 1 Sp = Ssp 1 1 Xb = Xba 1 1 
R1 =EcoR 1 1 Bs=Bsm 1 1 and RV=EcoR V. The nucleotide sequence 
of the six introns are indicated above. 
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Many expression vectors are derivatives of pSV2, an SV40 early-region promoter 
vector (Subramani and Southern, 1983), and contain the SV40 small T antigen intron, 
and an SV40 polyadenylation signal. The pGL3 control vector contains SV40 promoter 
and enhancer sequences resulting in strong expression of luc+ in many types of 
mammalian cells. All pGL3 vectors contain a high copy number prokaryotic origin of 
replication for maintenance in E. coli, an ampicillin-resistance gene (Ampr ) for 
selection, and a filamentous phage origin of replication (f1 ori) for single stranded DNA 
(ssDNA) production. Restriction sites for insertion of DNA fragments are located 
upstream and downstream of the luciferase gene (Iuc+). Two of the upstream sites 
(Xho 1 and 8g/11 ) yield cohesive ends compatible with the downstream sites (Sail and 
8amH I ) respectively, allowing for interchange of DNA inserts (Promega Technical 
Manual). 
The luciferase gene is one of the most versatile reporter genes. Monitoring promoter 
activity using firefly luciferase has been described for cultured animal cells (Gould and 
Subramani, 1988 ; Brasier et al., 1988), bacteria (Wolk et al., 1991), insects and yeasts 
(Aflalo, 1990). Besides firefly luciferase, various other luciferases of eukaryotic and 
prokaryotic origin have been employed using different substrates and reaction 
conditions. 
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2.2. MATERIALS AND METHODS 
2.2.1 MATERIALS FOR CHEMICAL SYNTHESIS 
Cholesterylchloroformate, N-hydroxysuccinimide (NHS), dimethylaminopropylamine, N-
trityl glycine, ~-alanine, trityl chloride, dicyclohexylcarbodiimide (DCCI) and succinic 
anhydride were obtained from Sigma-Aldrich (St.Louis, MO, USA). Hydrazine, 
chloroform, methanol, pyridine, dimethylformamide (DMF), ethanol, ethyl acetate, 
sulphuric acid, diethylamine, ether, propan-2-ol, and Silica gel 60F254 chromatography 
plates were all purchased from Merck (Darmstadt, Germany). All other reagents used 
were of analytical grade. Infrared (IR) spectra were recorded with a Nicolet Impact 420 
spectrophotometer using the KBr disc technique (0.5% dilution). NMR spectra were 
obtained on a Gemini 300 instrument. Electrospray mass spectra were recorded on a 
Waters APIQ-TOF Ultima instrument (ES-TOF). 
Solvent system A = chloroform: methanol (9:1 v/v) 
Solvent system B = chloroform: methanol (9.5:0.5 v/v) 
2.2.2 SYNTHESIS OF CATIONIC CHOLESTEROL DERIVATIVE: 
N,N-DIMETHYLAMINOPROPYLAMINYLSUCCINYLCHOLESTERYL-
FORMYLHYDRAZIDE (MS09) 
The synthesis of N, N-d imethylaminopropylaminylsuccinylcholesterylformylhyd razide 
(MS09), was achieved in four steps, the initial step being the preparation of 
cholestrylformylhydrazide. (Figure 2.7). 
2.2.2.1 Preparation of Cholesterylformylhydrazide (MS04) 
Cholesterylchloroformate (1.13 g, 2.5 mmoles) was dissolved in 5 ml chloroform and the 
resultant solution was chilled to O°C. Hydrazine (240 mg, 7.5 mmoles) was added to 
about 3 ml chloroform and sufficient methanol (approximately 0.6 ml) was introduced to 
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ensure complete dissolution. This solution was also chilled to O°C. The chilled 
chloroformate solution was then added dropwise, with continual stirring, to the solution 
of hydrazine. The resultant milky solution was kept at room temperature overnight. The 
reaction was monitored by thin layer chromatography (TLC) using silica gel 60 F254 
chromatography plates, and solvent system A. Cholesterol containing compounds were 
visualised using a 33% sulphuric acid spray. The reaction mixture was concentrated in 
vacuo at 3rC to produce a crystalline mass. The product was recrystallised from 
methanol (100 ml) and chloroform (25 ml). The resultant crystals were filtered under 
vacuum and dried overnight under vacuum using a Xerotec Freeze Drier. Product 
produced a single spot by TLC (Rf 0.79, solvent A) with a mp of 225-227 °C and a 
yield of 917 mg (83%). 
IR (film): 3416 (b, N-H), 2929 (st, C-H), 1731 (m, C=O), 1495 (m, C=C). (Appendix 2C). 
1H NMR (300 MHz, DMSO d6) : 8 0.66 (s, 3H, C-CH3 ), 0.86 (d, 6H, CH-CH3 ), 0.91 (d, 
3H, CH-CH3 ), 0.99 (s, 3H, C-CH3 ), 3.88 (bs, 2H, NH2 ), 4.38 (m, 1 H, Chol-H3a ), 5.33 
(d, 1 H, Chol-H6 ), 7.93 (s, 1 H, NH ) ppm. (Appendix 1 C). 
MS,m/z, ES-TOF : 445.4358 [M + H+], 467.3932[M + Na+]. 
2.2.2.2 Preparation of Cholesterylformylhydrazide Hemisuccinate (MS08) 
Cholesterylformylhydrazide (89 mg, 0.2 mmoles) and succinic anhydride (20 mg, 0.2 
mmoles) were dissolved in 2 ml DMF:pyridine (1:1 v/v). The reaction mixture was 
maintained at room temperature overnight. The reaction was monitored by TLC in 
solvent system A. The reaction mixture was evaporated to dryness under reduced 
pressure in a Buchi Rotavapor-R, to produce a thin white film on the walls of the flask. 
Ethanol (3 ml) was added to the flask and the product crystallized out as fine white 
crystals. The crystalline suspension was heated to induce the crystals to redissolve in 
the ethanol. Thereafter they were left to recrystallise at 4°C in the refrigerator. Crystals 
were filtered and dried overnight using a Buchi TO-50 pistol drier. The product gave a 
single spot by TLC (Rf 0.21, solvent A) with a mp of 195-196 °C and a yield of 58 mg 
(53%). 
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IR (film) : 3452 (b, N-H), 2934 (m, C-H), 1675 (m, C=O), 1567 (w, C=C). (Appendix 2G). 
1H NMR (300 MHz, DMSO d6) : 8 0.64 (s, 3H, C-CH3 ), 0.83 (d, 6H, CH-CH3 ), 
0.89 (d, 3H, CH-CH3), 0.96 (s, 3H, C-CH3), 4.3 (m, 1 H, Chol-H3a), 5.34 (d, 1 H, Chol-
H6 ) ppm. (Appendix 1 D). 
MS, m/z, ES-TOF: 545.09 [M + H+] , 567.63 [M + Na+]. 
2.2.2.3 Preparation of N-hydroxysuccinimide Cholesterylformylhydrazide 
Hemisuccinate 
Cholesterylformylhydrazide hemisuccinate (82 mg, 0.15 mmoles), DCCI (62 mg, 0.3 
mmoles) and N-hydroxysuccinimide (NHS) (35 mg, 0.3 mmoles) were dissolved in 
DMF (1 ml). The reaction mixture was maintained at room temperature and the product 
monitored by TLC as described above. Complete reaction was detected after 48 hours. 
The dicyclohexylurea crystals (53 mg) were filtered off under vacuum and washed with 
DMF. The filtrate was reduced under vacuum in a rotary evaporator to a thin white film 
on the walls of the flask. The product was extracted using a CHCI3: H20 (1:1) mixture. 
The water layer was removed as it contained the water soluble NHS. The chloroform 
layer containing the product was treated with anhydrous Na2S04 to absorb any excess 
water. This was kept overnight at room temperature. 
The chloroform extract was carefully removed and evaporated to dryness in a rotary 
evaporator. To the dried product was added petroleum ether (60-aO°C, 10 ml), to 
dissolve any carbodiimide present. This was kept overnight at room temperature. The 
ether was then carefully removed using a Pasteur pipette and the product was dried 
using a rotary evaporator. The final product was recrystallised from ethanol and dried 
under vacuum in the Xerotec Freeze Drier. The product produced a single spot by TLC 
(Rf 0.93, solvent A) and a yield of 53 mg (55%). 
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2.2.2.4 Preparation of N,N-dimethylaminopropylaminylsuccinyl-
cholesterylformylhydrazide (MS09) 
To the N-hydroxysuccinimide ester of cholesterylformylhydrazide hemisuccinate 
(53 mg, 0.083 mmoles) was added dimethylaminopropylamine (36 mg, 0.35 mmoles), in 
H20:pyridine (3:7 v/v ; 0.5 ml). To obtain a homogeneous solution, however, H20:DMF 
(1:1 v/v; 1 ml) was added. The reaction mixture was maintained at room temperature 
and monitored by TLC in solvent system B, until the reaction had reached completion. 
The reaction mixture was applied to four 10 x 20 cm silica gel 60 F254 TLC plates which 
were developed in solvent system B. The product band was scraped off the plate and 
placed in a mixture of CHCb : CH30H (1:1 v/v ) to extract the product. The mixture was 
filtered using a small glass funnel, to remove the silica gel residue. The filtrate was 
evaporated to dryness in the rotary evaporator and dried in a Xerotec Freeze Drier. The 
product produced a single spot by TLC (Rf 0.16, solvent A) and gave a mp of 
155-156 °C with a yield of 20 mg (38%). 
IR (film) : 3441 (b, N-H), 2945 (m, C-H), 1634 (m, C=O), 1557 (w, C=C). (Appendix 2H). 
1H NMR (300 MHz, CDCb) : 80.65 (s, 3H, C-CH3), 0.84 (d, 6H, CH-CH3 ), 0.88 (d, 3H, 
CH-CH3 ), 0.98 (s, 3H, C-CH3 ), 2.26 (s, 6H, N-CH3 ),3.28 (q, -CH2 -CH2 -NH -), 4.48 
(m, 1 H, Chol-H3a ), 5.35 (bs, 1 H, Chol-H6) ppm. (Appendix 1 E). 
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N-HYDROXYSUCCINIMIDE ESTER OF CHOLESTERYLFORMYLHYDRAZIDE HEMISUCCINATE 
N,N-DIMETHYLAMINOPROPYLAMINYLSUCCINYLCHOLESTERYLFORMYLHYDRAZIDE (MS09) 
Figure 2.7: Scheme for the synthesis of N,N-dimethylaminopropylaminylsuccinyl-
cholesterylformylhydrazide (MS09) 
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2.2.3 SYNTHESIS OF CATIONIC CHOLESTEROL DERIVATIVE: 
GL YCYLCHOLESTERYLFORMYLHYDRAZIDE 
This synthesis was achieved in three steps (Figure 2.8). 
2.2.3.1 Preparation of N-tritylglycine NHS ester (MS07) 
N-tritylglycine (635 mg, 2 mmoles) was dissolved in DMF (2 ml). To this was added 
NHS (230 mg, 2 mmoles). Thereafter a solution of DCCI (433 mg. 2.1 mmoles) in DMF 
(2 ml) was added dropwise to the above reaction mixture. The mixture was then left in 
the dark for 24 hours. The reaction was monitored by TLC using the silica gel 60F254 
chromatography plates and solvent system A. The plates were sprayed with a 2% (w/w) 
HCI04 solution for the detection of the trityl group. After 24 hours, the reaction mixture 
was filtered under vacuum. The dicyclohexylurea crystals on the filter paper were 
discarded and the filtrate containing the product was evaporated to dryness using the 
rotary evaporator. This removed the DMF from the filtrate. The product was crystallized 
from ethanol. After crystallization most of the ethanol was removed using a Pasteur 
pipette. prior to rotary evaporation of the product to remove any further traces of 
ethanol. The resultant crystals were finally dried under vacuum in the Xerotec Freeze 
Drier overnight. The product was subjected to TLC in solvent system A. . NHS and 
NHS containing compounds were detected by viewing the TLC plate under UV254 
illumination. The trityl group was detected by using a 2% (w/w) HCI04 spray, and on a 
separate TLC plate the final product (active ester) was viewed using an active ester 
spray [14% (w/v) hydroxylamine hydrochloride, 3.5 M NaOH (20:8.5 v/v), which was 
sprayed first followed by a spray of FeCI3 in 1.2 M HCI (5% w/v)]. The single spot on the 
chromatograms was UV254 absorbing, trityl positive, and found to be an active ester 
confirming its structure. Rf 0.93, mp 126-128 °C ,yield 630 mg (76%). 
IR (film) : 3436 (b, N-H), 2929 (w, C-H), 1731 (s, C=O), 1060 (m, C-O). (Appendix 2F). 
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2.2.3.2 Preparation of N-tritylglycylcholesterylformylhydrazide (MS01) 
Cholesterylformylhydrazide (44.2 mg, 0.1 mmoles) and N-tritylglycine NHS ester (41.4 
mg, 0.1 mmoles) were dissolved in a mixture of DMF: pyridine (1:1 v/v) , in a total 
volume of 800 IJI. The reaction mixture was kept at room temperature overnight. The 
reaction was monitored by TLC in solvent system B. The product was extracted using a 
CHCb : H20 (1:1 v/v) mixture since the NHS dissolves in water and will be eliminated in 
the H20 layer. The CHCb extract was evaporated under reduced pressure and any 
excess pyridine co-evaporated with ethanol. The final product was crystallized from 
ethanol. The product was monitored using TLC and spraying with 33% sulphuric acid. 
Product produced a single spot by TLC (Rf 0.96, solvent B) with a mp of 108-110 °C 
and a yield of 63.7 mg (86%). 
IR (film) : 3436 (b, N-H), 2929 (st, C-H), 1449 (m, C=C), 1654 (m, C=O), 1378 (w, C-N), 
1510 (v, aromatic rings). (Appendix 2A). 
1H NMR (300 MHz, CDCb ) : () 0.68 (s, 3H, C-CH3), 0.86 (d, 6H, CH-CH3 ), 0.89 (d, 3H, 
CH-CH3 ), 0.99 (s, 3H, C-CH3), 3.1 (bs, 1 H, NH), 4.54 (m, 1 H, Chol-H3a ), 5.37 (d, 1 H, 
Chol-H6 ) , 7.2-7.4 (15H, trityl group) ppm. (Appendix 1A). 
MS, m/z, ES-TOF: 744.55 [M + H+] , 767.21 [M + Na+]. 
2.2.3.3 Preparation of Glycylcholesterylformylhydrazide (MS10) 
To N-tritylglycylcholesterylformylhydrazide (30 mg, 0.04 mmoles) was added 300 IJI 
CHCI3 to dissolve the crystals. To this was added 600 IJI glacial acetic acid and 60 IJI 
H20. The reaction mixture was maintained at room temperature for 3 hours. The 
product was monitored by TLC in solvent system B. TLC plates were first sprayed with 
ninhydrin to detect the presence of the amino groups and then with 33% H2S04 to 
detect the cholesteryl moiety. The reaction mixture was evaporated to dryness under 
reduced pressure and sufficient petroleum ether (100-120°C) was added to the sample 
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to remove any tritanol present in the reaction mixture. This mixture was then kept at 
room temperature overnight. 
The ether was finally removed with a Pasteur pipette and the mixture evaporated to 
dryness in a Rotavapor-R rotary evaporator, to produce a powder. The product gave a 
single spot by TLC (Rf 0.10, solvent 8) with a mp of 203-204°C and a yield of 19.1 mg 
(96%). 
IR (film) : 3441 (b, N-H), 2934 (m, C-H), 1649 (m, C=O), 1260 (w, C-N), 1432 (m, C=C). 
(Appendix 21). 
1H NMR (300 MHz, CDCb ) : 80.69 (s, 3H, C-CH3), 0.84 (d, 6H, CH-CH3 ), 0.89 (d, 3H, 
CH-CH3), 0.99 (s, 3H, C-CH3), 3.49 (2H, NH2 ), 4.53 (m, 1 H, Chol-H3a ), 5.36 (bs, 
1 H, Chol-H6 ) ppm. (Appendix 1 F). 
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Figure 2.8: Scheme for the synthesis of glycylcholesterylformylhydrazide (MS10). 
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2.2.4 SYNTHESIS OF CATIONIC CHOLESTEROL DERIVATIVE: 
~-ALANYLCHOLESTERYLFORMYLHYDRAZIDE 
The preparation of ~-alanylcholesterylformylhydrazide was carried out in four steps 
(Figure 2.9). 
2.2.4.1 Preparation of N-trityl-~-alanine (MS06) 
~-alanine was N-tritylated by a method described by Zervas and Theodoropoulos (1956) 
for the N-tritylation of amino acids. To a solution of ~-alanine (1780 mg, 20 mmoles) in 
diethylamine (12 ml, 120 mmoles), H20 (12 ml) and propan-2-01 (32 ml) was added 
powdered trityl chloride (7.2 g, 26 mmoles) in 10 equal aliquots with continuous stirring 
for one hour. The resulting milky solution was kept overnight at room temperature. 
Thereafter H20 (80 ml) was added to the overnight solution. The resulting solution was 
extracted twice with CHCb (2 x 100 ml), and the extract washed with H20 (2 x 20 ml). 
The extract was concentrated under vacuum using a rotary evaporator. The final traces 
of CHCI3 were removed by co-evaporation with 96% ethanol. The crude product was 
dissolved in ether (40 ml) together with a few drops of diethylamine. The sample was 
cooled to allow the diethylammonium salt of the N-trityl-~-alanine to crystallize. 
The free N-trityl-~-alanine was obtained by dissolving the diethylammonium salt in H20 
(50 ml) and KOH (128 ml, 0.05 M). The liberated diethylamine was removed by rotary 
evaporation for about 10 minutes. The solution was then filtered using a buchner funnel. 
The precipitate was discarded and the supernatant was retained and kept in the cold. 
The product was obtained by acidification of the supernatant with acetic acid to a pH of 
about 5.0. The product was filtered using a buchner funnel and dried under vacuum 
using the Xerotec Vacuum Freeze Drier. The product was monitored by TLC in solvent 
system A, using both a ninhydrin spray for amino group detection and H2S04 for 
cholesterol group detection. Product produced a single spot by TLC (Rf 0.51, solvent 
A) with a mp of 184-185°C (Ariatti and Hawtrey, 1975; 184-185°C) and a yield of 
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1.96 mg (32%). IR (film) : 3446 (b, N-H), 2924 (w, C-H), 1705 (s, COOH), 1449 (m, 
C=C), 1255 (m, C-N). (Appendix 2E). 
2.2.4.2 Preparation of the NHS ester of N-trityl-~-alanine (MS05) 
N-Trityl-p-alanine (662 mg, 2 mmoles) was dissolved in DMF (2 ml). The sample was 
warmed gently to completely dissolve the N-Trityl-p-alanine. To this was added NHS 
(230 mg, 2 mmoles). A solution of DCCI (433 mg, 2.1 mmoles) in DMF (2 ml) was 
added dropwise to the above mixture. The reaction mixture was maintained overnight 
in the dark and at room temperature. Thereafter the reaction was monitored by TLC in 
solvent system B. The UV absorbing NHS was viewed under UV254, the trityl group 
was viewed using a 2% (W/w) HCI04 spray, and the final product (active ester) was 
viewed using an active ester spray [14% (W/v) hydroxylamine hydrochloride, 3.5 M NaOH 
(20:8.5 V/v), which was sprayed first followed by a spray of FeCh in 1.2 M HCI (5% W/v)]. 
The reaction mixture was then filtered under vacuum. The dicyclohexylurea was 
discarded. The supernatant containing the desired product was dried under reduced 
pressure using a rotary evaporator to remove any DMF residue. The product was 
dissolved with heating, using propan-2-01 and a mixture of CHCh : CH30H (1 :1 V/v). The 
reaction mixture was then allowed to cool for the product to crystallize out. Some of the 
solvent was removed under reduced pressure and the product was maintained at 4°C 
for complete crystallization to take place. The product was then filtered under vacuum 
and crystals dried in a Xerotec Freeze Drier overnight. Product produced a single spot 
by TLC (Rf 0.92, solvent B) with a mp of 178-180 °C (Ariatti and Hawtrey, 1975; 178-
179°C) and a yield of 221.8 mg (26%). 
IR (film) : 3452 (b, N-H), 2924 (w, C-H), 1736 (m, C=O), 1639 (m, aromatic rings). 
(Appendix 20). 
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2.2.4.3 Preparation of N-trityl-~-alanylcholesterylformylhydrazide (MS02) 
Cholesterylformylhydrazide (44.2 mg, 0.1 mmoles) and N-trityl-p-alanine NHS ester 
(42.8 mg, 0.1 mmoles), were dissolved in a mixture of DMF: pyridine (1:1 v/v) in a total 
volume of 800 IJI and the resulting solution kept at room temperature overnight. The 
reaction was monitored by TLC in solvent system 8. A mixture of CHCb : H20 (1:1 v/v) 
was added to the reaction mixture to extract the product. The free NHS was eliminated 
in the water layer and the chloroform extract was evaporated under reduced pressure. 
The excess pyridine was co-evaporated with ethanol. The product was crystallized from 
methanol and dried under reduced pressure. The product afforded a single spot by TLC 
(Rf 0.97, solvent 8) with a mp of 110-112 °C and a yield of 54.9 mg (72%). 
IR (film) : 3426 (b, N-H), 2929 (st, C-H), 1649 (m, C=O), 1460 (m, C=C), 1383 (w, C-N), 
1523 (v, aromatic rings). (Appendix 28). 
1H NMR (300 MHz,CDCb ) : 80.65 (s, 3H, C-CH3 ), 0.86 (d, 6H, CH-CH3 ), 0.89 (d, 3H, 
CH-CH3 ), 0.98 (s, 3H, C-CH3), 4.45 (m, 1 H, Chol-H3a ), 5.34 (bs, 1 H, Chol-H6 ) 7.18-
7.52 (15H, trityl group) ppm. (Appendix 18). 
MS, m/z, ES-TOF : 758.5532 [M + H+], 781 .55 [M + Na+]. 
2.2.4.4 Preparation of ~-alanylcholesterylformylhydrazide (MS11) 
N-trityl-p-alanylcholesterylformylhydrazide ( 49.9 mg, 0.066 mmoles ) was dissolved in 
CHCb (500 IJI). Approximately 100 IJI of 90% acetic acid was added to the reaction 
mixture, which was then incubated at 3rC and the product was monitored by TLC in 
solvent system 8 over a five hour period until the reaction had reached completion. The 
reaction mixture was thereafter evaporated to dryness to form a white film on the flask. 
Sufficient petroleum ether (100-120°C) was added to fully immerse the product which 
was kept at room temperature overnight. The ether was removed with a Pasteur pipette 
and the product dried in a rotary evaporator to produce a white powder. The product 
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was then recrystallised from ethanol and dried in the Xerotec Freeze Drier. The product 
afforded a single spot by TLC (Rf 0.08, solvent B) and a yield of 33.5 mg (98%). 
IR (film) : 3431 (b, N-H), 2934 (st, C-H), 1664 (m, C=O), 1250 (m, C-N), 1408 (m, C=C). 
(Appendix 2J). 
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Figure 2.9: Scheme for the synthesis of B-alanylcholesterylformylhydrazide (MS11). 
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2.2.5 PREPARATION AND CHARACTERISATION OF MS09, MS10 AND 
MS11 CONTAINING LlPOSOMES 
2.2.5.1 Materials 
DOPE was purchased from Sigma-Aldrich (St.Louis, MO, USA). 2-[4-(2-hydroxyethyl)-
piperazinyl]-ethanesulfonic acid (HEPES), glutaraldehyde, osmium tetroxide, propylene 
oxide, lead citrate, sodium chloride and chloroform were obtained from Merck 
(Darmstadt, Germany). The components of Spurr's Resin (GRL 4206, DER 736, NSA , 
S-1), were purchased from TAAB Laboratories, United Kingdom. Copper grids for 
electron microscopy were obtained from Capital Labs (KwaZulu-Natal, South Africa). 
Bovine serum albumin (BSA) was purchased from Roche Diagnostics (Mannheim, 
Germany). All other reagents were of analytical grade. 
2.2.5.2 Formulation of Cationic Liposomes 
The preparation of the cationic liposomes was adapted from the method employed by . 
Gao and Huang (1991). Liposome components (MS09, MS10 and MS11) were mixed in 
a 1:1 molar ratio respectively with DOPE as the 'helper' lipid, as set out in Table 2.1 
Table 2.1: The lipid components of cationic liposomes MS09 , MS10 and MS11. 
LlPOSOME COMPONENTS MOLAR RATIOS FOR RESPECTIVE LIPIDS (IJmoles) 
DOPE MS09 MS10 MS11 
Liposome MS09 2 2 - -
Liposome MS10 2 - 2 -
Liposome MS11 2 - - 2 
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The total reaction mixture of each formulation contained 4 j.Jmoles of lipid. The liposome 
components of each cationic liposome preparation were dissolved in CHCI3 and the 
resultant mixture evaporated to a thin film on the inside of a quickfit tube using a BOchii 
Rotavapor-R rotary evaporator. The thin film of sample was then rehydrated in 1 ml 
sterile HEPES buffer overnight (20 mM HEPES, 150 mM NaCI, pH7.5). The suspension 
was then vortexed and sonicated for five minutes at 20°C in a Transonic bath type 
sonicator and then placed at 4°C overnight. 
2.2.5.3 Characterisation of Cationic Liposomes using Transmission Electron 
Microscopy 
To one drop of each liposome suspension was added two drops of 5% bovine serum 
albumin (BSA) made up in 0.1 M Tris-HCI buffer (pH 7.2). BSA was added for the 
complexation of the liposome suspension thereby ensuring that a gel is produced. This 
was mixed and one drop of 25% glutaraldehyde was added. The resultant lemon 
coloured gels (after approximately 20 minutes) were then diced with a blade and 
transferred to a vial containing osmium tetroxide. The vials were capped and kept in the 
dark for 24 hours. Thereafter the samples were dehydrated for 15 minutes each in 70%, 
95% and in absolute ethanol. The gels were then placed successively in propylene 
oxide for 20 minutes, and then in propylene oxide:Spurr's resin (1:1 v/v) for another 20 
minutes. The samples were finally placed in pure Spurr's resin for 45 minutes. 
Thereafter the samples were embedded in beem capsules in vacuo at 60 0 C for 48 
hours. 
The resultant blocks were sectioned using a Reichert-Jung ultracut microtome. Sections 
were picked up onto C-200 copper grids. The grids were stained with uranyl acetate for 
10 minutes, washed with distilled water, stained with lead citrate for a 'further 10 
minutes, and washed again with distilled water. The stained sections were viewed 
using a Jeol 1010 Transmission Electron Microscope at 60 kV. Liposomes were 
photographed at a 2 second exposure on a fine grain release positive film. 
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2.2.6 LlPOPLEX FORMATION OF MS09, MS10 AND MS11 LlPOSOMES 
2.2.6.1 Materials 
The pGL3 control vector was purchased from Promega Corporation (Madison, USA), 
and amplified according to the manufacturers protocol. pBR322 plasmid DNA was 
supplied by Roche Diagnostics (Mannheim, Germany). Agarose was obtained from Bio-
rad Laboratories (Richmond, CA, USA). Tris-HCI, NaH2P04, HEPES, sodium chloride 
(NaCI), ethylene diamine tetra-acetic acid (EDTA), sodium dodecyl sulphate (SDS), 
glycerol, bromophenol blue, xylene cyanol, cholesterol hemisuccinate, CHCh, Whatman 
paper no.1 (1.3 cm), uranyl acetate and ethidium bromide were purchased from Merck, 
Darmstadt, Germany. Fetal bovine serum was obtained from Delta Bioproducts, 
Johannesburg, South Africa. All other reagent were of analytical grade. Formvar coated 
grids were prepared by the Electron Microscope Unit, University of KwaZulu Natal 
(Pietermaritzburg Campus). [3H]pRSVL ( specific activity: 2.1 x 106 cpm / IJg) DNA was 
supplied by Professor Hawtrey, University of Stellenbosch. 
The interactions between the various cationic liposomes and plasmid DNA were 
determined by gel retardation assays, dye displacement assays, transmission electron 
microscopy and nuclease digestion studies. In addition cationic cholesterol derivative 
MS09 was subjected to a DNA -binding assay. 
2.2.6.2 Gel Retardation Assays 
Varying ratios of different cationic liposome : DNA complexes were set up as in Table 
2.2 (MS09 liposomes), Table 2.3 (MS10 liposomes), and Table 2.4 (MS11 liposomes) 
respectively. All cationic liposome:DNA complexes were incubated for 30 minutes at 
room temperature for lipoplex formation. At the end of the incubation, 3 IJI of gel loading 
buffer / stop solution (50% glycerol, 0.5% bromophenol blue, 0.5% xylene cyanol in a 
2 x gel buffer) was added to all eight samples. The samples were then loaded onto a 
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1 % agarose gel and subjected to agarose gel electrophoresis for approximately 90 
minutes, at 50 V and in a 1 x electrophoresis I gel buffer (0.036 M Tris-HCI, 0.03 M 
NaH2P04, 0.01 M EDTA, pH 7.5). The gel was stained with ethidium bromide (1 I-Ig Iml) 
for 30 minutes and viewed under transillumination at 300 nm u$ing a UVP gel 
documentation system. Images were obtained and photographed at 320 millisecond 
exposure. 
Table 2.2: MS09 cationic Iiposome:DNA complexes. Incubation mixtures (10 1-11) in 20 
mM HEPES, 150 mM NaCI (pH 7.5) contained cationic liposome (0 - 6 I-Ig) 
and pGL3 DNA (0.5 I-Ig). 
L1POPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA {lJg} 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Liposome MS09 {lJg} - 0.5 1 2 3 4 5 6 
Table 2.3: MS10 cationic liposome:DNA complexes. Incubation mixtures (15 1-11) in 20 
mM HEPES, 150 mM NaCI (pH 7.5) contained cationic liposome (0 - 7 I-Ig) 
and pGL3 DNA (1 I-Ig). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA {lJg} 1 1 1 1 1 1 1 1 
Liposome MS10 {lJg} - 1 2 3 4 5 6 7 
Table 2.4: MS11 cationic liposome:DNA complexes. Incubation mixtures (15 1-11) in 20 
mM HEPES, 150 mM NaCI (pH 7.5) contained cationic liposome (0 - 7 I-Ig) 
and pGL3 DNA (1 I-Ig). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA {lJg} 1 1 1 1 1 1 1 1 
Liposome MS11 {lJg} - 1 2 3 4 5 6 7 
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2.2.6.3 Dye Displacement Assays 
This assay was adapted from that of Tros de Ilarduya et al., 2002. Ethidium bromide 
(1 tJg) was added to 500 tJl of 20 mM HEPES,150 mM NaCI, pH 7.5. This mixture was 
used to provide the baseline reading (0%) for fluorescence. Thereafter 6 tJg of pBR322 
DNA was added to the above solution and the reading taken was assumed to represent 
100% fluorescence. Aliquots of cationic liposome (10 tJg for MS09 ; 5 tJg for MS 1 Oand 
MS11), were added, stepwise to the solution until 90 tJg of MS09 liposome and 70 tJg 
of MS10 and MS11 liposomes had been added. The solutions were mixed thoroughly 
after each addition and fluorescence was measured in a Shimadzu RF-551 
spectrofluorometric detector, at an excitation wavelength of 520 nm and an emission 
wavelength of 600 nm, and at high sensitivity. Results were plotted relative to 100% 
fluorescence. 
2.2.6.4 Binding of Radiolabelled DNA to Lipid Impregnated Whatman No.1 
Paper Discs 
Lipids (0.3 tJmoles) were dissolved in CHCb (25 tJl) and applied to Whatman no.1 
(1.3 cm diameter) paper discs. After evaporation of the solvent, discs were suspended 
in 200 tJl buffer containing 0.25 M Tris-HCI (pH 7.6), 0.05 M NaCI, 2.5 mM EDTA, and 
pRSVL DNA (0.03 tJg , 6.4 x 104 cpm). Discs were incubated overnight at 18°C and 
then washed with 3 x 5 ml incubation buffer, air dried and then kept at 70°C for 15 
minutes. A control sample of CHCb (25 tJl) was also included. Radioactivity was 
measured by liquid scintillation. 
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2.2.6.5 Transmission Electron Microscopy of Lipoplexes 
(MS09, MS10, MS11) 
To one drop of the respective lipoplex suspension on parafilm was added 0.5% uranyl 
acetate. This was mixed and allowed to stand for three minutes. The matt surface of 
formvar coated grids were brought into contact with the lipoplex - uranyl acetate mixture 
for 3 minutes. Thereafter discs were air dried overnight and viewed in a Jeol 1010 
transmission electron microscope at 60 kV. 
2.2.6.6 Nuclease Digestion Assays 
liposome:DNA complexes were set up as in Table 2.5 (MS09), Table 2.6 (MS10) and 
Table 2.7 (MS11). 
Table 2.5: MS09 cationic liposome:DNA complexes. Incubation mixtures (20 1-11) in 20 
mM HEPES, 150 mM NaCI (pH 7.5) contained cationic liposome (0 - 14 
I-1g) and pGL3 DNA (1 I-1g). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA (~g) 1 1 1 1 1 1 1 1 
Liposome MS09 (~g) - - 4 6 8 10 12 14 
Table 2.6: MS10 cationic liposome:DNA complexes. Incubation mixtures (151-11) in 20 
mM HEPES, 150 mM NaCI (pH 7.5) contained cationic liposome (0 - 7 I-1g) 
and pGL3 DNA (1 I-1g). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA (~g) 1 1 1 1 1 1 1 1 
Liposome MS1 0 (~g) - - 2 3 4 5 6 7 
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Table 2.7: MS11 cationic liposome:DNA complexes. Incubation mixtures (15 1-11) in 20 
mM HEPES, 150 mM NaGI (pH 7.5) contained cationic liposome (0 - 7 I-Ig) 
and pGL3 DNA (1 I-Ig). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA (~g) 1 1 1 1 1 1 1 1 
Liposome MS11 (~g) - - 2 3 4 5 6 7 
Samples were made up to a total volume of 20 1-11 (MS09), or 15 1-11 (MS10 and MS11), 
with 20 mM HEPES, 150 mM NaGI, pH 7.5. Lipoplexes in tubes 3 to 8 were incubated 
at room temperature for 30 minutes. Thereafter fetal calf serum was added to lipoplexes 
in tubes 3 to 8 and to tube 2 containing only DNA, to a final serum concentration of 
10% C/v). Sample 2 to 8 were then incubated at 3rG for four hours. Therafter EDTA 
was added to a final concentration of 10 mM and sodium dodecyl sulphate (SDS) to a 
final concentration of 0.5% (W/v). The reaction mixtures were incubated further at 55°G 
for 20 minutes. 
At the end of the above incubation 3 1-11 of gel loading buffer was added to all eight 
samples. Samples were loaded onto a 1 % agarose gel and subjected to agarose gel 
electrophoresis for 90 minutes at 50 V in a 1 x electrophoresis buffer, as described for 
the gel retardation assays (2.2.6.2). The gel was stained with ethidium bromide (1 I-Ig 
Iml) for 30 minutes and viewed under 300 nm transillumination using a UVP gel 
documentation system. Images were obtained and photographed at 320 millisecond 
exposure. 
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2.2.7 CELL CULTURE AND TRANSFECTION STUDIES 
2.2.7.1 Materials 
Cell lines (HeLa, NIH-3T3, SNO, HepG2) were obtained from Highveld Biologicals (Pty) 
Ltd (Kelvin, South Africa). Trypsin-EDTA, and penicillin-streptomycin mixtures were 
purchased from Whittaker, M.A. Bioproducts (Maryland , USA). Fetal bovine serum was 
supplied by Delta Bioproducts (Johannesburg, South Africa). Minimum essential 
medium (MEM) with Earle's salts was obtained from Gibco-BRL, Life Technologies Ltd, 
(Inchinnan, Scotland). The Luciferase assay kit, and the pGL3 control vector (prior to 
amplification) were purchased from the Promega Corporation (Madison, USA). All tissue 
culture plasticware was obtained from Bibby-Sterilin (Staffordshire, England). The 
Bicinchoninic acid (BCA) Protein Assay Kit was supplied by Sigma-Aldrich (St.Louis, 
MO, USA). Dimethylsulfoxide (DMSO), crystal violet, formaldehyde were supplied by 
Merck (Darmstadt, Germany). All other reagents were of analytical grade. 
2.2.7.2 Growth and Maintenance of Cell Lines 
Preparation of Culture Medium: 
MEM powdered medium intended for 1 litre of medium was dissolved in 900 ml of 18 
Mohm water. To this solution was added 10 mmoles sodium hydrogen carbonate, 20 
mmoles HEPES, and 20 ml of antibiotic (5000 units penicillin G and 5000 I-Ig 
streptomycin sulphate I ml). The pH was adjusted with sodium hydroxide to pH 7.2 - 7.3. 
The medium was then made up to 1 litre with 18 Mohm water. The culture medium was 
filter-sterilised with the aid of a Cole-Palmer Masterflex (model 7017-12) peristaltic 
pump, through a Sterivex-GS, 0.22 I-Im bell filter unit, into autoclaved 250 ml Schott 
bottles (200 ml aliquots). Before the medium could be added to the cells for growth, fetal 
bovine serum (FBS) was added to the medium to a final concentration of 10% (v/v). 
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Propagation of HeLa, SNO, NIH-3T3 and HepG2 Cells: 
All cells were received from Highveld Biologicals in 2 x 25 cm2 flasks in MEM, and were 
immediately incubated at 37°C overnight. Thereafter the medium from the cells was 
decanted, and the cells washed with 5 ml phosphate buffered saline (PBS) (150 mM 
sodium chloride, 2.7 mM potassium chloride, 1 mM potassium dihydrogen phosphate, 
6 mM di-sodium hydrogen phosphate, pH 7.5). Excess PBS was removed and 1 ml 
trypsin-EDTA mixture (0.25% w/v trypsin, 0.1% w/v EDTA) was added to the cells for 
trypsinisation. Trypsinisation of the cells was observed under a Nikon TMS inverted 
microscope (incubation times were 3 minutes for HeLa, 3T3 and SNO, but 5-10 minutes 
for HepG2 at 37°C). The trypsin solution was then removed and the flasks lightly 
tapped against the base of the palm in order to dislodge the trypsinised cells. Thereafter 
approximately 1 ml of medium (MEM + 10% FCS + antibiotics), was added to the cells. 
The cells were split in ratios of 1:2 (HepG2 cells) or 1:3 into 2 or 3 x 25 cm2 flasks, 
each containing 5 ml medium. The cells were incubated at 37°C and medium was 
changed at the required intervals. Once cells had reached confluency they were once 
again trypsinised and split appropriately as required. Cells were routinely frozen and 
stored in a -80 ° C biofreezer. 
Cryopreservation and Reconstitution of HeLa, SNO, NIH-3T3 and HepG2 Cells: 
Confluent cells were washed with PBS and trypsinised. The cells were then pelleted by 
centrifugation at 1000 rpm for 3 minutes in a MSE bench top centrifuge. The cells were 
then resuspended in 0.9 ml medium and 0.1 ml DMSO. This cell suspension was 
dispensed into a cryogenic ampoule and sealed. The cells were frozen to about -70°C 
using a cold probe, at a drop rate of 1°C / minute, from room temperature before being 
transferred to the -80°C biofreezer for storage. 
The cells were reconstituted when required by removing ampoules from the low 
temperature storage and immediately placing them in a 37°C water bath. Directly after 
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thawing, the ampoules were wiped with ethanol, and the cells were pelleted by 
centrifugation (1000 rpm for 3 minutes). The supernatant was discarded into a waste 
bottle, and the cells were resuspended in 1 ml fresh complete medium. The medium 
was changed after 24 hours, and the cells were monitored with frequent medium 
changes until they reached confluency. All cell lines were photographed on FP4 film 
using a Nikon camera attached to the inverted microscope, with sensitivity set at 200 
and an exposure time of 2 seconds. 
2.2.7.3 Growth Inhibition Assays 
Cells were trypsinised and seeded into a 24 well plate at varying seeding densities. For 
studies involving liposome MS09 the seeding density was 2.0 x 104 cells/well for HeLa 
cells, 1.8 x 104 cells/well for SNO cells, 2.1 x 104 cells/well for NIH-3T3 cells and 1.8 x 
104 cells/well for HepG2 cells. For liposome MS10 the seeding density was 2.6 x 104 
cells/well for HeLa cells, 2.2 x 104 cells/well for SNO cells, 2.3 x 104 cells/well for NIH-
3T3 cells and 2.0 x 104 cells/well for HepG2 cells, and for liposome MS11 the seeding 
density was 2.75 x 104 cells/well for HeLa cells, 2.0 x 104 cells/well for SNO cells, 2.2 x 
104 cells/well for N I H-3T3 cells and 2.1 x 104 cells/well for HepG2 cells. Wells in row 1 
received no cells and were used to obtain a blank (0) reading. Cells were incubated for 
24 to 36 hours and allowed to attach to the wells and grow to semi-confluency. The 
liposome:DNA [pGL3 DNA (0.5 I-Ig or 1 I-Ig)] complexes were set up as outlined in 
Tables 2.8, 2.9, 2.10. The reaction mixtures were all made up to a constant volume with 
20 mM HEPES, 150 mM sodium chloride, pH 7.5, and incubated at room temperature 
for 30 minutes. 
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Table 2.8: MS09 cationic liposome:DNA complexes. Incubation mixtures (10 ~I) in 20 
mM HEPES, 150 mM NaCI (pH 7.5) contained cationic liposome (0-7 ~g) 
and pGL3 DNA (0.5 ~g). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 
pGL3 DNA (lJg) - 0 0.5 0.5 0.5 0.5 
Liposome MS09 (lJg) - 0 3 5 6 7 
Table 2.9: MS10 cationic liposome:DNA complexes. Incubation mixtures (15 ~I) in 20 
mM HEPES, 150 mM NaCI (pH 7.5) contained cationic liposome (0-7 ~g) 
and pGL3 DNA (1 ~g). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 
pGL3 DNA (lJg) - 0 1 1 1 1 
Liposome MS10 (lJg) - 0 4 5 6 7 
Table 2.10: MS11 cationic liposome:DNA complexes. Incubation mixtures (15 ~I) in 20 
mM HEPES, 150 mM NaCI (pH 7.5) contained cationic liposome (0-7 ~g) 
and pGL3 DNA (1 ~g). 
LIPOPLEX COMPONENTS 1 2 3 4 5 6 
pGL3 DNA (lJg) 0 1 1 1 1 
Liposome MS11 (lJg) - 0 4 5 6 7 
The cells were prepared by first removing the growth medium and replacing it with 0.5 
ml of serum free medium. The reaction complexes were then added to the wells 
containing the cells. The assays were carried out in quadruplicate. The cells were then 
incubated at 37°C for 4 hours. Thereafter, the medium was replaced with complete 
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medium (MEM + 10% FCS + antibiotics). The cells were incubated again at 37 °C for a 
further 48 hours. The cells were then quantified by the method of Schellekens and Stitz, 
1980, which suggests that the viable cells will adhere to the flask surface and can be 
quantified by staining as described. The cells were washed twice with PBS and stained 
with 200 IJI crystal violet solution ( 0.5% w/v crystal violet, 0.8% w/v sodium chloride, 5% 
v/v formaldehyde, 50% v/v ethanol) for 20 minutes. The stain was then removed and the 
cells washed extensively with water. The multiwell plate was then dried for 24 hours, 
and the stain extracted with 2-methoxyethanol (0.5 ml) over a period of 36 hours, with 
gentle rocking (20 rev / minute) on a Stuart Scientific STR 6 platform shaker. 
Absorbance values for the samples were then read in a Novospec spectrophotometer, 







Liposome MS09 : pGL3 DNA complexes 
Liposome MS10 : pGL3 DNA complexes 
Liposome MS11 : pGL3 DNA complexes 
Lipofectin™: pGL3 DNA complexes 
Transfection of all lipoplexes was conducted using four cell lines viz. HeLa, NIH-3T3, 
SNO and HepG2 cells. Lipofectin™, a commercially available liposome preparation was 
utilized as a comparator. All cells were trypsinised and seeded at varying densities in 
24 well plates. The cells were then allowed time to attach to the wells and to grow to 
semi-confluency. The transfection complexes (a - d) were then set up in quadruplicate 
for all cell lines as described in Tables 2.11 , 2.12, 2.13 and 2.14. The transfection 
efficiencies of the three cationic liposome:DNA complexes (a - c) in the presence of 
10% serum were also evaluated. 
84 
(a) Liposome MS09 : pGL3 DNA complexes 
Transfection complexes were added to 24-well plates containing cells at a seeding 
density of 2.25 x 104 cells/well for HeLa cells, 1.8 x 104 cells/well for SNO cells, 2 x 104 
for NIH-3T3 cells/well and 1.9 x 104 cells/well for HepG2 cells. For transfection in the 
presence of 10% FCS the seeding densities were 2.35 x 104 cells/well for HeLa cells, 
2.23 x 104 cells/well for SNO cells, 2.15 x 104 for NIH-3T3 cells/well and 2.1 x 104 
cells/well for HepG2 cells. 
Table 2.11 : MS09 transfection complexes as added to 24-well plates. Control 1 
contained only cells, control 2 contained cells and pGL3 DNA (0.5 ~g) 
only. Test samples 1 to 4 contained varying amounts of liposome MS09 
(3, 5, 6 and 7 ~g respectively). pGL3 DNA was kept constant at 0.5 ~g. All 
complexes were made up in a final volume of 1 0 ~I with 20 mM HEPES, 
150 mM sodium chloride (pH 7.5). 
Reaction Components Control Control Test Test Test Test 
1 2 1 2 3 4 
HeLa / SNO / 3T3 / HepG2 Cells + + + + + + 
Liposome MS09 {1-I9} - - 3 5 6 7 
pGL3 DNA {1-I9} - 0.5 0.5 0.5 0.5 0.5 
(b) Liposome MS10 : pGL3 DNA complexes 
Transfection complexes were added to 24-well plates containing cells at a seeding 
density of 2.6 x 104 cells/well for HeLa cells, 2.2 x 104 cells/well for SNO cells, 2.3 x 104 
cells/well for NIH-3T3 cells and 2 x 104 cells/well for HepG2 cells. For transfection in the 
presence of 10% FCS the seeding densities were 2.25 x 104 cells/well for HeLa cells, 
2.4 x 104 cells/well for SNO cells, 2.1 x 104 cells/well for NIH-3T3 cells and 1.8 x 104 
cells/well for HepG2 cells. 
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Table 2.12: MS10 transfection complexes as added to 24-well plates. Control 1 
contained only cells, control 2 contained cells and pGL3 DNA (1 I-Ig) only. 
Test samples 1 to 4 contained varying amounts of liposome MS10 (4,5,6 
and 7 I-Ig respectively). pGL3 DNA was kept constant at 1 I-Ig. All 
complexes were made up in a final volume of 20 1-11 with 20 mM HEPES, 
150 mM sodium chloride (pH 7.5). 
Reaction Components Control Control Test Test Test Test 
1 2 1 2 3 4 
HeLa / SNO / 3T3 / HepG2 Cells + + + + + + 
Liposome MS 10 (1-I9) - - 4 5 6 7 
pGL3 DNA (1-I9) - 1 1 1 1 1 
(c) Liposome M511 : pGL3 DNA complexes 
Transfection complexes were added to 24-well plates containing cells at a seeding 
density of 2.75 x 104 cells/well for HeLa cells, 2 x 104 cells/well for SNO cells, 2.2 x 104 
cells/well for NIH-3T3 cells and 2 x 104 cells/well for HepG2 cells. For transfection in the 
presence of 10% FCS the seeding densities were 2.1 x 104 cells/well for HeLa cells, 2.3 
x 104 cells/well for SNO cells, 2 x 104 for cells/well N I H-3T3 cells and 1.8 x 104 cells/well 
for HepG2 cells. 
Table 2.13: MS 11 transfection complexes as added to 24-well plates. Control 1 
contained only cells, control 2 contained cells and pGL3 DNA (1I-1g) only. 
Test samples 1 to 4 contained varying amounts of liposome MS10 (4,5,6 
and 7 1-19 respectively). pGL3 DNA was kept constant at 1 1-19. All 
complexes were made up in a final volume of 20 1-11 with 20 mM HEPES, 
150 mM sodium chloride (pH 7.5). 
Reaction Components Control Control Test Test Test Test 
1 2 1 2 3 4 
HeLa / SNO / 3T3 / HepG2 Cells + + + + + + 
Liposome MS11 (1-I9) - - 4 5 6 7 
pGL3 DNA (1-I9) - 1 1 1 1 1 
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(d) Lipofectin™ : pGL3 DNA complexes 
Transfection complexes were added to 24-well plates containing cells at a seeding 
density of 2.25 x 104 cells/well for HeLa cells, 1.8 x 104 cells/well for SNO cells, 2 x 104 
cells/well for NIH-3T3 oells and 1.9 x 104 cells/well for HepG2 cells. 
Table 2.14: Lipofectin™ transfection complexes as added to 24-well plates. Control 1 
contained only cells, control 2 contained cells and pGL3 DNA (1 I-Ig) only. 
Test samples 1 to 4 contained varying amounts of lipofectin (4,5,6 and 7 
I-Ig respectively). pGL3 DNA was kept constant at 1 I-Ig. Lipoplexes were 
incubated in serum free medium in a final volume of 100 1-11. 
Reaction Components Control Control Test Test Test Test 
1 2 1 2 3 4 
HeLa / SNO / 3T3 / HepG2 Cells + + + + + + 
Lipofectin ™ {1-I9} - - 4 6 8 10 
pGL3 DNA {1-I9} - 1 1 1 1 1 
Lipofectin TM:DNA complexes were prepared according to manufacturer's protocol in 
quadruplicate. Lipofectin™ reagent (4, 6, 8, 10 I-Ig ), and pGL3 DNA (1 I-Ig) were 
diluted separately in 50 1-11 serum free medium. Both solutions were allowed to stand for 
30 minutes before they were combined. The two solutions were then mixed and 
incubated for a further 15 minutes at room temperature, for lipoplex formation. The 
lipoplexes were then added to the cells and transfection conducted as described below. 
Typically liposome:DNA complexes (a - c) were incubated at room temperature for 30 
minutes prior to addition to cells. The cells were prepared by removal of the growth 
medium, washing with 0.5 ml PBS and replenishing with 0.5 ml serum free medium 
(MEM + antibiotics). For the evaluation of transfection efficiency in the presence of 10% 
serum the medium utilized was complete medium (MEM + antibiotics + 10% FCS). 
Thereafter the transfection complexes (Iipoplexes) were added to the cells. The cells 
were then incubated at 3rC for 4 hours. After 4 hours the medium was removed and 
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replaced with complete growth medium (MEM + antibiotics + 10% FCS). The cells were 
incubated for a further 48 hours at 3rC after which they were assayed for luciferase 
activity using the luciferase assay system (Promega). 
2.2.7.5 Luciferase Assay 
The luciferase assay was carried out using the Promega Luciferase Assay system. The 
luciferase assay reagent (20 mM tricine, 1.1 mM magnesium carbonate hydroxide, 
pentahydrate, 2.7 mM magnesium sulphate, 0.1 mM EDTA, 33.3 mM dithiothreitol, 270 
I-IM coenzyme A , 470 I-IM luciferin, 530 I-IM ATP), was prepared by adding 10 ml of the 
given luciferase assay buffer to one vial of Iyophilised luciferase assay substrate. The 
cell culture lysis reagent (5x) [25 mM Tris-phoshate, pH 7.8 ; 2 mM dithiothreiotol ; 2 
mM 1,2-diaminocyclohexane-N,N,N',N'-tetra-acetic acid, 10% (v/v) glycerol, 1 %(v/v) 
Triton X-100], was diluted with distilled water to produce a 1 x stock. Both reagents 
were equilibrated to room temperature. 
The cells were prepared by first removing the growth medium and washing twice with 
PBS (2 x 0.5 ml) being careful not to dislodge any of the attached cells. A minimal 
amount of 1 x cell culture lysis reagent (80 1-11) was added to cover the cells. The 
multiwell plate was then placed on a platform rocker for 15 minutes. Thereafter the 
attached cells were dislodged from the wells and the cell solution was transferred to a 
microcentrifuge tube. The cells were spun briefly (5 seconds) in an Eppendorf 
microcentrifuge at 12 000 x g to pellet the large debris. The cell free extracts 
(supernatants) were retained to be assayed for luciferase activity. To 20 1-11 of cell free 
extract at room temperature was added 100 1-11 of luciferase assay reagent. The reaction 
mixture was immediately mixed and placed in a luminometer (Lumac Biocounter 1500). 
The light produced was measured for a period of 10 seconds. The protein determination 
of the cell free extracts was performed using the BCA assay (Sigma) with BSA as the 
standard protein (Smith et al., 1985). 
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2.3 RESULTS AND DISCUSSION 
2.3.1 PREPARATION OF CATIONIC CHOLESTEROL DERIVATIVES 
Three novel cationic cholesterol derivatives were synthesized for formulation into 
cationic liposomes (Figures 2.7, 2.8, 2.9). Each of these derivatives has a cholesterol 
anchor in common, but they differ in the lengths of their relatively polar spacer arms and 
the cationic head groups. MS09 has the longest spacer arm and a dimethylammonium 
head group. Of the two amino acid-containing derivatives, MS11 (the ~-alanyl 
derivative) has just one extra carbon in its spacer arm compared to MS 10 (the glycyl 
derivative). Both compounds have simple primary amino head groups. The head groups 
become protonated at physiological pH and thus behave as cationic headgroups, 
potentiating transfection. These compounds were all used in the formulation of three 
novel cationic liposomes which were assessed for their transfection efficiency in four 
different cell lines in vitro. As expected, the transfection efficiencies of the three 
liposome formulations were significantly different (2.3.4.3). This will be discussed later 
in this chapter. 
It is assumed that derivatives that possess headgroups with a primary amine or a bulky 
tertiary amine produce lower transfection efficiencies than derivatives with a secondary 
amine headgroup (Hasegawa et al., 2002). Furthermore the use of hydrophobic 
components ensure that cationic lipids assemble into lipid bilayer vesicles on dispersion 
in aqueous media, shielding the hydrophobic portion of the molecule and exposing the 
amine group/s to the aqueous medium. These amine groups are the DNA-binding 
moieties and upon electrostatic interaction with the DNA molecule, condense the larger 
liposomal structures into smaller transportable units or lipoplexes (Brown et al., 2001). 
This can be seen in section 2.3.3.4. 
Structure-activity relationship studies have also shown that the number of amine groups 
per molecule and the distance between the headgroup and the hydrophobic units 
affects gene delivery (Remy et al., 1994 ; Wheeler et al., 1996a). Finally the addition of 
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a cationic lipid into a liposomal formulation that has a good surface hydration will lead to 
increased transfection activity (Bennett et al., 1996). The nature of a cationic lipid can 
be related to its aqueous stability, hydrophilic-hydrophobic balance, solubilizing power, 
affinity for membrane lipids and proteins, and biodegradability (Lasic, 1997). 
2.3.2 PREPARATION AND CHARACTERISATION OF MS09, MS10 AND MS11 
CONTAINING LlPOSOMES 
2.3.2.1 Formulation of Cationic Liposomes 
Cationic liposomes were successfully formulated using the method described. This was 
revealed using transmission electron microscopy. Liposomes were easily prepared 
using equimolar amounts of cationic lipid and DOPE. DOPE is often used as a helper 
lipid because most cationic surfactants form micelles but not liposomes. The addition of 
a phospholipid such as DOPE that has a strong tendency to adopt an inverted 
hexaganol structure (H11 phase) was found to be very important. DOPE assists in the 
formation of liposomes with a significantly increased transfection efficiency, while it 
tends to reduce cytotoxicity of the cationic surfactants (Sternberg et al., 1994). The 
neutral lipid DOPE also plays a role in assisting fusion or membrane destabilisation in 
the cationic lipid-mediated DNA delivery mechanism. DOPE on its own is inactive as a 
transfection reagent (Gao and Huang, 1991), probably due to its inability to interact with 
DNA. 
It is likely that the cationic lipid reacts with DOPE in a 1:1 ratio to form a heterodimer in 
the liposomal bilayer. This heterodimer may be formed due to interaction between the 
negatively charged phosphate on DOPE and the ammonium group on the cationic lipid. 
Upon formation of the heterodimer, the polar head group will be rendered more 
hydrophobic due to charge neutralisation after formation of the ion pair. Compounds 
which contain the hydroxyl group will remain in contact with the aqueous phase, 
maintaining the integrity of the bilayer structure, whereas those lacking the hydroxyl 
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group may become buried within the aliphatic region , disrupting the bilayer structure 
(Feigner et al., 1994). 
2.3.2.2 Characterisation of Liposomes by Transmission Electron 
Microscopy 
Transmission electron microscopy revealed the unilamellar nature and the sizes of the 
different cationic liposome preparations. Liposome MS09 sizes varied from 80 nm to 
150 nm, liposome MS10 from 100 nm to 200 nm, and liposome MS11 from 50 nm to 
200 nm (Figures 2.10 to 2.12). A liposome size of 150 nm or less seems to favour the 
process of endocytosis ( Bertling et al., 1991). 
It was shown using cryoelectron microscopy that cationic liposomes can exist in a 
variety of shapes such as tubular, dumbbell , pear, oval or elongated oval shapes, in 
addition to spherical shapes. Liposomes sometimes also appear invaginated, lenslike 
or flat (Lasic, 1997). In our preparations predominantly spherical or oval shaped 
liposomes were observed. Liposome diameter and size dispersity are important 
parameters in drug delivery applications (Campbell et al., 2001). 
50 nm 
Figure 2.10: TEM of liposome MS09. Liposome size ranged from 80 nm to 150 nm. 
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100 nm 
Figure 2.11 : TEM of liposome MS10. Liposome size ranged from 100 nm to 200 nm. 
100 nm 
Figure 2.12: TEM of liposome MS11 . Liposome size ranged from 50 nm to 200 nm. 
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2.3.3 LlPOPLEX FORMATION OF MS09, MS10 AND MS11 LlPOSOMES 
Lipoplexes (liposome:DNA complexes) are usually produced within 20 minutes of 
incubation at room temperature. They were demonstrated using gel retardation assays, 
dye displacement assays, nuclease digestion assays and transmission electron 
microscopy. The cationic cholesterol derivative, MS09 was further characterized for its 
ability to bind DNA using a filter paper binding assay. 
2.3.3.1 Gel Retardation Assays 
Gel retardation analyses were carried out on all three lipoplexes (MS09, MS10 and 
MS11), each yielding a different pattern of binding with a specific optimum binding ratio 
( Figures 2.13 and Figure 2.14). 
Figure 2.13: Gel retardation study of MS09 cationic liposome:DNA complexes. 
Incubation mixtures (10 j.J1) in 20 mM HEPES, 150 mM NaCI (pH 7.5) 
contained varying amounts of cationic liposome in lanes 1-8 (0, 0.5, 1.0, 




Figure 2.14: Gel retardation study of (a) MS10 cationic liposome:DNA complexes, 
and, (b) MS11 cationic liposome:DNA complexes. 
Incubation mixtures (15 1-11) in 20 mM HEPES, 150 mM NaCI (pH 7.5) 
contained varying amounts of cationic liposome in lanes 1-8 (0, 1.0, 
2.0, 3.0, 4.0, 5.0, 6.0 and 7.0 I-Ig), while the pGL3 DNA was kept 
constant at 1.0 I-Ig. 
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The use of agarose gel electrophoresis serves to demonstrate the formation of 
complexes between DNA and cationic liposomes. In the absence of liposomes, the 
DNA would migrate into the gel, but in the presence of increasing liposome 
concentrations the DNA is bound to the cationic liposome and retarded and hence 
retained in the wells. It is accepted that uncomplexed DNA will migrate into the gel and 
the liposome:DNA complexes will not (Bertling et al., 1991). 
It can be seen that the plasmid DNA (pGL3) produced the expected two bands (lane 1), 
viz. the supercoiled form of DNA (bottom band) and the nicked circular form (top band) 
which is more clearly visible in Figure 2.13. As the respective cationic liposome 
concentration increased, more DNA was bound by the cationic liposome and hence less 
DNA entered the gel. This can be seen by the ethidium bromide staining intensity. DNA 
that did not migrate into the gel can also be seen stained in the wells. Complete 
retardation of the DNA in the case of each liposome was obtained at different 
liposome:DNA binding ratios viz. 12:1 (w/w) for MS09, 6:1 (w/w) for MS10 and 6:1 (w/w) for 
MS 11. These ratios will help to determine the optimum ratios for transfection studies. 
Complete retardation suggests that the negative charges of the DNA are completely 
titrated by the cationic liposome's positive charges. This sometimes produces large 
electroneutral complexes that do not migrate into the agarose gel matrix. These 
complexes can be seen, once stained with ethidium bromide, to be present in the wells. 
Precipitation of the electro neutral complexes may also occur in the sample wells. 
Occasionally precipitated complexes may float out of the wells during electrophoresis, 
or during the staining / washing process, and are hence not seen under UV light in the 
wells even after staining with ethidium bromide. In these cases no DNA will be 
detectable in the wells. Liposomes MS 10 and MS 11 bound at a lower liposome: DNA 
ratio (6:1) and a +/- charge ratio of 0.8, whilst the MS09 bound at a higher 
liposome:DNA ratio (12:1)and a +/- charge ratio of 1.3. 
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2.3.3.2 Dye Displacement Assays 
These assays showed that as the amount of liposome added to the DNA increased, the 
fluorescence emitted by the ethidium bromide was quenched due to the binding of 
cationic liposome to the plasmid DNA, hence displacing the ethidium bromide. This 
gradual decrease in fluorescence was observed with all three liposome formulations 
(Figure 2.15, Figure 2.16 and Figure 2.17). 
_ 100-4 "'-
?f!. "'-- .-. 
~ 80- "". 
w "'--. 
~ '--... 
~ 60- ~ 







o 5 10 15 20 
LlPOSOME:DNA (w/w) 
Figure 2.15: Ethidium bromide intercalation assay for cationic liposome MS09 at 
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Figure 2.16: Ethidium bromide intercalation assay for cationic liposome MS10 at 
varying liposome : DNA (w/w) binding ratios. 
_ 100~'-\ 
~ 
; 90- ."", 
o ., 
~ '. o 80- , 
ffl 'e 
0:: ~. 










o 2 4 6 8 10 12 
LlPOSOME:DNA (w/w) 
Figure 2.17: Ethidium bromide intercalation assay for cationic liposome MS11 at 
varying liposome:DNA (w/w) binding ratios. 
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Ethidium bromide is an aromatic planar cationic fluorophore whose fluorescence 
increases upon intercalation between base pairs of the double-stranded DNA (Even-
Chen and Barenholz, 2000). This was observed upon the initial addition of pBR322 
DNA to the ethidium bromide solution in buffer which resulted in a marked enhancement 
of its fluorescence emission at 600 nm. This increase in fluorescence can be explained 
by the steric protection from molecular oxygen, inducing dequenching that is 
proportional to the level of fluorophore intercalation (Even-Chen and Barenholz, 2000). 
This was taken as being the 100% fluorescence reading. Upon the stepwise addition of 
the respective cationic liposome preparation, a steady decrease in fluorescence was 
observed. This was due to the formation of the cationic liposome:DNA complex that 
causes displacement of the intercalated ethidium bromide from the DNA, hence 
reducing the emitted fluorescence. The decrease in fluorescence occurs since the 
ethidium bromide will now be fully accessible to quenching by molecular oxygen. This 
change of fluorescence can be used to assess the level oJ condensation or 
encapsulation of DNA (Even-Chen and Barenholz, 2000). The displacement of ethidium 
bromide from DNA is generally a rapid process and is usually completed within 30 
seconds (Xu and Szoka, 1996). Most cationic liposome preparations (DOTAP, 
DOTAP/DOPE, DOTAP/DOPC) were seen to displace ethidium bromide in a similar 
fashion (Xu et al., 1999). 
The fluorescence decreased steadily until a point was attained which seemed to 
correlate with total retardation in gel retardation assays. The maximum displacement of 
ethidium bromide was obtained for liposome MS09 (approximately 65%) at the total 
retardation ratio of 12:1. Liposomes MS10 and MS11 both achieved maximum 
displacement of ethidium bromide at a liposome:DNA ratio of 6:1 (W/w) , corresponding 
to the full retardation ratio obtained in band shift assays. The reduction in fluorescence 
at these points was, however, much less marked than that achieved by MS09 (29% and 
36% respectively). This may be indicative of tighter packing of DNA by the MS09 
liposomes and could account for the large differences in transfection efficiencies 
observed between MS09 lipoplexes and MS10 and MS11 lipoplexes (section 2.3.3.4). 
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Further increase in liposome:DNA ratios in the dye displacement assay resulted in the 
onset of turbidity and may account for the sharp decline in fluorescence observed at 
high ratios. 
2.3.3.3 Binding of Radiolabelled DNA to Lipid impregnated Whatman No.1 
Paper Discs 
The results obtained in this assay showed that cationic cholesterol derivative MS09 
binds very strongly to plasmid DNA (pRSVL DNA) (Table 2.15). This assay was 
conducted on cationic cholesterol derivative MS09 since it produced the highest 
transgene expression among the three cationic cholesterol derivatives in transfection 
assays. 
Table 2.15: Filter paper binding assay of cationic cholesterol derivative, MS09, 
compared against a control (CHCI3) and standards (cholesterol and 
cholesteryl hemisuccinate). 
COMPOUND cpm I J.Lmole* 
Cholesterol 596* 
Cholesteryl hemisuccinate 958* 
Cationic Derivative (MS09) 6708* 
CHCI3 control (25 jJl) 270 
This strong affinity of cationic cholesterol derivative MS09 for DNA also correlates with 
its high fluorescence quenching due perhaps to tight binding of DNA. 
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2.3.3.4 Transmission Electron Microscopy of Lipoplexes 
The enhancement of transfection efficiencies using non-viral methods such as 
liposomes requires a full understanding of the supramolecular structures of the cationic 
liposome:DNA complex and their interactions with the cell membrane (Safinya, 2001). 
This procedure was utilized to determine the size and ultrastructural morphology of the 
various lipoplexes formed at two different ratios. Each lipoplex was monitored at the 
ratio that produced complete retardation and at a higher ratio (Figures 2.18-2.20). 
In the case of MS09 liposomes, the diameter of the lipoplex ranged from 200 nm at 
the lower liposome:DNA ratio of 12:1 (+/- charge ratio of 1.3) to 300 nm at a higher 
liposome:DNA ratio of 14:1 (+/- charge ratio of 1.7). The MS10 liposomes, gave lipoplex 
diameters ranging from 250 nm for a liposome:DNA ratio of 6:1 (+/- charge ratio of 0.8) 
to 350 nm for a liposome:DNA ratio of 7:1 (+/- charge ratio of 1). MS11 liposomes gave 
lipoplexes with diameters ranging in size from 200 nm for a liposome:DNA ratio of 6:1 







Figure 2.18: TEM of MS091ipoplexes at two different Iiposome:DNA ratios: 
(a) 12:1 (+/- charge ratio of 1.3), and, 






Figure 2.19: TEM of MS10 lipoplexes at two different liposome:DNA ratios: 
(a) 6:1 (+/- charge ratio of 0.8), and, 






Figure 2.20: TEM of MS11 lipoplexes at two different liposome:DNA ratios: 
(a) 6:1 (+/- charge ratio of 0.8), and, 
(b) 7: 1 (+/- charge ratio of 1). 
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TEM studies of the various lipoplexes at different liposome:DNA ratios showed a variety 
of aggregates or complexes. Most of the lipoplexes appeared as groups or clusters of 
spherical, oblong or flattened liposomes. The ultrastructure of the lipoplexes seemed to 
depend on the liposome:DNA ratio. At low liposome:DNA (+/-) charge ratios the 
lipoplexes were more tightly packed and were smaller in size compared to lipoplexes at 
higher liposome:DNA (+/-) charge ratios, which seem to be larger and more loosely 
clustered. These types of aggregates or clusters have been described previously 
(Moodley et al., 2002) and were also referred to as resembling a cluster of blackberries 
(Cao et al., 2000). The lipoplex shape has also been characterized as resembling 
'beans" or "map-pins" immediately after liposome:DNA mixing. It was further noted that 
after thirty minutes, aggregation takes place and any definitive shape is lost (Sun et al., 
2004). The lipoplexes examined in this study were all freshly prepared to maintain their 
ultrastructural shape and no further maturation of the lipoplexes was allowed before 
fixing. 
Gershon et al., 1993, reported that at a DNA lipid (DOTMA) weight ratio of 1:1 
approximately half of the DNA molecules are bound to the liposomes and complexes 
appeared spherical even at the lower ratios. However at higher liposome concentrations 
all the DNA is covered by liposomes and smooth rod-like structures were visualised. 
Similar structures were also noted later using freeze fracture EM (Sternberg et al., 
1994), and small angle X-ray scattering (SAXS) (Radler et al., 1997 ; 1998). 
Furthermore it has been suggested that a hexagonal arrangement of lipid:DNA 
complexes can help to promote transfection (Koltover et al., 1998). Hence it can be 
said that the ultimate lipoplex shape is an important factor in determining transfection 
efficiency. This ultimate lipoplex shape depends on the size of the plasmid DNA, the 
type of liposome, and the mechanisms and conditions utilized for the lipoplex formation 
(Sun et al., 2004). 
As yet no concensus has been reached as to the exact structure or ultrastructure of the 
so called "active" cationic liposome:DNA complex. The interaction between DNA and 
cationic liposome is probably a process of self-assembly that is triggered by DNA-
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mediated fusion of liposomes and could involve some lipid rearrangement. The 
negatively charged plasmid DNA seems to act as a fusogenic agent, drawing together 
the positively charged liposomes and forming semi-fused liposomes or aggregates. It 
was found that lipoplex structures at the optimal ratio produce forms different from those 
at sub-optimal ratios (Sternberg et al. , 1994). 
Investigators have also utilized cryo-TEM to visualize lipoplexes. Results have 
suggested that the DNA molecules are usually entrapped between the liposomal 
membranes in clusters, and that with increasing amounts of DNA, free or loosely bound 
plasmids were seen (Li and Ma, 2001). In some instances much larger aggregates 
were produced that were made up of distinct globular units generally of a constant size 
(Radler et al., 1998). Depending on the pKa of a lipid, the pH can also affect the 
interaction of cationic liposomes with DNA and the structures of the lipoplexes (Li and 
Ma,2001). 
The 200 nm diameter lipoplex seems to predominate when complexes are prepared at 
net positive charge ratios (Zabner et al., 1995). There does not seem to be consensus 
on the exact lipoplex size required for efficient transfection amongst different 
researchers. It has been observed that liposome:DNA complexes with diameters in the 
0.4 to 1.4 IJm (Nakanishi, 2003) or 200 to 450 nm range (Templeton, 2003) were 
effective for gene transfection. For in vivo studies it is assumed that the larger the 
lipoplexes, the longer the circulation time in the blood (Templeton, 2003). However it 
has been suggested that large aggregates do not interfere with transfection and that 
since they cannot enter the cells by endocytosis, other cell entry mechanisms may be in 
place for the uptake of these larger complexes (Lasic, 1997). 
The transfection efficiency and the cell association and uptake of lipoplexes by CHO 
cells were seen to increase with increasing lipoplex size (Ross and Hui, 1999). The 
effect of lipoplex size on transfection effiCiency can be seen in the transfection studies 
presented in 2.3.4.3. The identification of the lipoplex that is most effective at delivering 
a gene could prove an extremely important factor in the improvement of gene transfer in 
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future studies.. It was shown that an increase in lipoplex size resulted in a decrease in 
transfection (Kawaura et al., 1998). 
It was observed that the lipoplex formation kinetics, and final lipoplex molar masses, 
geometric sizes, and density were all primarily determined by the DNA:cationic 
liposome charge ratio, with DNA concentration playing a very small role. Observation of 
charge ratios close to 1 showed that primary lipoplexes were unstable and subsequently 
aggregated to form DNA complexes, reaching a final stable state. For ratios above and 
below 1 the initial primary lipoplexes were stable and did not undergo any form of 
aggregation (Lai and van Zanten, 2002). It is assumed that if the lipoplex has an excess 
positive charge relative to the number of negatively charged phosphates of the plasmid 
DNA i.e. a net positive charge ratio (+ / -), the net surface charge (zeta potential) of the 
lipoplex will be positive. This is thought to facilitate the interaction with the anionic 
proteoglycans on the cell surface, and the lipoplex will be taken up by endocytosis 
(Zabner et al., 1995). It is further suggested that the diameter of the lipoplexes reaches 
a maximum when the surface potential is neutral. In vivo studies have shown that 
biodistribution of complexes after intravenous injection resulted in accumulation of 
positively charged complexes in the lung with little or no accumulation of negatively 
charged complexes (Ishiwata et al., 2000). 
Furthermore it is suggested that a hexagonal arrangement of lipid :DNA complexes 
helps to promote transfection (Koltover et al., 1998). 
2.3.3.5 Nuclease Protection Assays 
These studies were conducted to ascertain the protection afforded by the cationic 
liposomes to the bound DNA. All three lipoplexes (MS09:DNA, MS10:DNA and 
MS11 :DNA) afforded good protection of the DNA from digestion by serum nucleases, as 
seen in Figures 2.21 and 2.22 respectively. 
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Figure 2.21: Nuclease protection assay of cationic liposome MS09 and pBR322 DNA. 
Lane 1 : undigested plasmid pBR322 DNA (1 I-1g) 
Lane 2 : unprotected plasmid DNA (1 I-1g) digested by serum nucleases 
Lanes 2-8 : Varying amounts of cationic liposomes (0, 4, 6, 8, 10, 12, 14 
I-1g) with pBR322 DNA (1 I-1g) and serum (1 O%). 
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Figure 2.22: Nuclease protection assay of : 
(a) cationic liposome MS10 and pBR322 DNA, and, 
(b) cationic liposome MS11 and pBR322 DNA 
Lane 1 : undigested plasmid pBR322 DNA (1 IJg) 
Lane 2 : unprotected plasmid DNA (1 IJg) digested by serum nucleases 
Lanes 2-8 : Varying amounts of cationic liposomes (0, 2, 3, 4, 5, 6, 7 IJg) 
with pBR322 DNA (1 IJg) and serum (10%). 
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The addition of sodium dodecyl sulphate helps to liberate the bound and liposome 
protected DNA from the lipoplex so that it can be visualized on the agarose gel. The 
reaction between the positively charged cationic liposomes and the negatively charged 
DNA molecules via electrostatic forces results in the formation of highly organized 
supramolecular structures where the DNA molecules are condensed and protected 
against nuclease degradation (Pitard, 2002). This can be clearly seen in Figures 2.21, 
2.22. 
The naked DNA (lane 2) is not bound to liposomes and is extensively degraded by the 
presence of serum nucleases, whereas the DNA bound in lipoplexes is protected and 
not degraded, especially at the higher liposome:DNA ratios. The actual extent to which 
the DNA is protected by the liposomes will depend on the type of cationic liposome 
used. If the liposome:DNA association is not a strong or tight one, the nucleases may 
access and degrade the DNA, or, alternatively, destabilize the liposome:DNA complex 
(Yang and Huang, 1997). 
The inhibitory effect of serum on the transfection efficiency of cationic liposome:DNA 
complexes (lipoplexes) is a major obstacle to the application of a gene delivery vector 
both in vivo and in vitro. (Yang and Huang, 1997; Ross and Hui, 1999). 
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2.3.4 CELL CULTURE AND TRANSFECTION STUDIES 
2.3.4.1 Growth and Maintenance of Cell Lines 
The four different cell lines viz. HeLa (Human cervical carcinoma cells), NIH-3T3 
(mouse fibroblast cells), HepG2 (hepatocellular carcinoma cells) and SNO (human 
esophageal cancer cells) (Figures 2.23, 2.24, 2.25, 2.26), were successfully 
propagated in MEM + 10% heat inactivated fetal bovine serum + antibiotics. 
Trypsinised cells have a typical rounded appearance and can be seen for the HepG2 
cells in Figure 2.27. Cell growth, especially for HepG2 cells, at times was relatively slow, 
with cells only reaching confluency after 4 to 6 days. The HeLa, HepG2 and SNO cells 
are epithelial in morphology while the NIH-3T3 cells are fibroblasts. All cell lines were 
photographed using a Nikon camera attached to the inverted microscope at a 2 second 
exposure with a film speed of 200 ASA. 
Figure 2.23 : HeLa cells at semi-confluency. 
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Figure 2.24 : NIH-3T3 cells at semi-confluency. 
Figure 2.25 : HepG2 cells at semi-confluency. 
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Figure 2.26 : SNO cells at confluency. 




























Figure 2.28 : Growth inhibition studies of liposome MS09:DNA complexes in four cell 
lines in vitro. Liposome MS09 was varied (0, 3, 5, 6 , 7 I-lg) while the DNA 
(0.5 I-lg) was kept constant in a total volume of 0.5 ml MEM. A control 
sample (no liposome), containing only cells was assumed to have 100% 
survival. Data are presented as means ± S.D (n = 4). 
114 
100 




















Figure 2.29 : Growth inhibition studies of liposome MS10:DNA complexes in four cell 
lines in vitro. Liposome MS10 was varied (0,4,5,6,7 I-Ig) while the 
DNA (1 I-Ig) was kept constant in a total volume of 0.5 ml MEM. A control 
sample (no liposome), containing only cells was assumed to have 100% 























Figure 2.30 : Growth inhibition studies of liposome MS11 :DNA complexes in four cell 
lines in vitro. Liposome M11 was varied (0, 4, 5, 6, 7 j.Jg) while the DNA 
(1 j.Jg) was kept constant in a total volume of 0.5 ml MEM. A control 
sample (no liposome), containing only cells was assumed to have 100% 
survival. Data are presented as means ± S.D (n = 4). 
116 
2.3.4.3 Transfection Studies 
The three different cationic liposome formulations were tested for their in vitro 
transfection activity in four different cell lines viz. HeLa, NIH-3T3, SNO c;md HepG2 
cells. Transfection activity was also compared to the cationic liposome formulation, 
Lipofectin TM. Which is one of the first commercial lipofection agents and is an 
equimolar mixture of DOTMA and DOPE. Lipofectin ™ was found to successfully 
transfect DNA into many tissue types but performed poorly in mouse fetal brain cells 
(Sakurai et al., 2001). Significant transfection activity was observed for all three 
liposome formulations ( MS09 - Figure 2.31 and Figure 2.32; MS10 - Figure 2.33 and 
Figure 2.34; and MS11- Figure 2.35 and 2.36), with different liposome formulations 
showing optimal transfection activity at specific liposome:DNA ratios. Beyond the 
optimal liposome:DNA ratio (+/- charge ratio of 1.3 FOR MS09 and 0.8 for MS10 and 
MS11 lipoplexes) there is a noticeable drop in transfection activity especially for 
liposome MS09. This could be due to the formation of larger lipoplexes, as discussed 
in section 2.3.3.4, at higher liposome:DNA ratios, that do not easily facilitate 
endocytosis. For optimal transfection, complex aggregation as well as condensation are 
important considerations, and reinforce the thought that sizes of the lipoplexes are 
critical for gene transfection. Optimal transfection is thought to be a result of a delicate 
balance between the toxicity of a lipid and the level of expression (Lasic, 1997). 
Transfections with no liposome or DNA (control 1 ) and with naked DNA (control 2) were 
the controls employed against which transfection was measured. Transfection activity in 
these control cells showed negligible luminescence, as can be seen in Figures 2.31-
2.37). Liposome MS09 showed the highest transfection activity and performed much 
better in some cell lines than Lipofectin ™ (Figure 2.37). Transfection activity was 
greatest at liposome:DNA (+/-) charge ratio of 1.3 for MS09, and 0.8 to 1 for MS10 
and MS11. Optimal transfection was obtained at a liposome:DNA ratio of 8:1 (w/w) for 
Lipofectin™. It is suggested that the DNA:liposome mixing ratio Significantly affects the 
intracellular trafficking of plasmid DNA complexed to cationic liposomes (Sakurai et al., 
2000). The highest transfection activity for MS09 was observed for the HeLa cell line 
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which was 3 fold greater (387 x 106 LU / mg protein) than that of Lipofectin™ (1.10 x 
1 06 LU / mg protein) at its optimalliposome:DNA ratio. This is also extremely promising, 
considering that only 0.5 IJg pGL3 DNA was used in transfections with MS09 liposomes, 
while 1 IJg pGL3 was utilized for transfection with Lipofectin TM. Lipofectin ™ only 
performed slightly better (1.6 x 106 LU / mg) in the NIH-3T3 cell line when compared to 
MS09 (1.5 x 106 LU / mg protein). MS091iposomes in SNO (2.0 x 106 LU / mg) and 
HepG2 (1.3 x 106 LU / mg) cells also performed slightly better than Lipofectin™ 
(1.1 x 106 LU / mg for SNO cells and 1.0 x 106 LU / mg for HepG2 cells). Although 
liposomes MS 10 and MS 11 showed significant transfection levels, they were not as 
high as those achieved using Lipofectin ™ or liposome MS09. It has been suggested 
that HeLa cells may be more easily transfected than fibroblasts (eg. 3T3 cells) due the 
the observation that after translocation of the DNA into the nucleus, it disappears rapidly 
in fibroblasts, but remains for a longer period in HeLa cells (Coonrod et a/., 1997 ; 
Zhdanov et a/., 2002). 
Several factors are thought to influence the success of cationic liposome-mediated DNA 
transfer, viz: (Dass and Burton, 1999). 
(i) cell type and whether culture is primary or a subculture of a primary 
(ii) stage of cell in the growth cycle and cell seeding densities 
(iii) DNA:liposome ratios 
(iv) any chemical treatment of liposomes prior to addition of DNA 
(v) type and concentration of salts / biomolecules in liposome:DNA mixing 
medium and constitution of cell culture medium 
(vi) size of lipoplexes and time allowed for lipoplexes to mature before addition 
to cells 
(vii) dilution of Iiposome:DNA complex suspension 
(viii) incubation time of lipoplexes with cells, and 
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Figure 2.31 : Transfection studies of liposome MS09:DNA complexes (with and without 
incubation in 10% serum) in (a) HeLa cells and (b) NIH 3T3 cells 
in vitro . Liposome MS09 was varied (0, 3, 5 ,6 ,7 IJg) while the DNA 
(0.5 IJg) was kept constant in a total volume of 0.5 ml MEM. Control 1 
contains only cells and control 2 contains naked DNA and no liposome. 
Data are presented as means ± S.D (n = 4). 
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Figure 2.32 : Transfection studies of liposome MS09:DNA complexes (with and without 
incubation in 10% serum) in (a) SNO cells and (b) HepG2 cells in vitro. 
Liposome MS09 was varied (0, 3, 5, 6, 7 I-Ig) while the DNA (0.5 I-Ig) 
was kept constant in a total volume of 0.5 ml MEM. Control 1 contains 
only cells and control 2 contains naked DNA and no liposome. 
Data are presented as means ± S.D (n = 4). 
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Figure 2.33 : Transfection studies of liposome MS10:DNA complexes (with and without 
Incubation in 10% serum) in (a) HeLa cells and (b) 3T3 cells in vitro. 
Liposome MS1 0 was varied (0,4, 5, 6, 71-19) while the DNA (1.0 1-19) 
was kept constant in a total volume of 0.5 ml MEM. Control 1 contains 
only cells and control 2 contains naked DNA and no liposome. 
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Figure 2.34 : Transfection studies of liposome MS10:DNA complexes (with and without 
Incubation in 10% serum) in (a) SNO cells and (b) HepG2 cells in vitro. 
Liposome MS1 0 was varied (0,4, 5, 6, 7 1-19) while the DNA (1.0 1-19) 
was kept constant in a total volume of 0.5 ml MEM. Control 1 contains 
only cells and control 2 contains naked DNA and no liposome. 
Data are presented as means ± S.D (n = 4). 
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Figure 2.35 : Transfection studies of liposome MS11 :DNA complexes (with and without 
Incubation in 10% serum) in (a) HeLa cells and (b) 3T3 cells in vitro. 
Liposome MS11 was varied (0, 4, 5, 6, 7 1-19) while the DNA (1.0 1-19) 
was kept constant in a total volume of 0.5 ml MEM. Control 1 contains 
only cells and control 2 contains naked DNA and no liposome. 
Data are presented as means ± S.D (n = 4). 
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Figure 2.36 : Transfection studies of liposome MS11 :DNA complexes (with and without 
Incubation in 10% serum) in (a) SNO cells and (b) HepG2 cells in vitro. 
Liposome MS10 was varied (0,4, 5, 6, 7 ~g) while the DNA (1.0 ~g) 
was kept constant in a total volume of 0.5 ml MEM. Control 1 contains 
only cells and control 2 contains naked DNA and no liposome. 
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Figure 2.37 : Transfection studies of Lipofectin TM:DNA complexes in four cell lines 
in vitro. Lipofectin ™ was varied (0, 4, 6, 8, 10 I-lg) while the DNA (1.0 I-lg) 
was kept constant in a total volume of 0.5 ml MEM. Control 1 contains 
only cells and control 2 contains naked DNA and no liposome. 
Data are presented as means ± S.D (n = 4). 
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During the preparation of this thesis the synthesis of two cholesterol-based cationic 
lipids with a p-alanine [2-(N-p-alanyl)aminoethyl-cholesteryl ether], and a glycine [2-(N-
glycyl)aminoethyl-cholesteryl ether] head group that are similar to head groups of our 
MS 10 and MS 11 derivatives was reported. These 2 cationic lipids showed large 
differences in their transfection efficiency, with the p-alanyl derivative being 10-24 fold 
more efficient in transfecting CHO, COS-1 and HepG2 cells than its glycyl analog. This 
was attributed to the extra methylene group of the p-alanine in its polar head group 
region (Singh and Chaudhuri , 2004). In our studies, however MS11 (p-alanyl derivative) 
showed only a slight increase in optimal gene expression over the MS10 (glycyl 
derivative) in HeLa cells (2% increase), NIH-3T3 (10% increase) and HepG2 (1.5% 
increase), but a somewhat higher increase in SNO cells (30%). Although spacer 
lengths in the p-alanyl and glycyl compounds reported by Singh and Chaudhuri are 
similar to those in MS11 and MS10 respectively, the spacer is attached to the 
cholesteryl moiety at its 3 position by an ether linkage rather than the carbamoyl linkage 
which is the case in the study reported here. 
Transfections with liposomes MS09, MS10 and MS11 were also conducted in 10% 
serum to ascertain the effect of the serum components on transfection efficiency and to 
provide some insight into the future possibility of using these liposome formulations for 
in vivo experiments. From the results obtained it can be seen that the incubation of 
lipoplexes for the four hour period in 10% serum containing medium resulted in a 
decrease in transfection activity, with the HepG2 system being the least affected. This 
could be attributed to the protection afforded by the liposomes to the DNA molecules as 
seen in the nuclease digestion assays. It has been proposed that the efficiency of 
cationic liposome-mediated gene expression often decreases with addition of serum 
(Yang and Huang, 1997). Some investigators have even reported a total inhibition of 
transfection after incubation with serum for as little as two hours (Nchinda et al. , 2002). 
The influence on transfection efficiency of lipoplexes by cationic liposome:DNA ratios, 
liposome type, incubation time in polyanion containing media, time of serum addition 
are all mediated through lipoplex size. Lipoplexes at a 2:1 charge ratio were seen to 
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grow in size in media containing polyanions. Size growth of the lipoplexes may be 
.halted by the addition of serum to the incubation medium and large lipoplexes may help 
to overcome the inhibitory effects of the added serum (Ross and Hui, 1999). It has 
been reported that maximum gene expression occurs at intermediate stablilty, because 
stable complexes restrict DNA transcription and unstable complexes permit rapid 
degradation of the plasmid DNA ( Luo and Saltzman, 2000). 
Cationic liposome mediated transfections are often conducted in serum-free medium at 
least for the first few hours. A longer incubation time with the lipoplexes ego four hours 
vs one hour results in a higher amount of internalized lipoplex and hence a higher 
degree of transfection (Zuhorn et a/., 2002). This serum free medium which is removed 
after a few hours (4 hours in the experiments conducted in this study), does not affect or 
displace the liposome:DNA complex from the cell surface, since the DNA and liposome 
remain tightly complexed and bound to the cell surface. These phenomena were also 
observed using an inverted light microscope. The liposome:DNA complex therefore will 
be continuously internalised into the cell from the cell surface. Transfection of plasmid 
DNA is closely related to the problem of condensation of its molecules as the plasmid 
may be too large to effectively overcome the cellular membrane barrier. The formation 
of relatively small lipoplexes of 100 to 350 nm in diameter as seen in Section 2.3.3.4, is 
favourable for transfection. The transfected DNA is probably transported efficiently 
through the nuclear membrane during interphase, and it is assumed that the breakdown 
of the nuclear membrane during mitosis is crucial for the entry of the transfected DNA 
into the nucleus. Transfection efficiency hence depends upon cell division. 
When using medium containing serum in the four hour incubation of lipoplexes, it is 
believed that polyvalent negatively charged molecules such as albumin, present in the 
serum may compete in charge interactions (Harrison et a/., 1995). However the 
complete mechanism of serum inhibition of transfection is still unclear. Lipoplexes 
interact with blood components due to their strong positive charge. Binding of serum 
proteins on the lipoplexes is thought to be due to non-specific electrostatic interactions 
(Sakurai et a/., 2001). The charged components of the serum may bind to the 
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metastable particles, and either facilitate aggregation or interfere with polynucleotide 
coating (Ahearn and Malone, 1999). The adsorption of negatively charged proteins 
neutralizes the cationic charge of the complex and also increases their size, which in 
turn will lead to a reduction in gene expression. If the size of the complex exceeds 5 ~m 
in diameter during preparation or after interaction with serum components, it will not 
pass through capillaries and results in embolization of downstream tissues (Nishikawa 
and Huang, 2001). If however sufficient time is allowed for mature particles to form 
before addition of serum, there will be no decrease in transfection activity. Factors such 
as higher temperatures, concentration, higher liposome:DNA ratios, all increase the 
speed at which serum resistance is obtained (Yang and Huang, 1998). Fetal bovine 
serum was found to inhibit binding of cationic and anionic liposomes to rat liver 
parenchymal cells (Hoekstra and Scherphof, 1979). 
A crucial step in the overall transfection process is the endosomal release of lipoplex 
and / or DNA into the cytosol. Hence, even if a substantial uptake of lipoplexes into 
cells occurs, failure of significant endosomal escape of plasmid prior to arrival of 
lipoplexes into Iysosomes, where degradation occurs, will result in reduced transfection. 
This is an important factor to consider when comparing transfection efficiencies of 
different cell lines. Differences occur in efficiency of lipoplex internalization, endosomal 
escape and processing of DNA into the nucleus in different cells (Zuhorn et al., 2002). 
Although there is a correlation between delivery of DNA and gene expression, it is often 
found that DNA delivery into the nucleus of a particular cell is efficient but little or no 
gene expression is achieved (Templeton, 2003). 
Both the quality of plasmid DNA and the transfection reagent used strongly influences 
the results of transfection experiments (Singer et al., 1999). The pGL3 plasmid DNA 
utilized in our study was amplified and prepared according to the manufacturer's 
protocol (Promega). It was a pure sample, free from contaminants, with a 260:280 ratio 
of not less than 1.8. Most of the plasmid was in the form of supercoiled DNA with less 
closed circular forms present. The use and choice of a suitable reporter gene 
expression system is also of great importance. The luciferase assay system was used 
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for the detection of transient gene expression in the cells. The increased sensitivity and 
ease of detection of the firefly luciferase has an appeal over the other reporter gene 
assays. Its increased sensitivity, especially over the CAT assay, allows transfection of 
fewer cells, using less material and a shorter turn-around time (Fulton and Van Ness, 
1993). 
The reaction catalysed by the firefly luciferase has the highest quantum efficiency 
known of any chemiluminescent reaction (Seliger and McElroy, 1960). Luciferase, is a 
monomeric protein (61 kD), that does not require post-translational processing for 
enzymatic activity, and can hence function as a genetic reporter immediately upon 
translation (de Wet ef al., 1985). The overall ATP-dependent reaction catalysed by the 
firefly luciferase is the oxidative decarboxylation of beetle luciferin, producing light 
emission (photon) at a wavelength of 562 nm. The principle of the luciferase reaction 
can be divided into a two stage process as set out below. 
Mi+ 
1. Luciferase + Luciferin + AlP > Luciferase.luciferyl-AMP + ppi 
2. Luciferase.luciferyl-AMP + O2 > Luciferase + oxyluciferin + AMP + CO2 +hv 
(light) 
The first reaction involves the formation of luciferase.luciferyl-AMP. The second 
reaction involves the decarboxylation of the luciferase.luciferyl-AMP to produce 
oxyluciferin, CO2 , AMP and light (hv). 
The coenzyme A (CoA) is also used as a substrate for luciferase. Oxidation occurs 
instead from luciferyl-CoA, as in the Promega assay system. The flash of light emitted 
by the luciferase assay rapidly decays after the enzyme and substrate are mixed. The 
system used in this assay produces a light intensity that is constant for up to several 
minutes. This light intensity, since it measures the rate of catalysis by the luciferase 
enzyme, is therefore dependent upon temperature. Optimum temperature for luciferase 
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activity is around room temperature (20 - 25 D C). Hence the requirement for all the 
reagents to be equilibrated to room temperature before starting the assay procedure. 
This overall process of transfection has many uses in medical research. It allows 
proteins whose functions are not well understood to be expressed in cultured cells (as 
seen above), so that their behaviour may be monitored. Liposome mediated transfection 
has also shown potential in predicting the optimal treatment for tumour cells by 
determining the tissue-specific expression of the target gene in prostate cancer cells 
(Suzuki et al., 2001). 
2.4 CONCLUSION 
From the results obtained it can be concluded that the three novel cationic liposomes 
are capable of significant transfection activity. It is accepted that the transfection 
efficiency, mediated by mixtures of cationic lipids and neutral "helper lipids" varies 
widely and unpredictably (Safinya, 2001). The most important result to emerge was that 
cationic liposome MS09 showed extremely high transfection levels in vitro in all four cell 
lines, and performed better than Lipofectin ™ in the three human transformed epithelial 
cell lines, HeLa, HepG2 and SNO. Furthermore its relatively low toxicity to cells in vitro 
makes it a suitable formulation for further studies. In order to increase the efficiency of 
transfection by cationic liposomes one could add a targeting ligand or a built-in targeting 
moiety in the liposomal formulation for cell-specific delivery. For this reason the cationic 
cholesterol derivative MS09, which yielded the best results, was utilised in studies 
described in Chapters 3 and 4, where it was formulated with targeting moieties to direct 
liposomes to the transferrin receptor (HeLa cells) and the asialoorosomucoid receptor 
(HepG2 cells) respectively. In both chapters, liposomes were prepared from MS09 and 
other novel cholesteryl derivatives as a prelude to the construction of larger assemblies 
intended for targeted delivery. 
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CHAPTER THREE 
TARGETING OF CATIONIC BIOTINYLATED LlPOSOMES TO TRANSFERRIN 
RECEPTORS 
3.1 TARGETING OF LlPOSOMES 
The rate of entry of lipoplexes into cells varies with cell type and is generally a slow 
process (Zabner et a/., 1995). To speed up this process and to improve the cell 
specificity of gene expression by a Iiposome:DNA complex, the incorporation of a 
homing device into the complex is necessary (Remy et. a/., 1995; Nishikawa and 
Huang, 2001). The exploration of the potential of site-specific and targeted drug and 
gene delivery systems has gained enormous interest recently. The possibility of 
targeting genes or drugs to specific tissues and cells, as well as facilitating their uptake 
and cytoplasmic delivery has rendered liposomes as a versatile carrier system with 
numerous potential applications in medicine. Targeting provides an added advantage 
over non-targeted delivery systems in that it could prevent or minimize the side-effects 
of drugs or genes in healthy tissue in addition to enhancement of drug or gene uptake 
(Minko, 2004). It is possible that liposomes can bind to different cell surface receptors 
on different cells and that they could utilize more than one type of receptor on a 
particular cell (D(jzg(jne~ and Nir, 1999). 
A characteristic difference between normal and tumour cells which may be exploited is 
essential for targeting. This could be a structure expressed solely on tumour cells. 
However, there are very few known structures exclusively expressed on tumour cells. 
There could also be a difference in the number of an expressed structure. These 
structures, called tumour-associated antigens, are also often found in the organs from 
which the tumour originated. Antibodies are the most commonly used biomolecules in 
targeting against tumour-associated antigens. Other types of biomolecules suggested 
for targeting are hormones or ligands, which are directed towards normal cellular 
receptors that are overexpressed in certain tumour cells. Such biomolecules include the 
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epidermal growth factor (EGF), asialoglycoprotein, folate, galactose, and transferrin that 
can be targeted to their respective receptors (Qian et al., 2002). 
These naturally occurring ligands to cell surface receptors offer some advantages over 
antibodies, such as lack of immunogenicity, low toxicity, biodegradability and low 
preparation costs (Qian et al., 2002). The EGF-targeted liposomes may be useful in 
tumour targeting as many carcinoma cells show relatively high expression of this 
receptor (Kikuchi et al., 1996). The folate receptor has been identified as a marker in 
ovarian carcinomas. Folate-targeted liposomes have also been designed for this 
purpose and targeted to cells that overexpress the folate receptor ( Lee and Low, 1994). 
In this chapter we deal with the use of the transferrin ligand (Tf) in targeting to 
transferrin receptors on HeLa cells. Transferrin is a well studied ligand for tumour 
targeting due to the upregulation of transferrin receptors in numerous cancer cell types 
(Cotton et al., 1990; Wagner et al., 1994; Bellocq et al., 2003). It is also one of the most 
widely used ligands for synthetic targeting systems. The efficient cellular mechanism of 
transferrin uptake has been exploited for the delivery of anticancer drugs, proteins, and 
therapeutic genes into proliferating malignant cells that overexpress transferrin 
receptors (Singh, 1999). Transferrin can be utilized for targeting either in the form of 
drug conjugates, hybrid systems with macromolecules or as liposomal-coated systems. 
Various drugs such as doxorubicin and chlorambucil have already been conjugated to 
transferrin for delivery to certain cancer cells. The use of Tf-coupled liposomes for drug 
(eg doxorubicin) delivery has enhanced uptake by cells via receptor mediated 
endocytosis (U and Qian, 2002). Other Tf conjugates such as Tf-polylysine (Cotton et 
al., 1990; Wagneretal., 1991; Curiel etal., 1992; Schoeman etal.,1995), Tf-PEI (Ogris 
et al., 1999; Kursa et al., 2003) and Tf-protamine enhanced liposomes (Tros de lIarduya 
et al., 2002) have been shown to be efficient carriers for the introduction of genes into 
various cells such as human leukemic cells (K-562) and hematopoietic cells. Tf-PEI 
conjugates have been used to efficiently mediate topical gene transfer to the lungs after 
intratracheal nebulisation (Rudolf et al., 2002). The transferrin receptor also offers great 
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promise in the delivery of therapeutic agents across the blood-brain barrier to the brain 
(Li et a/., 2002). 
For in vivo systems this process of targeted delivery, can be roughly divided into two 
phases viz. the transport phase in which the liposome travels from the site of 
administration to the target cells, and the effector phase that includes the specific 
binding of the liposome to the target cell receptor, and subsequent delivery of the bound 
gene or drug of interest (Mastrobattista et a/., 1999). 
3.1.1 The Transferrin (Tf) ligand 
Iron is transported in blood plasma and intestinal fluids bound to a carrier protein called 
transferrin (Tf). The iron requirement of any cell or tissue is particularly high during 
periods of cell proliferation and growth (Taylor and Morgan, 1990). Hence the Tf 
concentration in plasma varies in humans at different stages of the life cycle and in 
certain diseases. The serum transferrin concentration is about 2.5 mg/ml (35 IJM) with 
30% bound to iron (Li and Qian, 2002). The liver is the prime synthesizer of transferrin 
(Morgan, 1969), while a significant amount is also produced in the brain (Takeda, 
2001 ). However the levels of brain transferrin decrease with age and a dramatic 
decrease is observed in neurodegenerative diseases such as Alzheimer's disease or 
Parkinson's disease (Takeda, 2001). 
Transferrins are 80 kDalton single-chain polypeptides of 670-700 amino acids (Li and 
Qian, 2002), and consist of two similarly sized homologous Nand C lobes with a 
minimum molecular weight in the range of 35-45 kDaltons (Baker et al., 1968), which 
are further divided into two similarly sized domains (N1 and N2 in the N lobe and C1 
and C2 in the C lobe). The C lobe has a carbohydrate chain attached with sialic acid 
residues which could affect the binding of metals to Tf. The most common Tf contains 
two biantennary complex-type glycans with a total of four sialic acid residues (Nagaoka 
and Maitani, 2001). The two iron binding sites are located within the interdomain cleft of 
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each lobe. These sites bind, with high affinity, one Fe3+ atom in combination with one 
col- ion. Fe3+ binding is reversible and pH dependent. The amino acid tryptophan 
seems to be involved in the iron binding site (Mazurier et al., 1976). Tf can exist in three 
forms in the serum, viz. apotransferrin (no Fe3+), monoferric Tf (one Fe3+) and diferric Tf 
(two Fe3+) (Mizutani et al., 1999). 
The best known transferrins are serum transferrins that are found in blood, bile, 
amniotic fluid, cerebrospinal fluid, lymph, colostrum and milk; ovotransferrin found in 
egg white; lactoferrin found in mammalian milk, secretions (tears, saliva, mucus) and in 
white blood cells; and melanotransferrin (p97) that is found anchored to the membrane 
surface of melanocytes and other cells. All transferrins except lactoferrin are acidic 
proteins with the diferric species having an isoelectric point (pI) value of around 5.6-5.8 
(Li and Qian, 2002). The transferrin ligands used in these studies are the serum 
transferrins. 
3.1.2 The Transferrin Receptor (TfR) 
There are two types of receptors on cells that are potentially able to mediate the uptake 
of Tf, viz. the specific Tf receptor which has a higher affinity for diferric Tf than the 
monoferric Tf, and, the asialoglycoprotein receptor which is believed to mediate the 
endocytosis and cellular acquisition of iron bound to asialotransferrin (Morgan, 1991). 
The reaction between Tf and TfR is reversible, pH dependent and influenced by the iron 
content of the Tf. At physiological pH, the receptor has a high affinity for iron-saturated 
Tf, especially diferric Tf, but a lower affinity for apotransferrin (Morgan, 1999). The TfR 
is a transmembrane homodimer made up of two subunits containing 760 amino acids 
each (Kuhn et a/., 1984), joined by disulphide bonds at cysteine 89 and 98. The 
homodimer of TfR can bind up to two molecules of Tf. Human TfR is synthesized in the 
endoplasmic reticulum and post-translationally modified with both phosphates and fatty 
acyl groups (Qian et al., 2002). Oligosaccharides account for 5% of the receptor's 
90 kDalton subunit molecular mass. Tf receptors on the outer face of the plasma 
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membrane bind iron loaded Tf with a very high affinity. The C-terminal domain of Tf 
appears to mediate binding to the receptor (Zak et al., 1994). 
Transferrin receptors are predominant or elevated in various forms of cancer cells, 
including squamous cell carcinomas such as oral tumours, and seem to correlate with 
the aggressive or proliferative ability of tumour cells. Hence, transferrin receptors may 
be useful as potential targets for drug / gene delivery (Joo and Kim, 2002). These 
rapidly dividing cells can express from 10000-100000 TfR molecules per cell (Inoue et 
al., 1993). HeLa cells used in this study are amongst those cells that express the 
transferrin receptor (Derycke and De Witte, 2002). HeLa cells were found in some 
cases to express approximately 2 x 105 receptors /cell (Bridges and Smith, 1985). It 
was shown that cells in culture can also synthesise an increased number of Tf receptors 
when stimulated to proliferate (Iacopetta et al., 1982). Rat reticulocytes were found to 
express an average of 85 000 Tf receptor sites per cell (Morgan, 1981), and 
hepatocytes about 18 600 receptors per cell (Bridle et al., 2003). The Tf receptor has 
also shown potential for systemic p53 tumour suppressor gene therapy in a human 
breast cancer metastasis model ( Xu et al., 2002). 
Transferrin receptors have been identified to be sometimes overexpressed in various 
cell types, viz. aortic endothelial cells (Voinea et al., 2002), liver cells (hepatocytes) 
(Morgan, 1999), hepatic stellate cells, Kupffer cells, fibroblasts, neuronal cells ( Bridle et 
al., 2003), corneal endothelium cells (Tan et al., 2001), adipocytes (Tros de lIarduya et 
al., 2002), in glioma cells where the number of receptors seems to increase with the 
severity of the tumour (Eavarone et al., 2000) and in erythroblasts which have the 
highest number of Tf receptors (Vernet, 1999). Tf receptors can exist as cellular or 
serum Tf receptors. The serum Tf receptor is a truncated monomeric form of the cellular 
receptor and lacks its first 100 amino acids, and usually circulates as a Tf-TfR complex. 
Erythroblasts are the main source of serum TfR (sTfR) (Beguin, 2003). Serum 
transferrin receptors are unaffected in inflammatory diseases, infections, malignancies 
or cytolysis but are considered useful tools in diagnosis of different causes of anemia 
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(Vernet, 1999) and the bone marrow erythropoietic activity where there is either an 
8 fold or a 20 fold decrease in sTfR levels (Seguin, 2003). 
A second Tf receptor (TfR2) has been cloned and sequenced (Kawabata et a/., 1999). 
It has a similar function to TfR in Tf binding but its affinity for iron-loaded Tf is 25-fold 
lower. TfR2 is thought to be important in maintenance of iron haemostasis and is linked 
to the disorder of hemochromatosis (Li and Qian, 2002). 
3.1.3 The Uptake of Transferrin 
Cells possess endogenous pathways for internalization of macromolecules. The 
utilization of these pathways for the purpose of DNA delivery is advantageous. These 
cellular internalization pathways can be highly efficient, as seen in the internalization of 
Tf, which can be in the order of thousands of molecules per minute per cell. Hence, 
these pathways represent a potentially efficient physiological method for the transport of 
DNA across the cell membrane of eukaryotic cells (Curiel, 1996). The in vitro 
transfection efficiency of cationic liposomes can be increased when complexed to 
transferrin exploiting the mechanism of receptor-mediated endocytosis. Cells generally 
acquire iron from transferrin via receptor-mediated endocytosis of the transferrin-iron 
complex (Qian and Morgan, 1992). 
Transferrin is first bound to the Tf receptor on the cell surface to form a Tf-receptor 
(TfR) complex which accumulates at one end of the cell (capping), and is then 
internalized by endocytosis (Hibbs, 2000). This process involving invagination of 
clathrin-coated pits and formation of endocytotic vesicles requires the short, 61 amino 
acid intracellular tail of the Tf receptor molecule (Miller et a/., 1991). Tf binding is a 
simple chemical event and not dependent on any metabolic energy. After endocytosis 
the iron is released from the Tf within the endosomes (pH 5.0-5.5) and enters the 
cytosol to be incorporated into heme, utilized as a cofactor for aconitase, cytochromes 
and RNA reductase, or stored as ferritin , while the apotransferrin and the TfR are 
recycled to the cell surface. Apotransferrin has a much lower affinity for Tf receptors at 
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physiological pH than at acidic pH, but was shown to mediate significant levels of gene 
expression at different lipid/DNA (+/-) ratios (Simoes et al., 1999). 
The TfR seems to localize to three different populations of endosomal vesicle: those 
containing only Rab5, those containing Rab5 and Rab4, and those containing Rab4 and 
Rab11. These Rab endosomal proteins are small GTPases of the Ras superfamily 
(Jones et al., 2003). Rab5 and Rab4 are localized in the early endosomes and regulate 
fusion between the endocytotic vesicles and the early endosomes, and recycling. Hence 
they are important in endosomal trafficking (McCaffrey et al., 2001). Rab11 however 
has been shown to co-localise with internalized Tf in the pericentriolar recycling 
compartment of CHO and BHK cells (Ullrich et al., 1996), but does not affect transferrin 
recycling in Hela cells (Wallace et al., 2002). Tf-receptor complexes are recycled via 
exocytotic vesicles back to the cell membrane (Li and Qian, 2002), or, in the case of 
polarized cells, they can be transcytosed from the apical to the basolateral membrane 
(Jones et al., 2003). The apotransferrin is released, due to its low affinity for its receptor 
at pH 7.4, into the medium, and the receptors bind more iron-transferrin to repeat the 
cycle (Qian and Morgan, 1992 ; Savigni and Morgan, 1998). Tf and its receptor seem to 
recycle from the cell surface to intracellular sites without degradation, with an average 
recycling time of 3-4 minutes in rat erythrocytes (Morgan and Peters, 1985). This was 
also observed in K562 cells with about 150 000 TfR per cell and a mean transit time of 
about 10 minutes. This leads to high turnover numbers of about 2 x 104 Tf molecules 
internalized per minute (Wagner et al., 1994). 
Tf undergoes conformational changes during both Fe3+ uptake and release, that are 
crucial for the selective recognition by the receptor. The two lobes of Tf open and close, 
by a mechanism which is not completely understood (Qian et al., 2002). The transferrin 
molecule undergoes unfolding upon dissociation of the iron cations. However if one iron 
cation is removed the secondary structure of transferrin is not affected, but removal of 
the second iron cation results in simultaneous unfolding of the protein (Mazurier et al., 
1976). The rate limiting step for Tf-iron uptake by cells is the rate of Tf endocytosis 
which in turn is dependent, in part, on the number of recycling receptors in the cell (Qian 
and Morgan, 1992). Co-localization studies with transferrin, showed that it is 
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internalized via the c1athrin-coated endocytotic pathway, and that the internalization via 
caveolae do not seem significant (Zuhorn et al., 2002). Receptor-mediation, however 
only accounts for part of the Tf uptake, the remainder being derived from non-saturable 
adsorptive processes and fluid-phase endocytosis (Morgan, 1991). The endocytosis of 
Tf in the liver of rats was seen to increase during iron deficiency (Morgan et al., 1986). 
Various binding studies on rat reticulocytes have shown that the forces involved in Tf 
binding are a combination of weak forces such as hydrophobic, hydrogen bonding or 
van der Waals forces. Binding involves a single bimolecular interaction between Tf and 
the binding sites. Two types of interaction between Tf and reticulocytes exist, viz. 
adsorption and association reactions (Baker and Morgan, 1969). 
3.1.4 Streptavidin-Biotin Interaction 
The use avid ins offer an attractive approach to organ- or tissue-selective targeting. 
Avidin and streptavidin, the two biotin-binding proteins, can be targeted to specific 
tissues when modified with appropriate tissue markers. Their resistance to proteolytic 
enzymes supports long-term accumulation at the target tissue or organ, and their biotin 
binding sites permit the delivery of biotinylated molecules or carriers loaded with 
cytotoxic drugs or other bioactive substances (Chen et al., 2000). The high affinity of 
avidin for biotin was first exploited in histochemical applications in the mid-1970s. This 
egg-white protein and its bacterial counterpart, streptavidin, produced by Streptomyces 
avidinii, have since been utilized for diverse applications (Wilchek and Bayer, 1988). 
Avidin is a highly cationic 66 kDalton glycoprotein with an isoelectric point of about 
10.5. It is thought that avidin's positively charged residues and its oligosaccharide 
component (heterogeneous structures composed largely of man nose and N-
acetylglucosamine) can interact non-specifically with negatively charged cell surfaces 
and nucleic acids, sometimes causing background problems in some histochemical 
applications (Bayer et al., 1993). Therefore, instead of avidin, streptavidin has been 
frequently used due to the fact that it does not bind non-specifically. 
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Streptavidin is a non-glycosylated 52 800 Dalton protein with a near-neutral isoelectric 
point (pi 5-6), and exhibits less nonspecific binding than avidin. Since streptavidin is 
not a glycoprotein, its potential to bind to carbohydrate receptors is reduced. Both its pi 
value and its specificity reduce the chances of systemic clearance in vivo (Schnyder et 
al., 2004). However, streptavidin contains the tripeptide sequence Arg-Tyr-Asp (RYD) 
that apparently mimics the Arg-Gly-Asp (RGD) binding sequence of fibronectin, a 
component of the extracellular matrix that specifically promotes cellular adhesion. This 
universal recognition sequence binds integrins and related cell-surface molecules. 
Background problems sometimes associated with streptavidin may be attributable to 
this tripeptide. (Alon et al., 1993). Streptavidin is a small protein, which diffuses rapidly 
through leaky capillaries at sites of inflammation (Das et al., 2002) .. 
Avidin and streptavidin each bind four biotins per molecule with high affinity and 
selectivity. Biotin has both high affinity for streptavidin and rapid whole body clearance 
(Das et al., 2002). Amino acid residues are critical for stabilization of the tetrameric 
assembly and for the exceptionally tight binding of biotin. The binding of biotin to 
streptavidin involves a highly stabilized network of polar and hydrophobic interactions. 
Avidin, however, has a higher biotin affinity constant, probably due to the presence of 
additional hydrophobic and hydrophilic groups in its binding site (Livnah et al., 1993). 
Dissociation of biotin from streptavidin is hence reported to be about 30 times faster 
than dissociation of biotin from avidin (Piran and Riordan, 1990). Their multiple binding 
sites permit a number of techniques in which avidin or streptavidin can be used to 
bridge two biotinylated reagents. This bridging method, which is commonly used to link 
a biotinylated probe to a biotinylated enzyme in enzyme-linked immunohistochemical 
applications, often eliminates the background problems that can occur when using 
direct avidin or streptavidin-enzyme conjugates. 
Receptor-mediated endocytosis via the transferrin receptor using conjugates of 
streptavidin or avidin, biotinylated Tf and biotinylated polylysine and pRSVL DNA was 
described previously (Schoeman et al., 1995 ; Strydom et al., 1993). The addition of 2-4 
PEG chains to the above conjugate seemed to increase luciferase activity 4-5 fold in a 
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HeLa cell system (Robinson et al., 1997). The use of streptavidin as a linker between 
biotinylated polyethyleneglycol-phospholipid present in a liposome bilayer and an 
antibody raised against the rat Tf receptor in skeletal muscle was also recently 
investigated, and showed promising results for future targeting studies (Schnyder et al., 
2004). 
3.2 OUTLINE OF CHAPTER 
In this chapter we outline the synthesis of two biotinylated cholesterol derivatives, their 
formulation with cationic cholesterol derivative MS09 (chapter 2) and DOPE to produce 
liposomes, and the formation of a ternary complex between these biotinylated 
liposomes, plasmid DNA (pGL3) and a streptavidin-biotin-transferrin conjugate. The 
transferrin ligand (targeting moiety) was first conjugated to three biotin molecules which 
were then bound to streptavidin to produce a streptavidin-biotin-transferrin 
(streptavidinbiotransferrin) complex. The streptavidin in the conjugate acts as a bridge 
between the transferrin and the biotin that is anchored by the cholesterol group in the 
liposomal lipid bilayer. The aim of these studies was to determine whether these novel 
liposomal formulations coupled to Tf are taken up by transferrin-specific receptors on 
HeLa cells in vitro. 
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3.3 MATERIALS AND METHODS 
3.3.1 MATERIALS FOR CHEMICAL SYNTHESES 
Cholesteryl formylhydrazide was prepared as described in section 2.2.2.1. 
Biotinamidocaproate-NHS, DCCI, NHS, apotransferrin, ferric citrate and streptavidin 
were purchased from Sigma-Aldrich (St.Louis, MO, USA). Dry pyridine, citrate, 
dimethylformamide (DMF), sulphuric acid, p- dimethlyaminocinnamaldehyde, NaCI, 
Tris-HCI and silica gel 60F254 chromatography plates were obtained from Merck 
(Darmstadt, Germany). All other reagents were of analytical grade. 
Solvent system A = chloroform: methanol (9:1 v/v). 
3.3.2 PREPARATION OF BIOTINYLCHOLESTERYLFORMYLHYDRAZIDE (MSB1) 
(Figure 3.1) 
Initially, the N-hydroxysuccinimide ester of biotin was prepared by an adaptation of the 
method described by Wilchek and Bayer, 1990. Briefly, biotin (122 mg, 0.5 mmole), 
DCCI (99 mg, 0.48 mmole) and NHS (60 mg, 0.52 mmole) were dissolved in 1.2 ml 
DMF. The resultant dicyclohexylurea crystals were removed by filtration and the DMF 
was evaporated to dryness in a Buchii Rotavapor-R. The residue was extracted three 
times with ether. The biotin-NHS was recrystallised from isopropanol. Mp 198°C. 
Biotin-NHS (68 mg, 0.2 mmoles) and cholesterylformylhydrazide (88 mg, 0.2 mmoles) 
were dissolved with gentle heating in 4 ml dry pyridine. The reaction mixture was kept at 
room temperature in the dark for 48 hours and thereafter concentrated in a rotary 
evaporator. The product was then extracted with a CHCb : H20 (1:1 v/v) mixture. The 
NHS was removed in the water layer and the product dissolved in the chloroform layer. 
The chloroform layer was evaporated under reduced pressure and the extract then 
dissolved in a CHCI3 : ethanol (1:1 v/v) mixture. The solvent mixture was evaporated 
under vacuum and the product was dissolved in hot ethanol. The resultant clear solution 
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was kept at 4°C until crystal formation was complete. Excess ethanol was removed from 
the flask with a pasteur pipette and crystals dried in a rotary evaporator. 
The product was purified further by preparative TLC on 10 x 20 cm silica gel 60F254 
chromatography plates developed in solvent system A. Plates were viewed under 
UV254 light to locate the product bands, which were finally scraped off the plates and 
extracted in a CHCb : ethanol (1:1 v/v) mixture. The mixture was filtered to remove the 
silica gel and the filtrate evaporated to dryness in a rotary evaporator. The product was 
finally dissolved in ethanol (0.3 ml) and placed at 4°C overnight. The crystalline product 
was separated from the supernatant and dried by rotary evaporation. The product was 
monitored at each stage by TLC (silica gel 60F254 ) in solvent system A. A developed 
TLC plate was sprayed with a biotin spray (0.2% p-dimethlyaminocinnamaldehyde in 
2% sulphuric acid) to detect the biotin group that stained bright pink / red. The plate was 
then heated to produce the brown spots to indicate the presence of cholesterol. Product 
gave a single spot by TLC (Rf 0.52, solvent A) with a mp of 192-193°C and a yield of 
80.2 mg (60%). 
IR (film): 3288 (b, N-H), 2939 (st, C-H), 1695 (st, C=O), 1244 (m, C-N), 1465 (m, C=C), 
1045 (m, C-S). (Appendix 2K). 
1H NMR (300 MHz, CDCb) : 80.65 (s, 3H, C-CH3), 0,88 (d, 3H, J=6.5, C-CH3), 0.84 (d, 
6H, J=6.1, C-CH3), 4.32 (m, 1 H, biotin H), 4.48 (m, 2H, biotin H, Chol-H3u), 5.35 (bs, 1 H, 
Chol-H6). (Appendix 1 G). 
MS, m/z, ES-TOF : 693.6136 [M + Na+], 694.6306 [M + H + Na+]. 
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3.3.3 PREPARATION OF AMINOHEXANOYLBIOTINYLCHOLESTERYL-
FORMYLHYDRAZIDE (MSB2) (Figure 2) 
Biotinamidocaproate-NHS (aminohexanoylbiotin-NHS) (11.5 mg, 0.025 mmoles) and 
cholesterylformylhydrazide (11 .25 mg, 0.025 mmoles ) were dissolved in 400 IJI dry 
pyridine. The reaction mixture was kept at room temperature in the dark for 48 hours 
and thereafter evaporated to dryness in a rotary evaporator to produce a white film on 
the flask. Distilled water was added to completely cover the product. Free NHS was 
extracted into the water. The mixture was kept at 4°C overnight, and the water finally 
removed by filtration and product dried under vacuum. The product was monitored at 
each stage by TLC (silica gel 60F254 ) in solvent system A. The TLC plate was sprayed 
with a biotin spray to detect the biotin group and then heated to indicate the presence of 
cholesterol. Product produced a single spot by TLC (Rf 0.33, solvent A) with a mp of 
194-195°C and a yield of 17.8 mg (91%). 
IR (film) : 3446 (b, N-H), 2929 (st, C-H), 1669 (st, C=O), 1244 (w, C-N), 1460 (w, C=C), 
1032 (m, C-S). (Appendix 2L). 















































3.3.4 Preparation of Iron (Fe3+) loaded Transferrin 
This procedure was adapted from that of Kursa et a/., 2003. Ferric citrate buffer (25 1-11, 
10 mM) in citrate buffer (200 mM adjusted to pH 7.8 with NaHC03), was added to 
transferrin (5 mg). This iron-loaded transferrin was made up in a total volume of 1 ml 
with 20 mM HEPES, 150 mM NaCI (pH 7.4), giving a final concentration of 5 mg / ml. 
3.3.5 Preparation of Streptavidin(bio3-transferrin) 
This preparation was carried out as described by Schoeman et a/., 1995, at the 
University of Stellenbosch by Professor A.O. Hawtrey. Briefly, to streptavidin (3 mg, 
0.05 I-Imole) was added 2 ml 0.2 M NaCI, 0.005 M Tris-HCI (pH 7.6). This was mixed 
gently. To bi03-transferrin (0.55 ml, 4 mg, 0.05 I-Imole) was added 1.45 ml 0.2 M NaCI, 
0.005 M Tris-HCI (pH 7.6). The streptavidin and bi03-transferrin solutions were then 
mixed together quickly and checked for turbidity. This was kept at room temperature for 
one hour in the dark. Solutions were re-examined and were clear of any turbidity 
(Strydom et a/., 1993 ; Schoeman et a/., 1995). 
Reaction mixtures were split into aliquots containing 7.14 I-Ig/I-II or 0.87 I-Ig/I-II 
streptavidin (bi03-transferrin) and stored at -10°C. 
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3.3.6 PREPARATION AND CHARACTERISATION OF MSB1 and MSB2 
CONTAINING LlPOSOMES 
3.3.6.1 Materials 
The synthesis of MS09 is described in chapter two section 2.2.2. DOPE was purchased 
from Sigma-Aldrich (St.Louis, MO, USA). HEPES, glutarylaldehyde, osmium tetroxide, 
propylene oxide, lead citrate, sodium chloride and chloroform were obtained from 
Merck (Darmstadt, Germany). The components of Spurr's Resin (GRL 4206, DER 736, 
NSA , S-1), were purchased from TAAB Laboratories (Berkshire, United Kingdom). 
Copper grids for electron microscopy were obtained from Capital Labs (KwaZulu-Natal, 
South Africa). Bovine serum albumin (BSA) was purchased from Roche Diagnostics 
(Mannheim, Germany). All other reagents were of analytical grade. 
3.3.6.2 Formulation of Biotinylated Liposomes containing: 
a) Biotinylcholesterylformylhydrazide (MSB1) and, 
b) Aminohexanoylbiotinylcholesterylformylhydrazide (MSB2) 
Components for liposome MSB1 and MSB2 were formulated in a 48:50:2 molar ratio of 
MS09:DOPE:MSB1/MSB2 with DOPE kept at a 2IJmoi (Table 3.1). 
Table 3.1 : Liposomal components of Biotinylated liposomes MSB1 and MSB2 
LlPOSOME FORMULATION MOLAR RATIOS FOR RESPECTIVE LIPIDS (lJmoles) 
DOPE MS09 MSB1 MSB2 
Liposome MSB1 2 1.92 0.08 -
Liposome MSB2 2 1.92 - 0.08 
Liposome components were dissolved in 1 ml CHCb and liposomes were prepared as 
described in chapter two, section 2.2.5.2. 
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3.3.6.3 Characterisation of Cationic Liposomes using Transmission Electron 
Microscopy: 
Both liposome formulations were prepared for characterization by TEM as described in 
chapter two, section 2.2.5.3, viewed in a Jeol 1010 transmission electron microscope at 
60 kV and photographed at a 2 second exposure on a fine grain release positive film. 
3.3.7 LlPOPLEX AND TERNARY COMPLEX FORMATION OF MSB1 AND MSB2 
LlPOSOMES WITH DNA AND TRANSFERRIN I STREPTAVIDIN 
(BI03• TRANSFERRIN) 
3.3.7.1 Materials 
The pGL3 control vector was purchased from Promega Corporation (Madison,WI, USA), 
and amplified according to the manufacturer's protocol. pBR322 plasmid DNA was 
supplied by Roche Diagnostics (Mannheim, Germany). Transferrin was purchased from 
Sigma-Aldrich (St.Louis,Mo,USA). Agarose was obtained from Bio-Rad Laboratories 
(Richmond, CA, USA). Tris-HCI, NaH2P04, HEPES, NaCI, EDTA, SDS, glycerol, 
bromophenol blue, xylene cyanol, , uranyl acetate and ethidium bromide were 
purchased from Merck (Darmstadt, Germany). Sypro red protein stain was purchased 
from Life Technologies (UK). Fetal calf serum was obtained from Delta Bioproducts 
(Johannesburg, South Africa). All other reagents were of analytical grade. Formvar-
coated grids were prepared by the Electron Microscope Unit, University of KwaZulu-
Natal (Pietermaritzburg Campus). 
3.3.7.2 Gel Retardation Studies of Biotinylated Liposome:DNA Complexes 
Varying ratios of different biotinylated liposome:DNA complexes were set up as 
indicated in Table 3.2 for MSB1 and Table 3.3 for MSB2 liposomes. All cationic 
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liposome:DNA complexes were incubated for 30 minutes at room temperature for 
completion of lipoplex formation. At the end of the incubation, 3 1-11 of gel loading buffer I 
stop solution (50% glycerol, 0.5% bromophenol blue, 0.5% xylene cyanol in a 2 x gel 
buffer) was added to all eight samples. The samples were then loaded onto a 1 % 
agarose gel and subjected to agarose gel electrophoresis for approximately 90 minutes, 
at 50 V and in a 1 x electrophoresis I gel buffer. The gel was stained with ethidium 
bromide (1 I-Ig Iml) for 30 minutes and viewed under transillumination at 300 nm using a 
UVP gel documentation system. Images were obtained and photographed at 320 
millisecond exposure. 
Table 3.2: MSB1 liposome:DNA complexes. Incubation mixtures (10 1-11) in 20 mM 
HEPES, 150 mM NaCI (pH 7.5) contained cationic liposome (0 - 7 I-Ig) and 
pGL3 DNA (1 I-Ig). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA (~g) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Liposome MSB1 (~g) 0 1 2 3 4 5 6 7 
Table 3.3: MSB2 liposome:DNA complexes. Incubation mixtures (10 1-11) in 20 mM 
HEPES, 150 mM NaCI (pH 7.5) contained cationic liposome (0 - 6 I-Ig) and 
pGL3 DNA (1 I-Ig). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA (\-19) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Liposome MSB2 (~g) 0 0.5 1 2 3 4 5 6 
3.3.7.3 Gel Retardation Studies of Transferrin:DNA Complexes 
Varying ratios of different transferrin:DNA mixtures were set up as shown in Table 3.4. 
Transferrin:DNA mixtures were incubated for 20 minutes at room temperature. At the 
end of the incubation, 3 1-11 of gel loading buffer I stop solution (50% glycerol, 0.5% 
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bromophenol blue, 0.5% xylene cyanol in a 2 x gel buffer) was added to all eight 
samples. The samples were then loaded onto a 1 % agarose gel and subjected to 
agarose gel electrophoresis as indicated in 3.2.7.2. The gel was stained with ethidium 
bromide (1 I-Ig Iml) for 30 minutes and viewed under transillumination at 300nm using a 
UVP gel documentation system. Images were obtained and photographed at 320 
millisecond exposure. 
Table 3.4: Transferrin:DNA mixtures. Incubation mixtures (50 1-11) in 20 mM HEPES, 
150 mM NaCI (pH 7.5) contained transferrin (0 - 50 I-Ig) and pGL3 DNA 
(0.5 I-Ig). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA {1-I9} 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Iron laoded transferrin {1-I9} - 5 10 15 20 30 40 50 
3.3.7.4 Gel Retardation Studies of Streptavidin (bio3.transferrin): 
Liposome:DNA Complex for MSB1 and MSB2 Liposomes 
Varying ratios of different streptavidin (bio3-transferrin):liposome:DNA complexes were 
set up as indicated in Tables 3.5 and 3.6. The streptavidin (bio3-transferrin) complexes 
were first added to the liposomes and mixed prior to addition of DNA. After addition of 
the DNA the complexes were incubated for a further 30 minutes. At the end of the 
incubation, 3 1-11 of gel loading buffer I stop solution (50% glycerol, 0.5% bromophenol 
blue, 0.5% xylene cyanol in a 2 x gel buffer) was added to all eight samples. The 
samples were then loaded onto a 1 % agarose gel and subjected to agarose gel 
electrophoresis as described in 3.2.7.2. The gel for samples in Table 3.5 was stained 
with ethidium bromide (1 I-Ig Iml) for 30 minutes and gel for samples in Table 3.6 was 
stained for protein with a Sypro Red ™ stain for 60 minutes, and viewed under 
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transillumination at 300 nm using a UVP gel documentation system. The images were 
obtained and photographed at 320 millisecond exposure. The latter samples were also 
stained for protein with a 0.5 % Coomassie Blue G250 solution for 20 minutes. 
Background staining was removed by destaining in a methanol : acetic acid : water 
(3:1:6 v/v) mixture for 3 to 4 hours before photographing the gels under white light at a 
280 millisecond exposure. 
Table 3.5: Streptavidin (bi03-transferrin):liposome:DNA complexes. Incubation 
mixtures (20 ~I) in 20 mM HEPES, 150 mM NaCI (pH 7.5) contained 
streptavidin (bi03-transferrin) (0-12 ~g) , liposome MSB1 or MSB2 (6 ~g) 
and pGL3 DNA (1 ~g). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA {119} 1 1 1 1 1 1 1 1 
Liposome MSB1 or MSB2 {119} - 2 3 4 5 6 7 8 
streptavidin {bioJ -transferrin} {119} - 6 7 8 9 10 11 12 
Table 3.6: Streptavidin (bi03-transferrin):liposome:DNA complexes. Incubation 
mixtures (20 ~I) in 20 mM HEPES, 150 mM NaCI (pH 7.5) contained 
streptavidin (bi03-transferrin) (1 0 ~g), liposome MSB1 or MSB2 (0-8 ~g) 
and pGL3 DNA (1 ~g). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA {119} 1 1 1 1 1 1 1 1 
Liposome MSB1 or MSB2 {119} - 2 3 4 5 6 7 8 
streptavidin {bio;j -transferrin} {119} - 10 10 10 10 10 10 10 
151 
3.3.7.5 Dye Displacement Assays 
Dye displacement assays were carried out in four different ways to ascertain 
liposome:DNA binding and the effect of transferrin and streptavidin(bio3-transferrin) on 
binding of DNA. 
(a) Addition of biotinylated liposomes to DNA-ethidium bromide solution 
This assay was conducted in a manner similar to that described in Chapter 2, Section 
2.2.6.3. Ethidium bromide (1 I-Ig) was added to 500 1-11 of 20 mM HEPES,150 mM NaCI, 
pH 7.5. This mixture was used to provide the baseline reading (0%) for fluorescence. 
Thereafter 6 I-Ig of pBR322 DNA was added to the above solution and the reading taken 
was assumed to represent 100% fluorescence. Aliquots of each biotinylated liposome, 
MSB1 and MSB2 (6 I-Ig, 2.2 1-11), were added, stepwise to the solution until 60 I-Ig of 
each liposome had been added. The solutions were mixed thoroughly after each 
addition and fluorescence was measured in a Shimadzu RF-551 spectrofluorometric 
detector, at an excitation wavelength of 520 nm and an emission wavelength of 600 nm, 
and at high sensitivity. Results were plotted relative to 100% fluorescence. 
(b) Addition of liposome:transferrin (1 :2) complex to DNA 
Ethidium bromide (1 I-Ig) was added to 500 1-11 of 20 mM HEPES,150 mM NaCI, pH 7.5. 
This mixture was used to provide the baseline reading (0%) for fluorescence. Thereafter 
6 I-Ig of pBR322 DNA was added to the above solution and the reading taken was 
assumed to represent 100% fluorescence. Aliquots (3 1-11) of each liposome:transferrin 
complex (3.9 I-Ig lipid and 7.8 I-Ig transferrin) were added stepwise to the solution until 
the total lipid was 39 I-Ig and the total transferrin was 78 I-Ig. The solutions were mixed 
thoroughly after each addition and fluorescence was measured as explained above 
(3.3.7.5a). 
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(c) Addition of streptavidin (bi03.transferrin) complex to Iiposome:DNA 
complex 
Ethidium bromide (1 ~g) was added to 500 ~I of 20 mM HEPES,150 mM NaCI, pH 7.5. 
This mixture was used to provide the baseline reading (0%) for fluorescence. Thereafter 
a biotinylated liposome:DNA lipoplex (6:1 w/w) , 36 ~g lipid and 6 ~g pBR322 DNA) was 
added to the above solution and the fluorescence reading recorded and reported as 
arbitary fluorescence units. Aliquots (2 ~I , 1.74 ~g) of the streptavidin (bio3-transferrin) 
complex were added stepwise to the solution until 26.1 ~g of the streptavidin (bio3-
transferrin) had been added. The solutions were mixed thoroughly after each addition 
and fluorescence was measured as explained in 3.3.7.5a. 
(d) Addition of transferrin to Iiposome:DNA complex 
Ethidium bromide (1 ~g) was added to 500 ~I of 20 mM HEPES,150 mM NaCI, pH 7.5. 
This mixture was used to provide the baseline reading (0%) for fluorescence. Thereafter 
a biotinylated liposome:DNA mixture (6:1 w/w) , 36 ~g lipid and 6 ~g pBR322 DNA) was 
added to the above solution and the fluorescence reading recorded and reported as 
arbitary fluorescence units. Aliquots (2 ~I, 4 ~g) of iron loaded transferrin were added 
stepwise to the solution until a total of 28 ~g of transferrin had been added. The 
solutions were mixed thoroughly after each addition and fluorescence was measured as 
described in 3.3.7.5a. 
3.3.7.6 Transmission Electron Microscopy of Lipoplexes (MSB1 and MSB2) 
and Liposome:DNA:streptavidin(bi03.transferrin) Ternary Complexes 
Sample preparation was as described in Section 2.2.6.4. The lipoplexes and ternary 
complexes were viewed in a Jeol 1010 transmission electron microscope at 60 kV. 
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3.3.7.7 Nuclease Digestion Assays of Ternary Complexes 
Liposome:DNA:streptavidinbiotransferrin complexes were set up as shown in Table 3.4. 
Table 3.4: Biotinylated liposome:DNA:streptavidinbiotransferrin complexes. 
Incubation mixtures (20 Ill) in 20 mM HEPES, 150 mM NaCI (pH 7.5) 
contained liposome MSB1 or MSB2 (0 - 8 1l9), pGL3 DNA (1 1l9) and 
streptavidinbiotransferrin (10 1l9). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 
pGL3 DNA (~g) 1 1 1 1 1 1 1 
Liposome MSB1 IMSB2 (~g) - - 3 4 5 6 7 





Samples were made up to a total volume of 20 III with 20 mM HEPES, 150 mM NaCI, 
pH 7.5. The streptavidin (bio3-transferrin) complexes were first added to the liposomes 
and mixed prior to addition of DNA. After addition of the DNA, the complexes were 
incubated for 30 minutes. The procedure followed was as described in chapter two , 
section 2.2.6.6. 
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3.3.8 CELL CULTURE AND TRANSFECTION STUDIES 
3.3.8.1 Materials 
HeLa cells were obtained from Highveld Biologicals (Pty) Ltd (Kelvin, South Africa). 
Trypsin-EDTA, and penicillin-streptomycin mixtures were purchased from Whittaker, 
M.A. Bioproducts (Maryland, USA). Fetal calf serum was supplied by Delta Bioproducts, 
(Johannesburg, South Africa). Minimum essential medium (MEM) with Earle's salts was 
obtained from Gibco-BRL, Life Technologies Ltd. (Inchinnan, Scotland). The Luciferase 
assay kit, and the pGL3 control vector (prior to amplification) were purchased from the 
Promega Corporation (Madison,WI, USA). All tissue culture plasticware was obtained 
from Bibby-Sterilin (Staffordshire, England). The Bicinchoninic acid (BCA) protein assay 
kit was supplied by Sigma-Aldrich (St.Louis, MO, USA). Coomassie blue G250, 
dimethylsulfoxide (DMSO), crystal violet and formaldehyde were supplied by Merck 
(Darmstadt, Germany). All other reagents were of analytical grade. 
3.3.8.2 Growth and Maintenance of HeLa cells 
The HeLa cell lines were propagated in MEM with 10% FCS and antibiotics, and 
maintained as described in chapter two, section 2.2.7.2. 
3.3.8.3 Growth Inhibition Assays 
HeLa cells were trypsinised and seeded into a 24 well plate at a seeding density of 2.2 x 
104 cells/well for both liposome MSB1 :DNA complexes and liposome MSB2:DNA 
complexes. The HeLa cell seeding density was 2.1 x 104 cells/well for both streptavidin 
(bi03-transferrin):liposome:DNA complexes. Wells in row 1 received no cells and were 
used to obtain a blank (0) reading, and wells in row 2 received only cells and no 
lipoplexes and was used to give the 100% reading. Cells were incubated for 24 to 36 
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hours and allowed to attach to the wells and grow to semi-confluency. The biotinylated 
liposome:DNA complexes and the streptavidin (bi03-transferrin):liposome:DNA [pGL3 
DNA, 1 I-1g)] complexes were set up as outlined in Tables 3.5 and 3.6 for both liposome 
MSB1 and MSB2. The lipoplexes were incubated for 30 minutes prior to addition to the 
cells. To make up the ternary complex, the streptavidin (bi03-transferrin) complexes 
were first added to the liposomes and mixed prior to addition of DNA. After addition of 
the DNA the complexes were incubated for 30 minutes. The reaction mixtures were all 
made up to a constant volume with 20 mM HEPES, 150 mM sodium chloride, pH 7.5. 
Table 3.5: MSB1 or MSB2:DNA complexes as added to 24-well plates. pGL3 DNA 
was kept constant at 1 I-1g. Incubation mixtures (10 1-11) in 20 mM HEPES, 
150 mM NaCI (pH 7.5) contained biotinylated liposomes (0-8 I-1g) and 
pGL3 DNA (1 I-1g). 
Reaction Components 1 2 3 4 5 6 
Liposome MSB1 or MSB2 (lJg) - - 4 5 6 8 
pGL3 DNA (lJg) - - 1 1 1 1 
Table 3.6: Streptavidin(bi03-transferrin):liposome:DNA complexes with liposomes 
MSB1 and MSB2. Incubation mixtures (20 1-11) in 20 mM HEPES, 150 mM 
NaCI (pH 7.5) contained streptavidin (bi03-transferrin) (10 I-1g), biotinylated 
liposome (0-8 I-1g) and pGL3 DNA (1 I-1g). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 
pGL3 DNA (lJg) - - 1 1 1 1 
Liposome MS09 (lJg) - - 4 5 6 8 
Streptavidin(bio;j -transferrin} (lJg) - - 10 10 10 10 
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3.3.8.4 Transfection studies with untargeted biotinylated liposomes 
(a) Liposome MSB1: pGL3 DNA complexes 
(b) Liposome MSB2 : pGL3 DNA complexes 
Transfection by lipoplexes (a) and (b) were conducted on the HeLa cell line in 
quadruplicate in the absence of FCS and in the presence of 10% FCS. A competition 
assay using iron loaded transferrin was also conducted. HeLa cells were trypsinised 
and seeded into a 24 well plate at a seeding density of 2.8 x 104 cells/well for both 
liposome MSB1 and liposome MSB2 for studies conducted in the absence of FCS. For 
studies conducted in the presence of 10% FCS the seeding densities were 2.7 x 104 
cells/well for both liposome MSB1 and liposome MSB2. For the competition assay the 
seeding densities were 2.5 x 104 cells/well for both liposome MSB1 and liposome 
MSB2. The cells were allowed time to attach to the wells and to grow to semi-
confluency. The transfection complexes for (a) and (b) were set up as described in 
Table 3.7. 
Table 3.7: MSB1 or MSB2 transfection complexes as added to 24-well plates. 
Control 1 contained only cells, control 2 contained cells and pGL3 DNA 
(1 I-Ig) only. Test samples 1 to 4 contained varying amounts of liposome 
MSB 1 or MSB2 (4, 5, 6 and 8 I-Ig respectively). pGL3 DNA was kept 
constant at 1 I-Ig. All complexes were made up to a final volume of 10 1-11 
with 20 mM HEPES, 150 mM sodium chloride (pH 7.5). 
Reaction Components Control Control Test Test Test Test 
1 2 1 2 3 4 
He La Cells + + + + + + 
Liposome MSB1 or MSB2 (1-I9) - - 4 5 6 8 
pGL3 DNA (1-I9) - 1 1 1 1 1 
The liposome:DNA complexes were incubated at room temperature for 30 minutes prior 
to addition to cells. The cells were prepared by removal of growth medium, washing 
with 0.5 ml PBS and replenishment with 0.5 ml serum free medium (MEM + antibiotics). 
For the evaluation of transfection efficiency in the presence of 10% serum the medium 
utilized was complete medium (MEM + antibiotics + 10% FBS). 
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A competition assay utilizing 200 IJg free iron loaded transferrin per well was also 
conducted. The iron loaded transferrin was added to the cells 10 minutes prior to the 
addition of the untargeted biotinylated lipoplexes. After the addition of the transfection 
complexes (Iipoplexes) to the cells, the cells were incubated at 3rC for 4 hours, after 
which the medium was removed and replaced with complete growth medium (MEM + 
antibiotics + 10% FCS). The cells were incubated for a further 48 hours at 3rC after 
which they were assayed for luciferase activity using the luciferase assay system 
(Promega) as described in chapter two section 2.2.7.5. The protein determination of the 
cell free extracts was performed using the BCA assay (Sigma) with BSA as the 
standard protein. 
3.3.8.5 Transfection Studies with Streptavidin(bio3.transferrin) Targeted 
Biotinylated Liposomes: 
(a) streptavidin(bio3.transferrin):liposome MSB1 :pGL3 DNA 
complexes 
(b) streptavidin(bio3.transferrin):liposome MSB2:pGL3 DNA 
complexes 
Transfection by ternary complexes (a) and (b) were conducted on the HeLa cell line in 
quadruplicate in the absence of FCS and in the presence of 10% FCS. A competition 
assay using excess iron loaded transferrin over streptavidin(bi03-transferrin) was also 
conducted. HeLa cells were trypsinised and seeded into a 24 well plate at a seeding 
density of 2.6 x 104 cells/well for both liposomes MSB1 and liposomes MSB2 for studies 
conducted in the absence of FCS. For studies conducted in the presence of 10% FCS 
the seeding density was 2.7 x 104 cells/well for both liposome MSB1 and liposome 
MSB2. For the competition assay the seeding density was 2.9 x 104 cells/well for both 
liposome MSB 1 and liposome MSB2. The cells were allowed time to attach to the wells 
and to grow to semi-confluency. The transfection complexes for (a) and (b) were set up 
as described in Tables 3.8. 
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Table 3.8: MSB1 or MSB2 ternary transfection complexes as added to 24-well plates. 
Control 1 contained only cells, control 2 contained cells and pGL3 DNA 
(1 ~g) only, and control 3 contained the optimal Iiposome:DNA (6:1 W/w) 
ratio for untargeted transfection. Test samples 1 to 3 contained varying 
amounts of liposome MSB1 or MSB2 (5, 6 and 8 ~g respectively). pGL3 
DNA was kept constant at 1 ~g. All complexes were made up in a final 
volume of 20 ~I with 20 mM HEPES ,150 mM sodium chloride (pH 7.5). 
Reaction Components Control Control Control Test Test Test 
1 2 3 1 2 3 
HeLa Cells + + + + + + 
Liposome MSB1 or MSB2 (I-Ig) - - 6 5 6 8 
pGL3 DNA (I-Ig) - 1 1 1 1 1 
streptavidin(bio" -transferrin} (1-I9) - - - 10 10 10 
The streptavidin(bio3-transferrin):liposome:DNA complexes were incubated at room 
temperature for 30 minutes prior to addition to cells. The cells were prepared as 
described in section 3.2.8.4. For the evaluation of transfection efficiency in the presence 
of 10% serum the medium utilized was complete medium (MEM + antibiotics + 10% 
FCS). 
For the competition assay 200 ~g free iron-loaded transferrin was utilized per well. The 
iron loaded transferrin was added to the cells 10 minutes prior to the addition of the 
targeted biotinylated complexes [streptavidin(bio3-transferrin):liposome:DNA]. After the 
addition of the ternary transfection complexes to the wells, the cells were then 
incubated at 3rC for 4 hours. The medium was then removed and replaced with 
complete growth medium (MEM + antibiotics + 10% FCS). The cells were incubated for 
a further 48 hours at 3rC and thereafter were assayed for luciferase activity using the 
luciferase assay system (Promega) as described in chapter two, section 2.2.7.5. The 
soluble protein in the cell free extracts was determined using the BCA assay (Sigma) 
with BSA as the standard protein. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 CHEMICAL SYNTHESES AND PROTEIN MODIFICATIONS 
3.4.1.1 Preparation of Biotinylated Cholesterol Derivatives 
Two novel biotinylated cholesterol derivatives were successfully synthesized (Figures 
3.1 and 3.2), by the condensation of N-hydroxysuccinimide activated biotinyl 
components and cholesterylformylhydrazide. Both derivatives have a common 
cholesterol anchor, but differ in the lengths of their spacer arms, with MSB2 having the 
longer spacer arm. Both compounds were used in the formulation of two novel 
biotinylated liposomes together with MS09 (chapter two) and DOPE, which were 
assessed for their transfection efficiency in the HeLa cell line with and without Tf as the 
targeting moiety. The transfection efficiencies of these two liposome formulations were 
not significantly different. They will be discussed later in this chapter. 
3.4.1.2 Preparation of iron (Fe3+) loaded transferrin 
It is accepted that transferrin binds strongly to the Tf receptor only if it is iron (Fe3+) 
loaded. For this reason the Tf (apotransferrin) was Fe3+ loaded and utilized in all studies 
conducted with Tf. Tf binds Fe3+ avidly with a dissociation constant of approximately 
1022 M-1. The Fe3+ iron complexes to the Tf only in the presence of an anion which is 
usually a carbonate, which serves as a bridging ligand between the Fe3+ and the Tf, 
with exclusion of water molecules from the two coordination sites (Aisen and Listowsky, 
1980). Hence sodium carbonate was used during the preparation. 
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3.4.1.3 Preparation of Streptavidin(bi03.transferrin) 
The streptavidin biotransferrin complex has three aminohexanoylbiotin moieties 
attached to Tf. The biotin content of Tf is generally kept low to prevent any cross-
linking of complexes and precipitation under normal buffer incubation conditions 
(Hawtrey and Ariatti, 1999), and to preserve the structural form with as little alteration to 
the protein as possible (Schoeman et a/., 1995). This TfR targeted complex was linked 
via the streptavidin component to the biotinylated liposome (Figure 3.5). 
3.4.2 PREPARATION AND CHARACTERISATION OF MSB1 and MSB2 
CONTAINING LlPOSOMES 
The two biotinylated liposomes were successfully formulated using the method 
described (section 2.2.5.2). This was confirmed using transmission electron microscopy. 
Liposomes were easily prepared using the cationic cholesterol derivative , MS09, the 
respective biotinylated cholesterol derivative (MSB1 or MSB2) and the neutral helper 
lipid, DOPE at the chosen ration of components. Liposomal suspensions were stable at 
4°C over several weeks and components did not precipitate out of solution. The ratio 
utilized for the formulation therefore was a favourable combination and other ratios were 
not explored. Hence the liposomes formulated contained a cationic component for 
interaction with the plasmid DNA molecule, a biotinylated cholesterol derivative, 
intended for interaction with streptavidin in the streptavidinbiotransferrin complex, and a 
helper lipid, DOPE, that assists in the fusogenic processes and plays a role in 
increasing transfection efficiency. 
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3.4.2.1 Characterisation of Liposomes by Transmission Electron 
Microscopy 
Transmission electron microscopy revealed the unilamellar nature and the sizes of the 
two biotinylated liposome formulations. Liposome MSB 1 presented vesicles in the 
50 nm to 200 nm size range, while MSB2 liposomes were from 100 nm to 300 nm in 
diameter (Figures 3.3 and 3.4). It is proposed that the liposome diameters or 
hydrodynamic radii and their population dispersity bear a direct relationship to liposome 
clearance rates in blood and can exert marked effects on the antitumour activity of 
therapeutic agents (Campbell et al., 2001). 
The size of liposomes and the rigidity of the liposomal membrane are also important 
factors for liposome removal by the reticuloendothelial system (RES). Small liposomes 
with less fluid membranes have longer half lives in the blood stream and are not easily 
opsonised by complement factors in the blood when compared to larger liposomes. 
Liposome sizes of 100-200 nm are also considered to be favourable for tumour 




Figure 3.3: Representative TEM of liposome MSB1. 
Liposomes ranged in size from 50 nm to 200 nm. 
100 nm 
Figure 3.4: Representative TEM of liposome MSB2. 
Liposomes ranged in size from 100 nm to 300 nm. 
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3.4.3 LlPOPLEX AND TERNARY COMPLEX FORMATION OF MSB1 AND 
MSB2 LlPOSOMES WITH DNA, AND WITH TRANSFERRIN I 
STREPTAVIDIN (BI03• TRANSFERRIN) 
Lipoplexes (liposome:DNA complexes) were generated by incubating liposomes and 
DNA at room temperature for 30 minutes although it is commonly held that 20 minutes 
under these conditions should suffice. The ternary complexes 
(streptavidinbiotransferrin:liposome:DNA complexes) were prepared by first adding the 
streptavidinbiotransferrin to the liposome followed by the DNA, allowing 15 minutes 
incubation after the addition of each component, thus providing sufficient time for the 
ternary complexes to form. All the complexes were monitored and characterized by gel 
retardation assays, dye displacement assays, nuclease digestion assays and 
transmission electron microscopy. The streptavidin-biotin interaction was therefore used 
to affix the transferrin moieties to the biotinylated liposomes (Figure 3.5). 
It was reported previously, using ferritin molecules conjugated via streptavidin to 
biotinylated liposomes, that specific binding to the liposomes incorporating biotinylated 
lipids can be impaired by unfavourable electrostatic repulsion. The charge of the 
liposomes was adjusted by the addition of a cationic surfactant in the lipid bilayer 
(Velev, 1997). The liposomes produced in this study also contain a cationic cholesterol 
derivative (MS09) which produced very effective lipoplexes (chapter two). Hence the 
ternary complex formed brings together favourable interactions between the three 
components. The liposomes become coated with the Tf ligands for specific interaction 
with the cognate cell surface receptors thereby transporting the plasmid DNA that is 






S = streptavidin 
l> = biotin 
Tf = transferrin 
c::::: ... --... x.---...... x.-----x",...-....... x,--...... x.-----..> DNA 
Figure 3.5: Schematic representation of the ternary complex formed between 
streptavidinbiotransferrin, biotinylated liposome and DNA. Compound 
MS09 is the liposome cationic component for binding to plasmid DNA. 
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3.4.3.1 Gel Retardation Studies of Biotinylated Liposome:DNA Complexes 
Agarose gel electrophoresis was once again utilized to demonstrate the formation of 
complexes between DNA and biotinylated liposomes. 
Gel retardation studies were conducted on both lipoplexes (MSB1 and MSB2), each 
yielding a similar pattern of binding with a specific optimum binding ratio ( Figures 3.6 
and 3.7). From the results of the agarose gel electrophoresis, it can be seen that the 
plasmid DNA (pGL3) produced the expected two bands (lane 1), viz. the supercoiled 
form of DNA (bottom band) and the nicked circular form (top band). As the amount of 
cationic liposome increased, more DNA was electrostatically bound to the cationic 
liposome and hence less DNA entered the gel as was visualised by the ethidium 
bromide intercalation. DNA that was bound to the liposomes and does not migrate into 
the gel can also be seen as an intense fluorescence in the wells. Complete retardation 
of the DNA in the case of each liposome was obtained at the same biotinylated 
liposome:DNA binding ratios viz. 6:1 (w/w). This complete retardation normally indicates 
that the negative charges of the DNA have been completely titrated by the cationic 
liposome's positive charges. 
These ratios were then used in determining the optimal ratios for the formation of 
ternary complexes with streptavidinbiotransferrin and to ultimately identify the optimum 
ratios for transfection studies. By retaining these liposome:DNA ratios in ternary 
complexes, it was expected that ionic interaction between streptavidinbiotransferrin and 
the liposome component would be minimized thus favouring the biotin-streptavidin 
interaction as the docking force. 
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Figure 3.6 : Gel retardation study of MSB1liposome:DNA complexes. Incubation 
mixtures (1 ° 1-11) in 20 mM HEPES, 150 mM NaCI (pH 7.5) contained 
varying amounts of liposome in lanes 1-8 (0, 1.0, 2.0, 3.0, 4.0,5.0, 6.0, 
7.0 I-Ig), while the pGL3 DNA was kept constant at 0.5 I-Ig per well. 
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Figure 3.7 : Gel retardation study of MS82 liposome : DNA complexes. Incubation 
mixtures (10 I-II) in 20 mM HEPES, 150 mM NaCI (pH 7.5) contained 
varyin9 amounts of cationic liposome in lanes 1-8 (0, 0.5,1 .0, 2.0, 3.0, 
4.0, 5.0, 6.0 1-19), while the pGL3 DNA was kept constant at 0.5 1-19 per 
well. 
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3.4.3.2 Gel Retardation Studies of Transferrin:DNA Complexes 
It is clear, from the results presented in Figure 3.8, that there is little if any binding of Tf 
to DNA (1 I-Ig) over a wide protein range (0-100 I-Ig) at pH 7.5. Hence ternary 
complexes, that are formed in this study, are held together largely by the biotin-
streptavidin interaction (biotinylated liposomes and streptavidinbiotransferrin), and the 
ionic forces (Iiposome and DNA). It has been suggested, using DOTAP/DOPE 
liposomes, that Tf binds to these vesicles via negatively charged groups on this ligand, 
at physiological pH, to afford complexes which bind DNA through a charge-charge 
interaction (Tros de lIIarduya and DOzgOne~ , 2000). 
In arriving at this conclusion it is assumed that any binding of Tf to DNA would produce 
larger complexes leading to a DNA band shift on agarose gel electrophoresis. However, 
the migration of the DNA exposed to large amounts of Tf was very similar to that of 
control DNA (Figure 3.8). This may be attributed, in part, to the fact that Tf molecules 
bear four negatively charged sialic acid residues (Nagaoka and Maitani, 2001), and 
hence is an acidic protein, with the diferric species having an isoelectric point (pi) in the 
range 5.6 - 5.8 (Li and Qian, 2002). It has previously been reported that Tf fails to 
interact with DNA as determined in a band shift assay (Huckett et a/., 1986). However, 
Joshee et a/., 2002, have suggested that Tf can interact with DNA to give a relatively 
stable complex. Based on evidence provided by electron microscopy, they have also 
proposed that a complex comprising DNA (1 I-Ig) and Tf (20 I-Ig) adopts an unusual 
toroidal ring structure (diameter: 160 nm) and a tail. Furthermore, the thickness of the 
DNA component was significantly greater than that of uncomplexed DNA. 
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Figure 3.8 : Gel retardation study of transferrin:DNA complexes. Incubation 
mixtures (15 ~I) in 20 mM HEPES, 150 mM NaCI (pH 7.5) contained 
varying amounts of transferrin in lanes 1-8 (0, 10, 20, 40, 60, 70, 80, 
1 00 ~g), while the pGL3 DNA was kept constant at 1.0 ~g. 
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3.4.3.3 Gel Retardation Studies of Streptavidin Biotransferrin: 
Liposome:DNA Complex for MSB1 and MSB2 Liposomes 
Agarose gel electrophoresis was once again used to detect retardation patterns, this 
time with the streptavidinbiotransferrin:liposome:DNA complexes. At low 
biotransferrin:liposome ratios the biotransferrin may bind to the liposomes by charge-
charge interactions which precludes binding of the DNA (lane 2, Figure 3.9; lanes 2 and 
3, Figure 3.10). However, as the biotransferrin concentration increases it appears that 
the biotin-streptavidin interaction becomes the dominant cohesive force and DNA is 
able to successfully compete for binding to the cationic bilayer. It is clearly visible from 
the fluorescence observed after ethidium bromide staining that the complete retardation 
of the ternary complexes for both liposome formulations was achieved at a 
streptavidinbiotransferrin:liposome:DNA ratio of 10:6:1 (Figures 3.9 and 3.10). The 
determination of this ratio was critical as it established the optimal ratio of the ternary 
complex to be utilized for transfection purposes. 
In separate binding studies the liposome amounts were varied from 0 to 8 I-Ig while the 
streptavidinbiotransferrin was kept constant at 10 I-Ig and the pGL3 DNA maintained at 
1 I-Ig. In this case the agarose gels were stained with a protein stain (Sypro Red™) and 
the fluorescence attributed to the protein was visualized under UV300 illumination. Thus 
it is noted in Figures 3.11 and 3.12 that the streptavidinbiotransferrin is liposome-bound 
and remains in or near the well. At low liposome concentration (lane 2, Figures 3.11 and 
3.12), some migration of the protein conjugate towards the anode may be seen. A 
similar result was observed when gels were stained with Coomassie Blue to detect the 
protein (Figure 3.13). It may be inferred, therefore, that at least 3 or perhaps 4 I-Ig of 
MSB1 or MSB2 liposomes are required to bind 10 I-Ig of streptavidinbiotransferrin. 
These results serve to affirm the ratios of components that have been selected for the 
transfection studies. 
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Figure 3.9 : Gel retardation study of ternary complex of streptavidin-
biotransferrin:MSB1 liposome : DNA complexes. Incubation mixtures 
(15 jJl) in 20 mM HEPES, 150 mM NaCI (pH 7.5) contained varying 
amounts of liposome in lanes 1-8 ( 0, 2.0, 3.0, 4.0, 5.0, 6.0,7.0,8.0 jJg) 
and pGL3 DNA (1.0 jJg). The streptavidinbiotransferrin was also varied 
(0, 6, 7, 8, 9, 10, 11, 12 jJg). 
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Figure 3.10: Gel retardation study of ternary complex of streptavidin-
biotransferrin:MSB2 liposome : DNA complexes. Incubation mixtures 
(15 1-11) in 20 mM HEPES, 150 mM NaCI (pH 7.5) contained varying 
amounts of liposome in lanes 1-8 (0,2.0,3.0, 4.0,5.0,6.0,7.0,8.0 I-Ig), 
and pGL3 DNA (1.0 I-Ig). The streptavidinbiotransferrin was also varied 




Figure 3.11: Gel retardation study of ternary complex of streptavidin-
biotransferrin:MSB1 liposome : DNA complexes. Incubation mixtures 
(15 1-11) in 20 mM HEPES, 150 mM NaCI (pH 7.5) contained varying 
amounts of liposome in lanes 1-8 (0, 2.0, 3.0, 4.0, 5.0, 6.0,7.0,8.0 I-Ig), 
while the pGL3 DNA and streptavidinbiotransferrin was kept constant 
at 1.0 I-Ig and 1 0 I-I~ respectively. Gel was stained to detect protein 




Figure 3.12: Gel retardation study of ternary complex of streptavidin 
biotransferrin:MSB2 liposome : DNA complexes. Incubation mixtures 
(15 IJI) in 20 mM HEPES, 150 mM NaCI (pH 7.5) contained varying 
amounts of liposome in lanes 1-8 (0,2.0,3.0,4.0,5.0,6.0,7.0,8.0 IJg), 
while the pGL3 DNA and streptavidin biotransferrin was kept 
constant at 1.0 IJg and 1 ° ~g respectively. Gel was stained to detect 




Figure 3.13: Gel retardation study of ternary complex of streptavidinbiotransferrin: 
MSB1 Iiposome:DNA complexes. Incubation mixtures (15 j.J1) in 
20 mM HEPES, 150 mM NaCI (pH 7.5) contained varying amounts of 
liposome in lanes 1-8 (0,2.0,3.0,4.0,5.0,6.0,7.0, 8.0 j.Jg), while the 
pGL3 DNA and streptavidinbiotransferrin was kept constant at 1.0 j.Jg 
and 10 j.Jg respectively. Gel was stained to detect protein with 
Coomassie Blue stain. MSB2 complexes produced the same result. 
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3.4.3.4 Dye Displacement Assays 
In these assays the 100% fluorescence reading at 600 nm emission, was taken after the 
initial addition of pBR322 DNA to the ethidium bromide solution in buffer, which 
resulted in a higher fluorescence reading due to the intercalation of the ethidium into the 
DNA. The assays using the plain liposome:DNA complexes showed the general trend 
seen in Chapter 2, in that as the amount of liposome added to the DNA increased, the 
fluorescence emitted by the ethidium bromide decreased due to the binding of the 
cationic component of the biotinylated liposome to the plasmid DNA, hence displacing 
the ethidium bromide. This decrease in fluorescence was observed with both 
biotinylated liposome formulations (Figure 3.14). The fluorescence decreased steadily 
until a point was attained which seemed to correlate with total retardation seen for 
lipoplexes in the gel retardation assays. The maximum displacement of ethidium 
bromide as measured by fluorescence was obtained for liposome MSB 1 and MSB2 at 
the total retardation ratio of liposome:DNA of 6:1 (W/W) , and charge (+/-) ratio of 0.7. The 
reduction in fluorescence (45-50%) was less than that obtained for the MS09 liposomes 
(60%) in Chapter 2. This could be due to the added biotinylated cholesterol component 
that is also present in the liposomal bilayer which may be partially obstructing the DNA 
association with the MS09 component although MSB1 and MSB2 are present at a low 
percentage in the bilayer (2%). 
For the addition of the liposome:Tf complex to the DNA (Figure 3.15), there was a rapid 
decrease in the fluorescence which seemed to stabilize at a Tf:liposome:DNA ratio of 
about 12:6:1 (w/w/w/) for both liposome formulations. As the Tf:liposome complex was 
added 3 1-11 at a time, the fluorescence intensity decreased due to binding of the DNA by 
the cationic component of the liposome. The negatively charged transferrin is expected 
to bind to the cationic liposomes by electroststic interactions. Results presented in 
Figure 3.15 confirm, however, that the plasmid DNA is able to displace the transferrin, 
as the dye displacement ceases at a liposome:DNA ratio of 6:1 (W/W) , the same value 
achieved in the absence of transferrin. In Figure 3.16, the lipoplex (biotinylated 
liposome:DNA , 6:1 w/w) was first added to the ethidium bromide solution prior to 
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addition of the streptavidinbiotransferrin complex. There was an initial gradual increase 
in fluorescence upon addition of the streptavidinbiotransferrin complex. This could be 
due to the binding of the streptavidinbiotransferrin complex to the biotinylated liposomes 
which would have coated the liposomes. This may have interfered with the binding of 
the DNA to the cationic component of the liposome, thereby partly releasing the DNA 
from the liposome. 
(a) Addition of biotinylated liposomes to DNA-ethidium bromide solution 
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Figure 3.14 : Ethidium bromide intercalation assay for liposomes MSB1 and MSB2 at 
varying liposome : DNA (w/w) binding ratios (section 3.3.7.5a). 
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(b) Addition of liposome:transferrin (1 :2) complex to DNA 
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Figure 3.15: Ethidium bromide intercalation assay for liposomes MSB1 and MSB2 
at varying Tf:liposome:DNA (w/w/w) binding ratios. Incubation mixtures 
(500 1-11) contained increasing amounts of a liposome:transferrin (1:2 w/w) 
solution (1 .3 I-Ig liposome and 2.6 I-Ig Tf /1-11 HEPES buffered saline), as 
indicated in the figure, and 6 I-Ig pBR322 plasmid DNA. 
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(c) Addition of streptavidinbiotransferrin complex to liposome:DNA 
complex 
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Figure 3.16: Ethidium bromide intercalation assay for liposome MSB1 and MSB2 at 
varying streptavidinbiotransferrin:liposome : DNA (W/w) binding ratios. 
Incubation mixtures (500 I-II) contained liposomes (36 I-Ig), pBR322 DNA 
(6 I-Ig) and increasing amounts of streptavidin(bio3transferrin} as indicated 
in the figure. 
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Figure 3.17: Ethidium Bromide intercalation assay for liposome MSB1 and MSB2 at 
varying transferrin:liposome:DNA (w/w) binding ratios. Incubation mixtures 
(500 J..II) contained liposomes (36 J..Ig) and pBR322 DNA 6 J..Ig) in HEPES 
buffered saline and increasing amounts of iron loaded Tf as indicated. 
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The released DNA then intercalates the ethidium bromide resulting in enhanced 
fluorescence. The increase in fluorescence observed was more dramatic for liposome 
MSB1 than for MSB2, suggesting that the liposome MSB2 which has a longer spacer 
offered less hinderence to the DNA bound to the liposome than is the case with 
liposome MSB1 which has a much shorter spacer. 
This increase in fluorescence was observed until about 6 j.Jg of 
streptavidinbiotransferrin had been added, from which point there was little or no 
change in fluorescence (flattening in the curve) until about 11 j.Jg of 
streptavidinbiotransferrin. This could be due to the fact that no further DNA was 
displaced from the liposomes. Thereafter there was a gradual quenching in the 
fluorescence which apparently marked the reassociation of DNA with the liposome 
complex. The plasmid DNA was able to bind to the cationic liposomal component which 
could have now become more readily accessible. It seems, therefore, plausible to 
suggest that the ionic interaction between the liposomes and streptavidinbiotransferrin 
assumes a lesser importance and that the modified transferrin remains liposome-bound 
largely through the biotin-streptavidin interaction. This is corroborated by the gel 
retardation studies which show a strong interaction of streptavidinbiotransferrin with 
liposomes that are also associated with a saturating amount of DNA (Figures 3.9 to 
3.13). 
When iron-loaded Tf (holotransferrin) was added to the liposome:DNA complex (Figure 
3.17), there was an initial sudden increase followed by a sudden drop in the measured 
fluorescence. This could be a result of the binding of the transferrin to the liposome 
displacing some of the DNA in the process. The ethidium bromide then intercalates into 
the DNA thereby increasing fluorescence levels. This binding of Tf reaches a peak at 
about 4 j.Jg after which fluorescence drops again very sharply to levels even below that 
of the initial reading, signalling the reattachment of the partially displaced DNA. The 
further drop in fluorescence is in agreement with the notion that the lipoplex contains 
more compacted DNA with increasing iron loaded transferrin . It is noteworthy that in this 
experiment liposomes and plasmid DNA were premixed at a ratio of 6:1 (W/w) , which 
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results in complete retardation of DNA in a band shift assay (Figures 3.6 and 3.7), and 
marks the saturation point for binding of the DNA to the liposomes in the dye 
displacement assay (Figure 3.14). 
3.4.3.5 Transmission Electron Microscopy of Iiposome:DNA complexes 
(MSB1 and MSB2) 
Lipoplexes were successfully assembled from MSB 1- and MSB2-containing cationic 
liposomes and plasmid DNA. After mixing the lipidic and nucleic acid components, a 30 
minute period at room temperature was allowed for maturation before samples were 
taken for TEM. The lipoplexes observed were very similar to those reported for the 
cationic liposomes not containing biotin appendages in chapter two. The size and 
ultrastrucuture of these lipoplexes were observed at their optimal transfection ratio of 
liposome:DNA (6:1 w/w) and charge (+/-) ratio of 0.7. Lipoplex sizes ranged from 100 to 
200 nm for MSB1 lipoplexes and 100 to 300 nm for MSB2 lipoplexes (Figure 3.18). 
Most of the lipoplexes appeared as aggregates or clusters of liposomes. Some of the 
lipoplexes appeared much more closely or tightly packed (especially the MSB1 
lipoplexes) than others. These lipoplexes were randomly dispersed and were not 
encountered as groups of lipoplexes. Studies have shown that highly positively charged 
complexes, where DNA is completely condensed, or highly negatively charged 
complexes with an excess of DNA over the lipid, exhibit an homogeneous size 
distribution of between 100 nm and 450 nm in diameter. Neutral complexes however 
are characterized by a heterogeneous size distribution from about 300 nm to 1200 nm 
in diameter with a much lower colloidal stability (Pedroso de Lima et al., 2001). 
The sizes of the lipoplexes are potentially important properties of synthetic gene 
delivery systems. DNA complexes can range from 50 to 1000 nm depending on 
DNAcarrier ratio, total concentrations, ionic strength of buffer, and kinetics of mixing, 
with the lower size limit not easily adjustable and hence intrinsic to that specific 






Figure 3.18 : TEM of biotinylated liposome:DNA complexes at optimal ratio of 6:1 
(~g / ~g) and charge (+/-) ratio of 0.7. Lipoplex sizes ranged from 
(a) 100 - 200 nm for liposome MSB1 :DNA, and, 
(b) 100 - 300 nm for liposome MSB2:DNA complexes 
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3.4.3.6 Transmission Electron Microscopy of MSB1 and MSB2 
streptavidinbiotransferrin: Iiposome:DNA complexes 
The ternary complexes formed (Figures 3.19 to 3.20) varied in size from 100 nm to 250 
nm for complexes with MSB1 at a streptavidinbiotransferrin:liposome MSB1 :DNA ratio 
of 10:6:1 (w/w/w), and 200 nm to 500 nm at a higher ratio of 10:7:1 (w/w/w). The 
complexes for liposome MSB2 varied in size from 150 nm to 300 nm at a ratio of 
10:6:1 (w/w/w) for the streptavidinbiotransferrin:liposome MSB2:DNA complexes , and 
from 200 nm to 500 nm at a higher ratio of 10:7:1. The ultrastructure of these 
complexes did not differ much from that of their corresponding lipoplexes (3.3.3.5) in 
that they formed clusters of varying sizes. Sizes reported for some Tf containing 
complexes using light scattering measurements ranged from 500 nm to 880 nm in 
diameter (Joshee et al., 2002). 
The DNA seemed to be condensed by the complex, which is important for efficient gene 
transfer. However there was one significant difference in these ternary complexes in 
that rod-like or elongated tubular forms were visible (Figure 3.19) at the higher charge 
ratio. These could be due to the fusion of the lipid membranes during formation of the 
ternary complex which completely covers the DNA, drawing the three components 
closer together. Such tubular or rod shaped structures have been observed previously 
for some lipoplexes (Gershon et al., 1993; Chiruvolu et al., 1994). These tubules were 
about 1 iJm in diameter and up to 100 iJm in length and most of them appeared 
entangled with each other (Chiruvolu et al., 1994). However this was not the case for 
lipoplexes prepared in the present study and rods seemed to be considerably shorter 
and occurred singly. The sizes of tubular structures were approximately 0.25 iJm in 
diameter and about 4 iJm in length (Figure 3.19b). Rod like structures were also 
observed at the higher charge ratio viz.( +/-) ratio of 1.5. It was suggested that these 
unusual structures are formed above the critical ratio and are complexes where the 
DNA molecules are packed and completely encapsulated within a smooth lipid bilayer 
(Gershon et al., 1993). The liposome: DNA charge ratio at which tubular formations were 







Figure 3.19 : TEM of streptavidinbiotransferrin: liposomeMSB1 :DNA complexes at 
(a) optimal transfection ratio of 10:6:1, and, 







Figure 3.20 : TEM of streptavidinbiotransferrin: IiposomeMSB2:DNA complexes at 
(a) optimal transfection ratio of 10:6:1, and, 
(b) at a higher ratio of 10:7: 1. 
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Furthermore some free liposomes were noted, unlike the preparations of plain 
lipoplexes, where it seemed that all the liposomes were complex-associated. Wagner et 
al., 1991, have also shown that Tf-complexes produced toroidal-like structures. 
It was found by some investigators that the inclusion of Tf in the formulation to produce 
a ternary complex, increased the size of the complex especially if the DNA is added 
last. If the Tf or the liposome was added last, the size of the complex was unchanged 
(Joshee et al. , 2002). Lipoplexes reported herein were prepared by the addition of the Tf 
component first followed by the DNA, and no prolonged maturation of the complexes 
(i.e> 30 minutes) was carried out. Transferrin (80 kDalton) itself, is approximately 2 
orders of magnitude smaller than the average lipoplex size of 200 nm. These 200 nm 
complexes can be accommodated in clathrin-coated vesicles since it was observed 
under electron microscopy that coated vesicle sizes from 100-200 nm exist. Hence, it 
has been suggested that clathrin-mediated endocytosis of particles exceeding 
diameters of 200 nm is possible and that the process may involve a considerable 
degree of size flexibility of the coated vesicles (Zuhorn et al. , 2002). The attachment of 
Tf to liposomes tends to increase the hydrodynamic radius of the Tf:liposome:DNA 
complex (Joo and Kim, 2002). Ideally, for successful endocytosis, the size of the ligand 
must not exceed the internal diameter of the coated pit. Vance and Vance (1991) have 
reported that the coated pit diameter lies within the 100-500 nm range. 
It has been suggested that ternary complexes of 400-500 nm in diameter are 
appropriate for transfection (Tokunaga et al., 2004). The average size of the most 
effective ternary complex in vitro utilizing Lipofectin ™ (Tf:liposome:DNA), as determined 
by light scattering was between 500-880 nm, and complex sizes ranged from 
400-1400 nm (Joshee et al., 2002). These complexes do not completely resemble the 
condensed lipoplexes seen by Gershon et al., 1993. Hence the results obtained by 
Joshee et al. , 2002, suggest that uncondensed DNA can also yield high transfection 
efficiency in liposome-based gene transfer systems. This is unlike the molecular 
conjugate based vectors where small vector sizes (up to 17 nm) produced high 
transfection rates (Perales et al. , 1994). 
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3.4.3.7 Nuclease Digestion Assays of Ternary Complexes 
These studies have shown that the ternary complexes effectively protected the plasmid 
DNA from attack by the serum nucleases. This could be due to the stability of these 
complexes or to their compaction by condensation. The ternary complexes as seen 
under electron microscopy are highly condensed supramolecular structures. This 
reinforces the notion that the DNA in these complexes is protected from nuclease 
degradation. 
The naked DNA (lane2, Figures 3.21a and b) is uncomplexed (absence of liposomes 
and streptavidinbiotransferrin), and is completely degraded by the presence of serum 
nucleases whereas the DNA bound in the ternary complexes is protected and 
undegraded, at all streptavidin(biotransferrin):liposome:DNA ratios. The actual extent to 
which the DNA is protected . by the liposomes will depend on the type of liposome 
utilized and the type of complex formed. If the ternary complex association is not a 
strong or tight one, the nuclease enzymes can easily access and degrade the DNA or 
alternatively destabilize the complex. It was observed by some investigators that 
ternary complexes prepared using streptavidin complexes seem to stabilize and protect 
the DNA from digestion by DNase enzymes (Xu et al., 1998). This could also account 
for the protection of the DNA revealed by agarose gel electrophoresis in the present 
study (Figures 3.21 ) 
It was seen using DNAlTf/PEI complexes that aggregates of the complexes were 
produced upon addition of serum, due to binding of serum proteins to the complexes 
(Ogris et al., 1999). However with our ternary complexes no aggregation or precipitation 
was observed upon addition of serum and there was no noticeable change in the 
turbidity of the liposomal solution. Hence it can be concluded that these ternary 
liposome complexes could be suitable vehicles for the safe transport of DNA into cells in 
vitro and could perhaps be useful in vivo. This observation seems to correlate with 
results obtained for transfection studies of the ternary complexes in the presence of 
10% fetal bovine serum. 
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Liposome clearance in vivo, however, will depend upon the amount of serum proteins or 
opsonins (complements, immunoglobulins and fibronectins) that are bound to the 
liposomes (Oku et al., 2000). 
(a) (b) 
Figure 3.21: Nuclease protection assay of ternary assemblies containing 
(a) MSB1, pBR322 DNA and streptavidinbiotransferrin, and, 
(b) MSB2, pBR322 DNA and streptavidinbiotransferrin. 
Lane 1 : untreated marker plasmid pBR322 DNA (1 I-Ig) 
Lane 2 : unprotected plasmid DNA (1 I-Ig) in the presence of 10% FCS 
Lanes 3-8 : Varying amounts of cationic liposomes (2, 3, 4, 5, 6, 7 I-Ig) 
with pBR322 DNA (1 I-Ig) and streptavidinbiotransferrin (10 I-Ig) and 10% 
FCS. 
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3.4.4 CELL CULTURE AND TRANSFECTION STUDIES 
3.4.4.1 Growth and Maintenance of HeLa cells 
The HeLa cells (Figure 2.28) were successfully propagated as outlined in chapter two. 
3.4.4.2 Growth Inhibition Assays 
These studies were conducted on the untargeted biotinylated liposome:DNA complexes 
and on the ternary complexes for both liposome preparations (MSB 1 and MSB2). As 
can be seen in Figures 3.22 and 3.23 there was a small but measurable difference in 
the growth inhibition levels for the plain lipoplexes and the ternary targeted complexes. 
The ternary complexes (streptavidinbiotransferrin:liposome:DNA) showed less 
cytotoxicity than the plain lipoplexes even at higher liposome ratios. This could be 
attributed to the presence of the transferrin component which is the only difference 
between the two types of complexes. It bears mentioning also that there were marked 
ultrastructural differences (TEM) between the targeted and untargeted assemblies 
(Figures 3.18 to 3.20). 
Maximum cell death recorded was 32% for liposome MSB1 :DNA (Figure 3.23) at a 
liposome:DNA ratio of 8:1, (+/-) charge ratio of 1.0, and 31 % for liposome MSB2:DNA 
(Figure 3.22) at the same ratio. The best survival rates observed were at the 
liposome:DNA ratio of 4:1, (+/-) charge ratio of 0.5, and were 91 % and 92% respectively 
for liposome MSB1 and MSB2. In the case of the ternary complexes the maximum cell 
death recorded at the highest streptavidinbiotransferrin:liposome:DNA ratio of 10:8:1 
was lower with 23% for both complexes (Figure 3.22 and 3.23). At the lower ternary 
complex ratio of 10:4: 1 the survival rate was 96% and 95% for complexes with liposome 
MSB1 and MSB2 respectively. The extent of cytotoxicity varies with different liposome 
formulation and also with the type of complexes being formed with the liposomes. The 
seeding density of cells in the plate could also playa role in the estimation of toxicity 
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levels in the different complexes and formulations. The general trend that the level of 
toxicity increases with increasing amounts of liposome is also observed for these 
liposomes. These low levels of toxicity are very important as they could indicate the 
potential of these novel liposomes, lipoplexes, and ternary complexes to be utilized in 
future in vivo studies. 
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Figure 3.22: Growth inhibition studies of liposome MSB1 :DNA and ternary 
complexes (streptavidinbiotransferrin:liposome MSB1 :DNA) to the 
HeLa cell line in vitro. The amount of liposome MSB 1 was varied 
(0,4, 5, 6 ,8 I-Ig) while the DNA (1 I-Ig) and streptavidinbiotransferrin 
(10 I-Ig) was kept constant in a total volume of 0.5 ml MEM. A control 
sample (no liposome), containing only cells was assumed to have 
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Figure 3.23: Growth inhibition studies of liposome MSB2:DNA and ternary 
complexes (streptavidinbiotransferrin:liposome MSB2:DNA) to the 
HeLa cell line in vitro. The amount of liposome MSB2 was varied 
(0,4, 5, 6 ,8 I-Ig) while the DNA (1 I-Ig) and streptavidinbiotransferrin 
(10 I-Ig) was kept constant in a total volume of 0.5 ml MEM. A control 
sample (no liposome), containing only cells was assumed to have 
100% survival. Data are presented as means ± S.D (n = 4). 
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3.4.4.3 Transfection studies with untargeted and targeted biotinylated 
liposomes: 
(a) liposome MSB1 :pGL3 DNA complexes 
(b) liposome MSB2:pGL3 DNA complexes 
(c) streptavidin(biotransferrin):liposome MSB1 :pGL3 DNA 
complexes 
(d) streptavidin(biotransferrin):liposome MSB2:pGL3 DNA 
complexes 
Tf-facilitated lipofection has been investigated by many researchers who have shown 
that it occurs with high efficiency. It was shown that the mixing of transferrin with a 
cationic liposome prior to addition of DNA, greatly enhanced the lipofection efficiency in 
Panc 1 cells. Hence it is proposed that the ligand-facilitated gene delivery depends on 
the order of mixing of these components. The most efficient method tested was the 
addition of the plasmid DNA last (Joshee et al., 2002). Our ternary complexes were all 
prepared by the initial addition of the Tf component to the liposome, followed by a 
period of incubation, and then the addition of the DNA followed by a further incubation. 
This seemed to afford reasonable transfection activity. Some results have suggested 
that the addition of Tf to the liposome prior to the addition of DNA prevents DNA 
condensation by the liposome and helps to segregate DNA-Tf complexes from the 
liposome, in addition to facilitating the endocytosis step which will increase delivery of 
the DNA to the cells (Joshee et al., 2002). It was found that a decrease in the net 
charge of a complex upon addition of DNA led to a decrease in the extent of binding, 
and cell association and fusion. However addition of Tf to the complexes resulted in a 
Significant increase in cell binding and transfection. Tf was found to trigger 
internalization of complexes and to mediate fusion with the endosomal membrane 
(Girao da Cruz et al., 2001). 
Transferrin is regarded as a potent ligand that affords effective receptor-mediated gene 
transfer (Rudolf et al., 2002). In this study the transfection efficiency probably depended 
on several factors viz. the biotinylated Tf containing three biotin moieties: the reaction 
between the biotinylated Tf and the streptavidin, the mole percentage of the biotinylated 
cholesterol derivative in the liposome formulation, and finally the interaction between the 
biotinylated liposome and the streptavidinbiotransferrin to produce a stable and efficient 
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complex for receptor mediated transfection. The results obtained for the untargeted and 
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Figure 3.24: Transfection studies of liposome MSB1 :DNA complexes (with and 
without incubation in 10% serum and in the presence of 200 I-Ig freeTf) 
in HeLa cells in vitro. Liposome MSB1 was varied (0,4,5,6,8 I-Ig) 
while the DNA (1 I-Ig) was kept constant in a total volume of 0.5 ml 
MEM. Control 1 contains only cells and control 2 contains naked DNA 
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Figure 3.25: Transfection studies of liposome MSB2:DNA complexes (with and 
without incubation in 10% serum and in the presence of 200 1-19 freeTf) 
in HeLa cells in vitro. Liposome MSB2 was varied (0, 4, 5 , 6 , 8 I-Ig) 
while the DNA (1 I-Ig) was kept constant in a total volume of 0.5 ml 
MEM. Control 1 contains only cells and control 2 contains naked DNA 
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Figure 3.26 : Transfection studies of streptavidin(biotransferrin}:liposome MSB1 :pGL3 
DNA complexes (with and without incubation in 10% serum and in 
the presence of 200 I-1g freeTf) in HeLa cells in vitro. Liposome MSB1 
was varied (0, 5 , 6 , 8 I-1g) while the DNA (1 I-1g) and streptavidin 
(biotransferrin) (10 I-1g) was kept constant in a total volume of 0.5 ml 
MEM. Control 1 contains only cells, control 2 contains naked DNA 
and no liposome, and control 3 contains liposome MSB1 :DNA (6:1) at 
optimal non-targeted ratio (absence of streptavidinbiotransferrin). Data 
are presented as means ± S.D (n = 4). 
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Figure 3.27: Transfection studies of streptavidin(biotransferrin):liposome MSB2:pGL3 
DNA complexes (with and without incubation in 10% serum and in 
the presence of 200 I-Ig freeTf) in HeLa cells in vitro. Liposome MSB2 
was varied (0, 5 , 6 , 8 I-Ig) while the DNA (1 I-Ig) and streptavidin 
(biotransferrin) (10 I-Ig) was kept constant in a total volume of 0.5 ml 
MEM. Control 1 contains only cells, control 2 contains naked DNA 
and no liposome, and control 3 contains liposome MSB2:DNA (6:1) at 
optimal non-targeted ratio (absence of streptavidinbiotransferrin. Data 
are presented as means ± S.D (n = 4). 
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The untargeted biotinylated liposomes (Figures 3.24-3.25), both showed a 20-25% 
drop in luciferase activity when transfection was conducted in 10% serum and a drop of 
about 10% upon addition of 200 IJg free iron-Tf added to each well prior to transfection, 
even at their optimalliposome:DNA (6:1 w/w) mixing ratios and a (+/-) charge ratio of 0.7. 
This could be due to the excess Tf that bound to the cell surface transferrin receptors 
coating the cells, thereby reducing transfection levels to a certain extent. The possibility 
that excess transferrin present in the medium destabilized the lipoplexes, in part, with 
some displacement of the plasmid DNA cannot be discounted. 
The Tf:liposome:DNA complexes (Figure 3.26-3.27) showed almost a two fold increase 
in transfection activity compared to the unconjugated liposomes, suggesting that the 
presence of the Tf component facilitates the uptake of the Tf:liposome:DNA complex 
into the HeLa cells by receptor mediated endocytosis. The partial uptake of these 
liposomes by receptor-mediated endocytosis was further confirmed by the transfection 
of these targeted liposomes in the presence of excess (200 IJg) free iron-Tt, where the 
luciferase activity dropped dramatically. The uptake of transferrin-targeted liposomes 
can be restricted by competition for the cognate receptor site by free transferrin. The 
addition of the free transferrin reduced the transfection activity with the Tf coupled 
liposomes by about 60-70% (+/- charge ratio of 0.7), to levels close to those obtained 
for the untargeted liposomes. Hence it can be proposed that any increase in 
transfection was due to the presence of the Tf ligand and the process of receptor-
mediated endocytosis. 
The transfection levels obtained in this competition assay could be due to normal non-
receptor-mediated lipofection processes and not due entirely to receptor mediation. It 
has been reported that any increase in transfection is eliminated when transfections are 
conducted in the presence of excess free transferrin (8ellocq et al., 2003). Some 
investigators have reported using up to 10 mg/ml of free transferrin in their competition 
assays with about a 72% drop in gene expression (Joo and Kim, 2002), while others 
have shown almost a total inhibition of luciferase activity (Schoeman et al., 1995). 
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The results obtained for our ternary complexes in the presence of 10% FBS did not vary 
significantly from the optimal transfection activity noted for complexes transfected in the 
absence of serum. Transfection levels dropped from 2-7%. This is a very small 
reduction in transfection and could be due to other contributing factors such as cell 
density and destabilization of complexes by serum components. Hence these ternary 
complexes seem to be quite stable in serum-containing medium. This finding is in 
contrast with corresponding experiments using untargeted lipoplexes where transfection 
activities were reduced by 12% at the optimalliposome:DNA ratio of 6:1 (w/w) (Figures 
3.24, 3.25, 3.26 and 3.27). It has been suggested that coating of lipoplexes with neutral 
or negatively charged proteins (eg. transferrin) may constitute a promising strategy to 
modulate their colloidal stability and transfection efficiency in the presence of serum 
(Pedroso de Lima et al., 2001). The use of serum-free medium was found to decrease 
the binding of diferric Tf to the cell surface by 30-60% whereas addition of fetal bovine 
serum to cells resulted in a rapid (2-3 minutes) concentration dependent increase in 
binding activity (Ward and Kaplan, 1986). 
It is reported that Tf-lipoplexes always mediate higher gene expression compared to 
plain lipoplexes in the presence or absence of serum. A five fold increase in transfection 
activity was also observed for complexes in 60% FBS (Tros de lIarduya and DOzgOne~, 
2000). Tf-lipoplexes are said to be superior to plain lipoplexes in transfecting HeLa cells 
in the presence of high concentrations of serum (Tros de lIarduya et al., 2002). The 
inhibitory effect of serum seems to be more evident at lower charge (+/-) ratios of the Tf-
complexes, while this inhibitory effect is overcome at higher charge ratios (+/-). 
Furthermore it was reported that prolonged incubation of Tf-liposome complexes prior to 
addition to the cells renders them serum resistant and that maturation of the complex is 
an essential element of serum-resistance. Serum resistance is also dependent on the 
charge ratio (+/-) and the incubation period (Tros de lIarduya and DOzgOne~, 2000). 
This molecular basis of serum resistance and the enhancement by serum is not 
completely understood. It is possible that the interaction of the transferrin-lipoplexes 
with the cell surface receptors facilitates uptake by the host cells, while plain lipoplexes 
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are coated with serum proteins and hence inhibited from interacting electrostatically with 
the cell surface. The presence of Tf on the lipoplexes could also hinder the 
complexation of serum proteins with the cationic lipids (DOzgOne!1 et al., 2003). 
Although liposomes resemble biomembranes in an in vivo system, they still appear as 
foreign objects for the host cell and they are recognized by the mononuclear phagocyte 
system (MPS), after interaction with plasma proteins. Hence liposomes are cleared 
from the bloodstream by the MPS and trapped by the reticuloendothelial system (RES) 
where macrophage-like cells reside (Oku et al., 2000). The transfection results 
obtained in serum are important since these ternary complexes exhibited relative 
stability under these conditions, and could have a potential for in vivo transfer. 
To increase the number of transferrin receptors for targeting purposes one could have 
grown cells in iron deficient medium for a period prior to transfection. This regulation of 
expression of Tf receptors by iron supply has been seen in many cell types in culture by 
using iron chelators such as desferrioxamine (Cotton et al., 1990), to reduce the iron 
supply in the medium (Taylor et al., 1991). Receptor denSity can also be increased by 
interfering with heme synthesis using succinyl acetone, or by stimulating the 
degradation of heme with cobalt chloride treatment (Cotton et al., 1990). It was found 
that in Hela cells, the intracellular heme content may be an important signal controlling 
transferrin receptor number (Ward et al., 1984). The rate of endocytosis of Tf was found 
to be extremely slow in He La cells (Girao da Cruz et al., 2001). 
It is proposed that transferrin enhances the transfection efficiency of a standard 
lipofection formulation by preventing DNA condensation, and facilitating endocytosis 
and nuclear targeting (Joshee et al., 2004). However the efficiency of Tf-lipoplexes in 
primary cells at high serum concentrations was enhanced using protamine, which 
condenses the DNA and promotes cellular entry, and increased gene expression by 
increasing nuclear localization of DNA. This was seen in both cultured cells and in 
various tissues in mice after intravenous administration (Tros de lIarduya et al., 2002). 
The use of pH-sensitive fusogenic peptides together with the cationic liposome and 
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targeting ligand was found to mediate efficient gene transfer to human macrophage 
cells in vitro, by promoting endosomal destabilization (Simoes et al., 1999). 
The spacer length of the biotinylated liposomes seems to have little impact on the 
transfection activity of the two liposomes with MSB2 liposomes being slightly better in 
transfecting cells by only about 5% at the optimal charge ratio. Transfection also 
increased with increased liposome: DNA charge ratio until the same optimal transfection 
ratio was reached for each complex. On further increase of the +/- charge ratio 
transfection activity declined as was the case with MS09, MS10 and MS11 lipoplexes in 
Chapter 2. 
3.5 CONCLUSION 
We have confirmed in these studies that transferrin-mediated endocytosis can be 
successfully exploited to target genes to the transferrin receptors on HeLa cells in vitro, 
using cationic liposomes as DNA carriers, and shown that the biotin-streptavidin 
interaction can be used to anchor the targeting ligand to the liposomal membrane 
bilayer. This could be extended to in vivo systems where Tf receptors are 
overexpressed, especially in some cancers. This targeted delivery system appears to 
be efficient and shows marked stability in 10% fetal bovine serum. The investigation of 
this system in vivo therefore seems warranted. Although the streptavidin component 
may exhibit spurious binding to integrins and related cell surface molecules (Das et al., 
2002), it is possible that in the assemblies studied here, the streptavidin component 
may be partially concealed and the implicated Arg-Tyr-Asp (RYD) sequence may be 
sufficiently adumbrated. 
Unfortunately the correlation of in vitro and in vivo efficacies is a fragile one, although in 
vitro experiments are carried out with strict controls. For clinical application one would 
have to ensure that the enhanced targeting and transfection efficiency of the liposomes 
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achieved for in vitro experiments be maintained. For example, the tumour suppressor 
gene p53 has been delivered successfully into tumours in vivo, but its expression is low 
due to a lower transfection efficiency when compared to viral vectors (Qian et al., 
2002). However, the influence and the complexities of the intrinsic effects and non-
specific interactions would be difficult to predict in any in vivo system. Our challenge 
would be to optimise the various parameters of this current targeted gene delivery 
system for possible future in vivo studies. 
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CHAPTER FOUR 
GL YCOTARGETING TO HepG2 CELLS IN VITRO 
4.1 INTRODUCTION 
Selective delivery of biologically active substances is designed to overcome nonspecific 
biodistribution of drugs or genes and to increase their local concentration at the target 
tissue. Certain strategies are based on carrier-mediated delivery to selective tissues 
and organs through ligands or modified vehicles such as liposomes that are recognized 
by receptors while others address molecules present on target cells. Gene transfer 
plays an important role in the development of new therapeutic concepts for liver 
diseases. Various gene and cell based therapies are emerging at a rapid pace, because 
they promise to be less invasive, less costly and at least as effective as currently 
established therapy protocols. Hence gene therapy models are being developed for a 
wide spectrum of liver diseases, including hereditary liver disorders, malignant liver 
diseases and viral hepatitis (Ott et al. , 2000). The characterization of sugar residues on 
cancer cells with lectins is used as a prognostic tool for cancer malignancy (Palliard, 
1999). 
The liver is one of the most important target tissues for gene therapy, given that it has a 
central role in metabolism (eg. lipoprotein metabolism in various cholesterolemias) and 
the secretion of circulating proteins (eg. clotting factors in hemophilia). The liver is a 
unique organ and harbours several other properties including a dual blood supply (80% 
portal and 20% systemic) for inflow and one outflow system viz. the hepatic vein. It is a 
regenerative organ and over 70% of the cells are hepatocytes (Galun, 2003). 
Hepatocytes are parenchymal cells in the liver and can be damaged in various 
pathological processes. Hence the delivery of therapeutic agents for attenuation of liver 
injury, inhibition of viral hepatitis replication or modification of hepatocyte-related 
metabolism should ideally be to the liver, and especially to the hepatocytes (Wu et al., 
2002). The endothelium of liver sinusoids (specialized capillaries) serve as an active 
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barrier between the circulating blood and hepatocytes. Liver sinusoidal epithelial cells 
lack a basal lamina and comprise unique pores (fenestrae), which act as filters for 
fluids, solutes, and particles that are exchanged between the sinusoidal lumen and the 
hepatocytes. These cells are also effective in the uptake of a wide variety of substances 
from the blood by receptor-mediated endocytosis. Some of these substances can be 
actively transferred across the endothelial barrier to surrounding tissues by a process 
called transcytosis (Cormier et al., 2004). 
Because its malfunction leads to critical metabolic damage affecting the entire body, the 
liver is a principal target organ for gene therapy. The efficacy of the particular therapy 
will depend largely on the ability to target specifically liver cells for corrective gene 
transfer. Receptor-mediated gene transfer is one of the most promising approaches to 
the problem, provided the relevant receptors are selectively expressed by hepatocytes 
(Hisayasu et al., 1999). Targeted delivery of DNA via receptors has been successfully 
applied using protein ligands to the hepatic asialoglycoprotein receptor (ASGP-R). The 
ASGP-R is a cell-surface receptor that is highly represented on hepatocytes. Thus, 
genes targeted to this receptor can be delivered in a highly selective manner to the liver. 
The asialoglycoprotein receptor on mammalian hepatocytes provides a unique means 
for the development of liver-specific carriers, such as Iiposomes, recombinant 
lipoproteins, and polymers for drug or gene delivery to the liver, especially to the 
hepatocytes (Wu et al., 2002). 
Asialoglycoprotein receptors on the plasma membranes of hepatocytes have been a 
focus of research interest for receptor-mediated targeting since Wu and Wu (1987) first 
introduced DNA into hepatocellular carcinoma cells and rat liver (Wu and Wu, 1988), in 
the form of a complex with asialoglycoprotein and polylysine. Significant expression of 
the luciferase gene in the pRSVL vector was found after targeting of a cationic lipid 
(DOGS)-asialoorosomucoid-DNA complex, to the hepatocyte like cell line, HepG2 
(Mack et al., 1994). An amphiphilic gelling agent was also added to asialoorosomucoid-
polylysine conjugates to enhance receptor-mediated gene delivery to HepG2 cells in 
vitro (Cho et al., 2000). Furthermore, the use of protamine to enhance targeted gene 
delivery by asialofetuin-lipoplexes to the asialoglycoprotein receptor both in cultured 
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cells in vitro and in the liVer of mice in vivo was reported (Arangoa et al., 2003). 
Liposomes have shown substantial potential in the targeting of specific cell types of the 
liver and may improve the targeting efficacy in the treatment of a variety of liver 
diseases, including inherited disorders such as hemophilia and low density lipoprotein 
(LDL) receptor deficiency (Wu and Zern, 1999). 
4.1.1 The HepG2 Cells and Asialoglycoprotein Receptors 
The human hepatoma cell line, HepG2, is used as a model in vitro gene delivery system 
for hepatocellular carcinomas and for the study of hepatocyte function. Hence to gain 
further knowledge on hepatocyte function in health and disease and to develop potential 
gene transfer therapies for hepatocellular carcinomas, successful transfection of HepG2 
cells must be demonstrated. 
The HepG2 cells are one of the two human cell lines that were isolated from liver 
biopsies of hepatoblastoma and hepatocellular carcinoma (Aden et al., 1979). HepG2 
cells are known to produce many plasma proteins, viz. a-fetoprotein, albumin, 
transferrin, haptoglobulin, fibrinogen, a-1-acid glycoprotein, ~-lipoprotein, plasminogen, 
and ceruloplasmin. Albumin and a-fetoprotein are the major secretory products of the 
HepG2 cell line. This tumour-derived cell line has the same biosynthetic capabilities of 
normal liver parenchymal cells (Knowles et al., 1980). Of the two human hepatoma 
derived cell lines, the Hep3B and the HepG2, the latter does not synthesize the hepatitis 
B virus surface antigen (HBsAg), which is thought to be the probable cause of 
hepatocellular carcinomas (Szmuness, 1978). 
HepG2 cells are known to possess approximately 225 000 asialoglycoprotein receptors 
per cell (Schwartz et.al., 1981). In growing cells approximately 85% of the functional 
receptors are on the cell surface and the remaining 15% are internal. The maximal rate 
of ligand uptake at 37°C is approximately 30 000 molecules per cell per minute. Hence 
each functional receptor can bind and internalise more than 50 ligand molecules during 
206 
a 6 hour period , or 1 ligand every 8 minutes (Schwartz et al., 1982). The 
asialoglycoprotein receptor recycles via endocytosis and is localized to the sinusoidal 
face of the hepatocyte plasma membrane (Saxena et al. , 2003). Due to its unique 
location within the microvilli clefts at the sinusoidal hepatocyte surface, abundance and 
high internalization capacity, the asialoglycoprotein receptor is widely used as a target 
for specific delivery of genes or therapeutic agents to hepatocytes (Rensen et al., 2001). 
Some of the physiological and pathophysiological functions of this receptor are the 
removal of desialylated serum glycoproteins and apoptotic cells, clearance of 
lipoproteins, and acting as sites of entry for hepatotropic viruses (Tozawa et al. , 2001). 
The hepatic asialoglyprotein receptor binds glycoproteins that have carbohydrate chains 
terminating in galactose and N-acetyl galactosamine residues, and endocytose the 
ligands for intracellular degradation (Wu et al., 2002). The human receptor is a hetero-
oligomeric complex with two homologous subunits (H1 and H2), each possessing a 
galactose binding site. The mature and fully glycosylated forms of the H1 and H2 
subunits are approximately 46 and 50 kDaltons, respectively (Saxena et al., 2002). 
These two receptor polypeptide subunits are similar in their primary structure to those 
receptors of the rat, that have three subunits, viz. RHL-1, RHL-2 and RHL-3 (Sawyer 
and Doyle, 1990). Both the surface and internal receptors are hetero-oligomers and 
retain their structure upon ligand internalization or receptor modulation (Herzig and 
Weigel, 1990). Each polypeptide subunit of the ASGP-R can bind at least a single 
galactose or N-acteylgalactosamine residue (Rensen et al., 2001). The specificity and 
affinity of ligand binding depends on the number and spatial arrangement of the 
galactose binding sites within the receptor complex. Although both subunits of the 
receptor are required for high affinity binding, binding can occur in the absence of one of 
the two units. For example, the asialoorosomucoid (ASOR) and asialofetuin (ASF) are 
able to bind to COS-7 cells expressing the major subunit H1 in the absence of the 
second subunit H2 (Bider et al., 1995). The H2 subunit is a minor subunit of the 
receptor and contains weak signals for endocytosis and recycling of ligands. Hence it 
cannot facilitate endocytosis in the absence of subunit H1. The H2 subunit is expressed 
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at a 3 fold higher concentration than the H1 subunit in the human asialoglyprotein 
receptor (Saxena et al., 2002). 
In humans the asialoglyprotein receptor is found mainly on hepatocytes, although they 
do occur extrahepatically in the thyroid, small and large intestines, the testis and 
possibly in the mesangial cells in the kidneys (Seow et al., 2002). Hepatocytes were 
also targeted using liposomes conjugated to the epidermal growth factor (EGF), since 
many carcinoma cells show a high expression of EGF receptors (Ishii et al., 1989). In 
hepatocytes the general sugar preference of the asialoglycoprotein receptors is N-
acetylgalactosamine (GaINAc) over galactose (Rensen et al., 2001) whereas the 
macrophage receptor binds both ligands with equal affinity (Iobst and Drickamer, 1996). 
The actual receptor-mediated endocytosis of asialoglycoprotein and galactosylated 
macromolecules is characterized by the vectorial movement of ligand-containing 
vesicles through the cytoplasm. The ligand-receptor complex is internalized from the 
cell surface into an acidic late endosomal compartment where the receptor and ligand 
dissociate and segregate, resulting in movement of ligand-containing vesicles towards 
lysosomal fusion, while receptor-containing vesicles recycle. It was demonstrated that 
the endosomal vesicles bind directly to microtubules in a manner that suggests that 
microtubules playa role in segregation of the ligand and receptor (Goltz et al., 1992). 
This was supported by evidence that the vesicles that contain the endocytosed ligand, 
asiaoloorosomucoid, can translocate for distances of up to 20 IJm or more and the 
ligands are released upon addition of ATP. The velocity of this movement is oscillatory 
(Murray et al., 2000). 
208 
4.1.2 Glycotargeting 
Lectins are present on the surface of many cells. Many lectins actively recycle from the 
membrane to the endosomes and efficiently take up glycoconjugates in a sugar-
dependent manner. Based on this, glycoconjugates especially those obtained by 
chemical means, are regarded as being good carriers of drugs, oligonucleotides, or 
genes (Monsigny et al., 1998). The term "glycotargeting" refers to the targeting by 
carrier molecules possessing carbohydrates that are recognized and internalized by 
these cell surface mammalian lectins. Receptor-mediated endocytosis is primarily the 
mechanism that is targeted. Glycosylation of liposomes can be achieved by coating 
with glycoprotein or incorporation of synthetic glycolipids (Kawakami et al., 2002). The 
use of sugar macromolecule conjugates or glycoconjugates may be divided into two 
types viz. those in which the macromolecule is itself the drug or therapeutic agent, or, 
those in which the macromolecule plays an important role in the delivery of a particular 
drug or therapeutic agent (Davis and Robinson, 2002). Many types of glycotargeting 
vehicles have been designed based on the covalent attachment of saccharides to 
proteins, polymers and other aglycones (Wadhwa and Rice, 2003). Carbohydrate-
conjugated polycations or lipids are considered the most effective transfection system 
for receptor-mediated transfer (DOzgOne~ et al., 2003). 
Glycosylated polylysines have been reported to show specificity in the delivery of 
nucleic acids into cells that express a given surface membrane lectin (Monsigny et al., 
1999). Galactose, has also been incorporated into DNA-polylysine complexes to 
selectively target DNA to hepatocytes that bear galactose receptors (Plank et al., 1992, 
Perales et al., 1997; Hashida et al., 1998; Hisayasu et al., 1999). Galactose-PEl-DNA 
complexes were also targeted to HepG2 cells in vitro with limited gene expression 
(Kunath et al., 2003). Proteins that have been chemically modified to harbor a sugar 
residue are called 'neoglycoproteins' (Palliard, 1999). Such neoglycoproteins were 
prepared by the glycosylation of bovine serum albumin (BSA) and targeted to rat 
hepatocytes (Kawaguchi et al., 1981), to parenchymal cells in mice (Nishikawa et al., 
1992) and to solid tumour-bearing mice (Noboru et al., 2001). Quaternary complexes 
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prepared from galactosylated BSA, poly-L-Iysine, DNA and a fusogenic peptide, 
achieved selective entry into HepG2 cells with high reporter gene expression (Han et 
al., 1999). Furthermore, cholesterol with an attached triantennary galactose cluster 
bound via a PEG type spacer was prepared and used to bind to the asialoglycoprotein 
receptor of the liver parenchymal cells (Biessen et al., 1994). Triantennary galactose 
clusters were also incorporated into high density lipoproteins for targeting to liver 
hepatocytes in vivo (Van Berkel et al., 1985), and into electroneutral lipospermine/DNA 
complexes and targeted to HepG2 cells in vitro (Schuber et al., 1998). 
In previous studies we have shown successful receptor-mediated gene delivery to 
HepG2 cells by ternary assemblies containing cationic liposomes and cationised 
asialoorosomucoid (Singh et al., 2001 b), and using complexes containing DNA, 
cationized asialoorosomucoid and activated cationic liposomes (Singh et al., 2003). 
Galactose modified a-helical peptides were utilized by some investigators to transfer 
genes into human hepatoma cells (HuH-7), and showed that transfection efficiency 
increased with increased number of modified galactose residues (Niidome et al., 2000). 
Low molecular weight chitosan was also galactosylated for hepatocyte targeting in vitro 
(Gao et al., 2003). Sterylglucoside containing cationic liposomes were utilized for liver-
directed gene transfer into the HepG2 cell line and in vivo into mice following 
intravenous injection, with significant gene expression (Hwang et al., 2001; Maitani et 
al., 2001). In mammals these terminal sugars (galactoses) are recognised by the high 
affinity hepatic asialoglycoprotein receptors that then removes them from circulation, 
and internalise them within the hepatocytes and catabolises them in the Iysosomes 
(Ashwell and Morel, 1974). 
In addition to the hepatocyte asialoglycoprotein receptor, the glycoprotein receptors 
present on the Kupffer cells in the liver also have an affinity for monosaccharide ligands 
such as galactose or N-acetylgalactosamine, and may function in a similar fashion 
(Fadden et al., 2003). 
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4.2 OUTLINE OF CHAPTER 
An attempt is made here to produce a synthetic targeted cationic liposome-mediated 
DNA carrier system for an in vitro study in a human hepatoma cell line (HepG2). 
Targeted transfection is expected to be facilitated by the formulation of glucopyranosyl-
and galactopyranosylcholesteryl derivatives with the cationic cholesterol derivative 
MS09 and the helper lipid, DOPE, to produce liposomes with a targeting potential. The 
sugar moiety present in the liposomal bilayer is intended to bear a specificity towards 
the membrane lectins in a configuration-dependent manner, while the cationic 
component is included to bind electrostatically to the negatively charged plasmid DNA. 
Conventional cationic liposomes have no inherent cell-specific targeting properties, and 
thus would not be expected to exhibit tissue-specificity in vivo. Hence it is hoped that 
the use of the these novel liposome formulations bearing the ligands D-
galactopyranose and D-glucopyranose in an a- or ~-glycosidic link with the cholesteryl 
anchor may help mediate the targeted transfection to the HepG2 cells line that displays 
specific cell surface (asialoglycoprotein) receptors. 
Not only is anomeric preference by the asialoglycoprotein receptor for the D-
galactopyranosyl entity being examined, but also the epimeric specificity relating to the 
C-4' configuration in the pyranosyl ring is being tested by formulating separate 
liposomes assembled in identical proportions to the galacto-liposomes, but containing 
glucopyranosyl cholesterol in both an a- and a ~-glycosidic link. The pGL3 plasmid 
DNA is once again used to detect transient expression in these HepG2 cells, since 
these cells lack luciferase activity. 
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4.3. MATERIALS AND METHODS 
4.3.1 MATERIALS FOR CHEMICAL SYNTHESIS 
I3-D-glucose pentaacetate was obtained from Sigma-Aldrich (St.Louis, MO, USA). The 
a,l3-galactose pentaacetate was supplied by Pfanstiehl Laboratories, Inc. (Waukegan, 
IL, USA). Glacial acetic acid, sodium bromide, hexane, cadium carbonate, cholesterol, 
ethanol, ethylacetate, p-anisaldehyde, sulphuric acid, dichloromethane, sodium 
bicarbonate, calcium chloride, toluene, silica gel 60 (70-230 mesh) and silica gel 60F254 
chromatography plates were all purchased from Merck (Darmstadt, Germany). All other 
reagents used were of analytical grade. 1 H NMR and 13C NMR spectra were recorded 
on a Gemini 300 instrument. 
Solvent system C = hexane:ethylacetate (8:3 v/v) 
Solvent system D = formic acid:ethylacetate:CHCb (1 :5:4 v/v/v) 






The cholesteryl glycosides were prepared by a modified Koenigs-Knorr procedure in 
which the respective C-1 bromo-tetra-O-acteyl monosaccharide in a 2:1 mole ratio with 
cholesterol was further activated by cadmium carbonate, a halophilic heavy metal salt 
promoter (Rogers and Thevan, 1986). 
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4.3.2.1 Bromination of Sugars 
To each peracetylated sugar (glucose pentaacetate and galactose pentaacetate, 20 
mmoles, 7.8 g), was added glacial acetic acid (100 ml). This was carried out in a glass 
flask with an inlet and outlet stem, connected to a sintered glass pad to facilitate 
bromination of the sugars. Samples were chilled to 4°C and bromination was initiated 
by the addition of H2S04 dropwise into a flask containing sodium bromide, and the 
generated HBr channeled into the respective samples via the inlet stem. The sugars 
were each brominated for a period of 15 minutes, with reaction mixtures turning a yellow 
to orange colour due to the presence of bromine in samples. The reaction mixtures 
were then maintained at room temperature for 2-3 hours and thereafter placed at 4°C 
until the bromination reaction had reached completion as determined by TLC using 
silica gel 60F254 chromatography plates and solvent system C. The plates were sprayed 
with a p-anisaldehyde spray (p-anisaldehyde: H2S04:ethanol , 5:5:90 v/v/v). 
At the end of bromination (i.e quantitative conversion of the sugar pentaactetates), the 
coloured, but clear solutions were each added to beakers containing crushed ice (400 
ml) respectively. These sugar-ice slurries were stirred and placed in separating funnels. 
Dichloromethane (130 ml) was added to the slurries to dissolve the sugar components. 
Extractions of the dichloromethane layers with distilled water (2 x 200 ml) and 1 % 
NaHC03 (100 ml) were carried out to remove residual acid. Extracted samples were 
added to flasks containing CaCI2 and dried overnight at 4°C. The CaCI2 was removed 
by filtration and reaction mixtures evaporated by rotary evaporation. Samples were co-
evaporated with toluene and then stored in 25-30 ml toluene. Each product yielded one 
major green coloured spot (Rf 0.56) on TLC plates developed in solvent system C and 
sprayed with p-anisaldehyde reagent. 
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4.3.2.2 Synthesis and isolation of: 
(a) Cholesteryl-~-D-tetra-O-acetylgalactopyranoside 
( b) Cholesteryl-a.-D-tetra-O-acetylgalactopyranoside 
(c) Cholesteryl-~-D-tetra-O-acetylglucopyranoside 
(d) Cholesteryl-a.-D-tetra-O-acetylglucopyranoside 
Cadmium carbonate (4 g, 22.7 mmoles) was added to cholesterol (10 mmoles, 3.86 g) 
in a round bottomed flask to absorb the liberated HBr. Toluene (75 ml) was added to 
the mixture and the flask was attached to the 'Dean and Stark' apparatus and immersed 
in an oil bath. The reagents were heated to boiling with continuous stirring and excess 
water was removed azeotropically in the 'Dean and Stark' apparatus. The 2,3,4,6-
tetra-O-acetyl-a.(~)-D-glucopyranosylbromide and 2,3,4,6-tetra-O-acetyl-a.W)-D-galacto-
pyranosylbromide (approximately 20 mmoles) in 30 ml toluene was added dropwise into 
the boiling cholesterol-toluene-CdC03 mixture. The reactions which yielded more water 
(removed azeotropically) were monitored against a cholesterol standard by TLC in 
solvent system C and using the p-anisaldehyde spray. The solutions turned bluish-
purple and the Cd(Brh precipitated out. Upon completion of the reactions, the mixtures 
were filtered through celite using a Hartley funnel. The precipitates were washed with 
toluene. The resultant honey coloured filtrates were kept in a deep freezer (-10°C). 
Each product yielded one major greenish-blue spot (Rf 0.31), and a minor product (Rf 
0.47) when examined by TLC (solvent system C, p-anisaldehyde spray). 
The reaction mixtures, cholesteryl-a.(~)-D-tetra-O-acetylglucopyranoside (25 ml) and 
cholesteryl-a.(p)-D-tetra-O-acetylgalactopyranoside (20 ml) in toluene were then 
evaporated in a rotary evaporator and residual toluene removed by co-evaporation with 
ethanol (2 x 3 ml). The final residue was dissolved in solvent system C (30 ml). A silica 
gel 60 column (70-230 mesh) with a total volume of 91 ml (2.1 cm x 26.5 cm) was set 
up. Aliquots of the reaction mixture were applied to the column which was then eluted 
with solvent system C. Fractions (5.5 ml) were collected after the first 20 ml for tetra-O-
acetylglucosylcholesterol and 40 ml for tetra-O-acetylgalactosylcholesterol of the eluate 
were discarded. The presence of each of the final products was monitored by TLC as 
described above. The required fractions were pooled and evaporated in a rotary 
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evaporator. The u-anomers of the sugars eluted earlier than the ~-anomers. Products 
were finally recrystallized from ethanol. 
Cholesteryl-fJ-D-tetra-O-acetylgalactopyranoside (Appendix 1 K). 
Mp 157-159°C; 1H NMR (300M Hz, CDCb): 80.65 (s,3H,C-CH3), 0.83 (d, 6H, J=6.6Hz, 
CH-CH3), 0.89 (d, 3H, J=6.5, CH-CH3), 0.96 (s, 3H, C-CH3), 1.96-2.12 (12H, 4 x CO-
CH3) , 3.47 (m, 1 H, Chol-H3a), 3.86 (t, J=7.0, H-5'), 4.05-4.19 (m, 2H, H-6'a, H-6'b), 4.52 
(d, 1H, J=8.0 Hz, H-1'), 4.99 (dd, 1H, J=10.4, 3.4 Hz, H-3'), 5.16 (dd, 1H, J=10.4, 7.9 
Hz, H-2'), 5.35 (m, 2H, H-4, Chol-H6). 
13C NMR (75 MHz, CDCb): sugar region: 8 100.29 (C-1 '), 69.07 (C-2'), 70.55 (C-3'), 
67.03 (C-4'), 71.02 (C-5'), 61.30 (C-6')ppm. 
Cholesteryl moiety: 811.86 (C-18), 18.72 (C-21), 19.36 (C-19), 21.05 (C-11), 22.57 (C-
26), 22.83 (C-27), 24.29 (C-15), 28.23 (C-16), 29.52 (C-2), 23.82 (C-23), 28.02 (C-25), 
31.86 (C-8), 31.94 (C-7), 35.78 (C-20), 36.18 (C-22), 36.71 (C-10), 39.52 (C-24), 39.74 
(C-12), 37.19 (C-1), 38.96 (C-4), 42.32 (C-13), 50.14 (C-9), 56.74 (C-14), 56.14 (C-17), 
80.35 (C-3), 122.19 (C-6), 140.33 (C-5) ppm. 
Cholesteryl-a-D-tetra-O-acetylgalactopyranoside (Appendix 1 H). 
Mp 194-197°C; 1H NMR (300MHz, CDCb) : 80.65 (s,3H,C-CH3), 0.84 (d, 6H, J=6.6 Hz, 
CH-CH3), 0.89 (d, 3H, J=6.5, CH-CH3), 0.98 (s, 3H, C-CH3), 1.97-2.12 (12H, 4 x CO-
CH3) , 3.43 (m, 1 H, Chol-H3a), 4.07 (t, 2H, J=7.0, 5.4, H-6'a, H-6'b), 4.32 (m, 1 H, H-5'), 
5.43 (m, 1 H, H-1 ') ppm. 
Cholesteryl-fJ-D-tetra-O-acetylglucopyranoside (Appendix 1 J). 
Mp 160-163°C (Seo et al., 1978 reported 160-164°C); 1H NMR (300M Hz, CDCb) : 8 
0.65 (s,3H,C-CH3), 0.83 (d, 6H, J=6.6 Hz, CH-CH3), 0.88 (d, 3H, J=6.5, CH-CH3), 0.96 
(s, 3H, C-CH3), 2.00-2.05 (12H, 4 x CO-CH3), 3.45 (m, 1 H, Chol-H3a), 4.08 (m, 2H, H-
6'a, H-6'b), 3.65 (dd, 1 H, J=7.5,2.3, H-5'), 4.93 (dd ,1 H, J=9.5,8.0, H-3'), 4.57 (d, J=7.9 
Hz, H-1 '), 5.18 (t, 1 H, J=9.4, H-2'), 5.33 (d, 1 H, J=5.0, Chol-H6), 5.05 (t, 1 H, J=9.6, H-
4'). 
13C NMR (75 MHz, CDCI3): sugar region: 8 99.64 (C-1 '), 71.68 (C-2'), 72.90 (C-3'), 
68.50 (C-4'), 71.47 (C-5'), 62.09 (C-6')ppm. 
Cholesteryl moiety: 8 11.85 (C-18), 18.72 (C-21), 19.36 (C-19), 21.04 (C-11), 22.57 (C-
26), 22.83 (C-27), 24.28 (C-15), 28.23 (C-16), 29.44 (C-2), 23.81 (C-23), 28.02 (C-25), 
31.85 (C-8), 31.94 (C-7), 35.78 (C-20), 36.18 (C-22), 36.71 (C-10), 39.52 (C-24), 39.74 
(C-12), 37.19 (C-1), 38.91 (C-4), 42.32 (C-13), 50.14 (C-9), 56.74 (C-14), 56.14 (C-17), 
80.09 (C-3), 122.18 (C-6), 140.34 (C-5) ppm. 
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Cholesferyl-a-D-fefra-O-acefylglucopyranoside (Appendix 1 I) 
Mp 201-203°C (Seo et a/., 1978 reported 202-204°C) 1H NMR (300MHz, CDCb) : 8 
0.65 (s,3H,C-CH3), 0.84 (d, 6H, J=6.5 Hz, CH-CH3), 0.89 (d, 3H, J=6.5, CH-CH3), 0.96 
(s, 3H, C-CH3) , 1.99-2.06 (12H, 4 x CO-CH3), 3.43 (m, 1 H, Chol-H3o.), 4.06-4.21 (m, 2H, 
H-6'a, H-6'b), 5.32 (d, 1 H, Chol-H6), 5.46 (t, 1 H, H-1 '). 
13C NMR (75 MHz, CDCb): sugar region: 8 94.23 (C-1 '), 71.04 (C-2'), 70.22 (C-3'), 
68.74 (C-4'), 67.21 (C-5'), 67.07 (C-6')ppm. 
Cholesteryl moiety: 8 11 .86 (C-18), 18.72 (C-21), 19.38 (C-19), 21.04 (C-11), 22.57 (C-
26), 22.84 (C-27), 23.82(C-23), 24.29 (C-15), 28.02 (C-25), 28.24 (C-16), 31.86 (C-8), 
37.20(C-1), 39.52 (C-24), 39.73 (C-12), 42.31 (C-13), 50.09 (C-9), 56.13 (C-17), 56.70 
(C-14), 122.21 (C-6), 140.30 (C-5) ppm. 





The tetra-O-acetyl a- and ~-anomers were quantitatively deprotected separately to 
produce the corresponding gluco- and galacto-cholesterol derivatives. All reaction 
mixtures were monitored by TLC in solvent system D. Solvent (CHCI3, ethanol) was 
removed by rotary evaporation at 25°C and the residue was triturated in water at 4°C to 
remove sodium acetate and excess sodium ethoxide. The powdery white precipitate 
was suspended in water and stored overnight at 4°C. thereafter water was removed by 
filtration and products were dried in vacuo in a Buchi-TO pistol drier (60°C). All products 
produced one spot (Rf 0.21). 
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(a) Cholesteryl-a-D-glucopyranoside (M5aGLU) 
Chloroform (0.5 ml) and sodium ethoxide (0.15 ml, 0.33 mmoles) was added to the 
tetra-O-acetylglucocholesterol (19.5 mg, 0.03 mmoles). The resultant mixture turned 
cloudy and was kept at room temperature overnight in a cupboard before proceeding as 
described above, 
13C NMR (75 MHz, C5D5N): sugar region: 8 98.81 (C-1 '), 73.18 (C-5'), 72.50 (C-3'), 
71.39 (C-4'), 70.62 (C-2'), 62.21 (C-6') ppm. 
Cholesteryl moiety: 811.76 (C-18), 18.72 (C-21), 19.24 (C-19), 21.04 (C-11), 22.47 (C-
26), 22.72 (C-27), 23.87 (C-23), 24.27 (C-15), 27.98 (C-25), 28.28 (C-16), 31.84 (C-8), 
37.14 (C-1), 39.47 (C-24), 39.73 (C-12), 42.24 (C-13), 50.08 (C-9), 56.10 (C-17), 56.60 
(C-14), 121.61 (C-6), 140.98 (C-5) ppm. 
(b) Cholesteryl-~-D-glucopyranoside (M5~GLU) 
Chloroform (2 ml) and sodium ethoxide (0.5 ml, 1.1 mmoles) was added to the tetra-O-
acetylglucocholesterol (100 mg, 0.14 mmoles). The resultant mixture turned cloudy and 
was kept at room temperature overnight in a cupboard . A white amorphous product was 
obtained by the procedure outlined above. 
Mp 256-260°C (Seo et al., 1978 reported 257-260°C). 1H NMR (300 MHz, C5D5N) : 8 
0.54 (s,3H,C-CH3), 0.77 (d, 6H, J=6.6 Hz, CH-CH3), 0.85 (d , 3H, J=6.5, CH-CH3), 4.85 
(d, 1 H, J=7.6, H-1 '). 
13C NMR (75 MHz, C5D5N): sugar region: 8 102.84 (C-1 '), 76.51 (C-5'), 75.03 (C-3'), 
72.32 (C-2'), 69.86 (C-4'), 62.03 (C-6') ppm. 
Cholesteryl moiety: 811.76 (C-18), 18.72 (C-21), 19.20 (C-19), 21.05 (C-11), 22.47 (C-
26), 22.72 (C-27), 23.87 (C-23), 24.26 (C-15), 27.98 (C-25), 28.29 (C-16), 31.82 (C-8), 
37.26 (C-1), 39.48 (C-24), 39.73 (C-12), 42.24 (C-13), 50.12 (C-9), 56.10 (C-17), 56.60 
(C-14), 121.66 (C-6), 140.77 (C-5) ppm. 
(c) Cholesteryl-a-D-galactopyranoside (M5aGAL) 
Chloroform (0.5 ml) and sodium ethoxide (0.15 ml, 1.1 mmoles) was added to the tetra-
O-acetylgalactosylcholesterol (14.8 mg, 0.02 mmoles). The resultant mixture turned 
cloudy and was kept at room temperature overnight in a cupboard. A non-crystalline 
white powder was obtained by work-up as described. 
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1H NMR (300 MHz, CDCb, C5D5N) : 80.58 (s,3H,C-CH3), 0.81(d , 6H, J=5.6, CH-CH3), 
0.85 (d, 3H, J=7.0, CH-CH3), 0.89 (s, 3H, C-CH3), 5.29 (d, 1 H, J=3.8, H-1 '). 
13C NMR (75 MHz, CDCb, C5D5N): sugar region: 8 98.29 (C-1 '), 76.51 (C-5'), 75.03 
(C-3'), 72.32 (C-2'), 69.86 (C-4'), 62.03 (C-6') ppm. 
Cholesteryl moiety: 8 11.87 (C-18), 18.81 (C-21), 19.31 (C-19), 21.11 (C-11), 22.60 (C-
26), 22.85 (C-27), 23.96 (C-23), 24.35 (C-15), 28.07 (C-25), 28.35 (C-16), 31.91 (C-8), 
37.16 (C-1), 39.57 (C-24), 39.81 (C-12), 42.33 (C-13), 50.13 (C-9), 56.18 (C-17), 56.70 
(C-14), 121 .63 (C-6), 140.89 (C-5) ppm. 
(d) Cholesteryl-~-D-galactopyranoside (M5~GAL) 
Chloroform (1.5 ml) and sodium ethoxide (0.35 ml, 0.76 mmoles) was added to the 
tetra-O-acetylgalactosylcholesterol (69 mg, 0.10 mmoles). The resultant mixture turned 
cloudy immediately and was kept at room temperature overnight in a cupboard. Work-
up was as described. 
Mp 270-273°C. 1H NMR (300 MHz, CDCb, C5D5N) : 80.58 (s,3H,C-CH3), 0.84 (d, 6H, 
J=4.0 Hz, CH-CH3), 0.88 (d, 3H, J=6.5, CH-CH3), 4.35 (d, 1 H, H-1 '). 
13C NMR (75 MHz, CDCb, C5D5N): sugar region: 8 102.26 (C-1'), 74.84 (C-2'), 78.63 
(C-3'), 71.43 (C-4'), 78.09 (C-5'), 62.61 (C-6') ppm. 
Cholesteryl moiety : 8 11.88 (C-18), 18.80 (C-21), 19.31 (C-19), 21 .11 (C-11), 22.60 (C-
26), 22.86 (C-27), 23.95 (C-23), 24.35 (C-15), 28.08 (C-25), 28.35 (C-16), 31.89 (C-8), 
37.30 (C-1), 39.57 (C-24), 39.81 (C-12), 42.33 (C-13), 50.18 (C-9), 56.18 (C-17), 
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Figure 4.1: Scheme for the synthesis of cholesteryl-a-D-glucopyranoside and 
cholesteryl-~-D-glucopyranoside. 
a = glacial acetic acid/H2S04 /NaBr, 15 minutes. 
b = dichloromethane/CHCb ; c = dH20 /1 % NaHC03 / CaCI2 ,4°C. 
d = CdC03 / toluene / cholesterol; e = column chromatography. 
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Figure 4.2: Scheme for the synthesis of cholesteryl-a-D-galactopyranoside and 
cholesteryl-p-D-galactopyranoside 
a = glacial acetic acid/H2S04 /NaBr, 15 minutes. 
b = dichloromethane/CHCh; c = dH20 /1 % NaHC03 / CaCI2 ,4°C. 
d = CdC03 / toluene / cholesterol; e = column chromatography. 
f = CHCh / sodium ethoxide. 
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4.3.3 PREPARATION AND CHARACTERISATION OF CATIONIC 
CHOLESTERYLGLUCO- AND GALACTOPYRANOSYL LlPOSOMES 
4.3.3.1 Materials 
DOPE was purchased from Sigma-Aldrich (St.Louis, MO, USA). 2-[4-(2-hydroxyethyl)-
piperazunyl]-ethanesulfonic acid (HEPES), sodium chloride and chloroform were 
obtained from Merck (Darmstadt, Germany). Formvar coated copper grids were 
prepared by the Electron Microscope Unit, University of KwaZulu Natal 
(Pietermaritzburg Campus). Cationic cholesterol derivative (MS09), was prepared as 
described in Chapter 2. All other reagents were of analytical grade. 
4.3.3.2 Formulation of Gluco- and Galactopyranosylcholesterol-Containing 
Liposomes 
Liposome components for each liposome MSaGLU, MS~GLU, MSaGAL and 
MS~GAL were formulated in a 4:4:1 molar ratio of MS09:DOPE: 
MSaGLU/MS~GLU/MSaGALlMS~GAL with DOPE kept at 2 IJmol (Table 4.1). 
Table4.1 : Liposomal components of Biotinylated liposomes MSaGLU/MS~GLU and 
MSaGALlMS~GAL 
LlPOSOME MOLAR RATIOS FOR RESPECTIVE LIPIDS (lJmoles) 
FORMULATION 
DOPE MS09 MSaGLu/MS~GLU MSaGAL/MS~GAL 
Liposome MSaGLU/MS~GLU 2 2 0.5 -
Liposome MSaGAL/MS~GAL 2 2 - 0.5 
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The gluco- and galactopyranosylcholesterol derivatives were first dissolved in pyridine 
(200 ~I) and then added to the other liposomal components. Thereafter CHCb (1 ml) 
was added to dissolve all components and liposomes prepared as described in chapter 
two, section 2.2.5.2. 
4.3.3.3 Characterisation of Gluco and Galacto- Containing Liposomes using 
Transmission Electron Microscopy: 
To one drop of the respective liposome suspension on parafilm was added 0.5% uranyl 
acetate. This was mixed and allowed to stand for three minutes. The matt surface of 
formvar coated grids was brought into contact with the liposome - uranyl acetate mixture 
for 3 minutes. Thereafter discs were air dried overnight and viewed in a Jeol 1010 
transmission electron microscope at 60 kV. 
4.3.4 LlPOPLEX FORMATION 
4.3.4.1 Materials 
pGL3 control vector was purchased from Promega Corporation ,Madison,USA. and 
amplified previously according to manufacturers protocol. pBR322 plasmid DNA was 
supplied by Roche Diagnostics, Germany. Agarose was obtained from Bio-rad 
Laboratories, Richmond, CA, USA. Tris-HCI, NaH2P04, HEPES, NaCI, EDTA, SDS, 
glycerol, bromophenol blue, xylene cyanol, , uranyl acetate and ethidium bromide were 
purchased from Merck, Darmstadt, Germany. Fetal calf serum was obtained from Delta 
Bioproducts, Johannesburg, South Africa. All other reagent were of analytical grade. 
Formvar coated grids were prepared by the Electron Microscope Unit, University of 
KwaZulu Natal (Pietermaritzburg Campus). 
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4.3.4.2 Gel Retardation Assays 
Varying ratios of the four different liposome:DNA complexes were set up as shown in 
Table 4.2. All liposome:DNA complexes were incubated for 30 minutes at room 
temperature for lipoplex formation. At the end of the incubation, the procedure outlined 
in section 2.2.6.2 was followed closely. 
Table 4.2: MSuGLU/MSpGLU and MSuGALlMSpGAL liposome:DNA complexes. 
Incubation mixtures (101-11) in 20 mM HEPES, 150 mM NaCI (pH 7.5) 
contained liposome (0 - 5 I-Ig) and pGL3 DNA (0.5 I-Ig), for each of the 
four liposome formulations respectively. 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 
pGL3 DNA (lJg) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Liposome (lJg) - 1 1.5 2 2.5 3 3.5 




This assay was conducted as outlined in section 2.2.6.3, for all four liposome 
formulations. Having calibrated the spectrofluorimeter for 0% and 100% fluorescence 
as described (2.2.6.3), aliquots of each liposome (3 I-Ig), were added, stepwise to the 
respective solutions until 45 I-Ig of each liposome had been added. Each solution was 
mixed thoroughly after each addition and fluorescence was measured in a Shimadzu 
RF-551 spectrofluorometric detector, at an excitation wavelength of 520 nm and an 
emission wavelength of 600 nm , and at high sensitivity. Results were plotted relative to 
100% fluorescence. 
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4.3.4.4 Transmission Electron Microscopy of lipoplexes 
The procedure carried out was the same as described in chapter two, section 2.2.6.5. 
4.3.4.5 Nuclease Digestion Assays 
Liposome:DNA complexes were set up as in Table 4.3 for all four liposome 
formulations. 
Table 4.3: MSaGLU/MS~GLU and MSaGALlMS~GAL liposome:DNA complexes. 
Incubation mixtures (10 1-11) in 20 mM HEPES, 150 mM NaCI (pH 7.5) 
contained cationic liposome (0 - 141-1g) and pGL3 DNA (1 I-Ig). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 7 8 
pGL3 DNA (\Jg) 1 1 1 1 1 1 1 1 
Liposome (\Jg) - - 1 2 4 5 6 7 
Samples were each made up to a total volume of 10 1-11 with 20 mM HEPES, 150 mM 
NaCI, pH 7.5. Digestion, electrophoresis of samples and gel photography were carried 
out as described in section 2.2.6.6. 
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4.3.5 CELL CULTURE AND TRANSFECTION STUDIES 
4.3.5.1 Materials 
Asialofetuin was obtained from Sigma-Aldrich, USA. All other materials used in the 
culture of HepG2 and HeLa cells and their transfection are those listed in section 
2.2.7.1. 
4.3.5.2 Growth and Maintenance of Cell Lines 
The HepG2 and HeLa cell lines were propagated in MEM with 10% FCS and antibiotics, 
and maintained as described in chapter two, section 2.2.7.2. 
4.3.5.3 Growth Inhibition Assays 
HepG2 and HeLa cells were trypsinised and seeded into a 24 well plate at varying 
seeding densities. The seeding densities were 2.2 x 104 cells/well for HeLa cells and 1.8 
x 104 cells/well for HepG2 cells, for liposomes MSuGLU and MSpGLU, and 2 x 104 
cells/well for HeLa cells and 1.9 x 104 cells/well for HepG2 cells, for liposomes MSuGAL 
and MSpGAL. Wells in row 1 received no cells and were used to obtain a blank (0) 
reading. Cells were incubated for 24 to 36 hours and allowed to attach to the wells and 
grow to semi-confluency. The liposome:DNA [pGL3 DNA (1 IJg)] complexes for all four 
of the liposome formulations were set up as outlined in Tables 4.4. The reaction 
mixtures were each made up to a constant volume with 20 mM HEPES, 150 mM 
sodium chloride, pH 7.5, and incubated at room temperature for 30 minutes. 
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Table 4.4: MSaGLU/MS~GLU and MSaGALlMS~GAL liposome:DNA complexes. 
Incubation mixtures (15 1-11) in 20 mM HEPES, 150 mM NaCI (pH 7.5) 
contained each liposome (0- 7 I-Ig) and pGL3 DNA (1 I-Ig). 
LlPOPLEX COMPONENTS 1 2 3 4 5 6 
pGL3 DNA (lJg) - 0 1 1 1 1 
Liposome (lJg) - 0 4 5 6 7 
The cells were prepared as described previously by first removing the growth medium 
and replacing it with 0.5 ml of serum free medium. The reaction complexes were then 
added to the wells containing the cells. The assays were carried out in quadruplicate. 
After a 4 hour incubation at 37°C, the medium was replaced with complete medium 
(MEM + 10% FCS + antibiotics). The cells were incubated again at 37 °C for a further 
48 hours and quantified as explained in chapter two, section 2.2.7.3. 
4.3.5.4 Transfection Studies 
(a) Liposome MSaGAL : pGL3 DNA complexes 
(b) Liposome MS~GAL : pGL3 DNA complexes 
(c) Liposome MSaGLU : pGL3 DNA complexes 
(d) Liposome MS~GLU : pGL3 DNA complexes 
Transfection of all four lipoplexes were conducted using two cell lines viz. the HepG2 
cell line that contains the asialoorosomucoid receptor, and the HeLa cell line which does 
not, and may be considered an appropriate control cell line. All cells were trypsinised 
and seeded at varying densities in 24 well plates. The cells were allowed time to attach 
to the wells and to grow to semi-confluency. The transfection complexes (a - d) were 
then set up in quadruplicate for both cell lines as shown in Tables 4.5. The transfection 
efficiencies of all four Iiposome:DNA complexes (a - d) in the HepG2 cell line was 
evaluated in the absence of serum, the presence of 10% serum and in the presence of 
an excess (300 I-Ig) asialofetuin. Furthermore transfection was monitored in the HeLa 
cell line as a control. 
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Table 4.5 Transfection complexes as added to 24-well plates. Control 1 contained 
only cells, control 2 contained cells and pGL3 DNA (1 IJg) only. Test 
samples 1 to 4 contained varying amounts of each liposome (4,5,6 and 7 
IJg respectively). pGL3 DNA was kept constant at 1 IJg. All complexes 
were made up in a final volume of 15 IJI with 20 mM HEPES, 150 mM 
sodium chloride (pH 7.5). 
Reaction Components Control Control Test Test Test Test 
1 2 1 2 3 4 
HeLa / HepG2 Cells + + + + + + 
Liposome {1-I9} - - 4 5 6 7 
pGL3 DNA {1-I9} - 1 1 1 1 1 
(i) Liposome MSaGAU MS~GAL : pGL3 DNA complexes 
Transfection complexes were added to 24-well plates containing cells at a seeding 
density of 1.9 x 104 cells/well for HeLa cells, and 1.8 x 104 cells/well for HepG2 cells. 
For transfection in the presence of 10% FCS and competing (300 IJg) asialofetuin, the 
seeding densities for the HepG2 cells were 2 x 104 cells/well and 1.9 x 104 cells/well 
respectively. 
(ii) Liposome MSaGLUI MS~GLU : pGL3 DNA complexes 
Transfection complexes were added to 24-well plates containing cells at a seeding 
density of 2 x 104 cells/well for HeLa cells, and 1.9 x 104 cells/well for HepG2 cells. For 
transfection in the presence of 10% FCS and competing (300 IJg) asialofetuin, the 
seeding densities for the HepG2 cells were 2 x 104 cells/well and 1.8 x 104 cells/well 
respectively. 
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4.4 RESULTS AND DISCUSSION 
4.4.1 PREPARATION OF CHOLESTERYL GLYCOSIDES 
Four cholesteryl glycosides (MSaGLU, MS~GLU, MSaGAL and MS~GAL) were 
synthesized for the study of their asialoorosomucoid receptor-targeting potential when 
incorporated into the bilayer of cationic liposomes. The hydrophobic 
perhydrocyclopentanophenanthrene fused ring system of cholesterol interacts with the 
other hydrophobic membrane components in the liposome bilayer while the 3~-OH 
group, which would ordinarily project into the hydrophilic environment, has been used to 
forge a glycosidic link with the a and ~ anomers of D-glucose and D-galactose. The 
syntheses were effected by a Koenigs-Knorr procedure from the appropriately 
protected bromo-sugar and cholesterol under anhydrous conditions (Rogers and 
Thevan, 1986). During the course of this project, Wimmer and co-workers reported a 
similar procedure for the preparation of glucoside and galactoside derivatives of cyclic 
(secondary) alcohols in good yield using cadmium carbonate as promoter under 
anhydrous conditions (Wimmer et al., 2004). 
Structures were confirmed by reference to 1H and 13C NMR spectra recorded in CDCb 
for the intermediate cholesteryl-tetra-O-acetylglycosylpyranosides and in C5D5N 
(deuteropyridine) for the deprotected final products. 13C signal assignments for the 
cholesteryl moieties were very similar to one another in the eight cholesteryl glycosides 
generated and closely resembled assignments reported previously in a study of 
glycosidation shifts in 13C NMR spectra of related sterylglycosides (Seo et al., 1978). 1H 
NMR spectra of the carbohydrate components were very similar to those reported by 
Agrawal (1992), while the 13C NMR spectra of the tetra-O-acetylglucoside and 
galactoside components were very similar to those reported by Seo et al., 1978. 1H 
peak assignments for the tetra-O-acetyl-~-D-galactoside entity were virtually identical to 
those reported by Ren et al., 2001, in a study of galactosylated dendrimers containing 
multiple primary amino groups. 
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4.4.2 PREPARATION AND CHARACTERISATION OF GLUCO- AND 
GALACTOPYRANOSYLCHOLESTEROL CONTAINING LlPOSOMES 
Each of the four liposomes contained the cationic cholesterol derivative MS09 (chapter 
two), the neutral lipid DOPE and one of the four prepared glyco-containing cholesterol 
derivatives viz. cholesteryl-a-D-glucopyranoside, cholesteryl-p-D-glucopyranoside, 
cholesteryl-a-D-galactopyranoside, and , cholesteryl-p-D-galactopyranoside. 
Liposomes prepared here are constituted from MS09, DOPE and cholesterylglycosides. 
The glycoside component has been limited to 9% on a w/w basis, a level at which it is 
estimated that sufficient targeting character will be expressed. Other ratios were not 
explored. It is apparent, however, that the sugar density in a liposome/glycolipid is 
critical. It was observed that at a loading ratio of 5% (w/w) the liposome/glycolipid 
particles are efficiently processed by the asialoglycoprotein receptor, whereas at a 
loading ratio of 50% (w/w) uptake was not blocked by excess asialofetuin, suggesting a 
less specific uptake of the liposome/glycolipid particles (Davis and Robinson, 2002). A 
large number of galactose or glucose residues could interfere with the electrostatic 
interaction of the liposome with DNA. Investigations by Nishikawa et al., 1998, using 
poly-L-Iysine showed that the optimal modification of the poly-L-Iysine with galactose 
was between 14%-16%. 
These liposomes are bifunctional with each liposome possessing a cationic component 
(MS09) for binding to the DNA molecule and a terminal galactose or glucose component 
for targeting to the galactose or asialoglycoprotein receptor on the HepG2 cells (Figure 
4.3). All liposome formulations were stable at 4°C for several weeks and showed no 






o = terminal galactose / glucose moiety 
Figure 4.3: Schematic representation of the cationic gluco / galacto containing 
liposomes and their interaction with the negatively charged DNA 
molecule and the cell surface receptor on the HepG2 cells. Diagram 
not drawn to scale. 
4.4.2.1 Characterisation of Gluco and Galacto-Containing Liposomes using 
Transmission Electron Microscopy 
Transmission electron microscopy revealed the formation of predominantly spherical or 
oval vesicles and confirmed the unilamellar nature of all liposome preparations. 
Liposome MSuGAL sizes varied from 100 nm to 200 nm, liposome MSpGAL from 50 
nm to 150 nm, liposome MSuGLU from 50 nm to 200 nm, and MSpGLU from 100 to 
200 nm (Figures 4.4 to 4.7). 
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100 nm 
Figure 4.4: TEM of liposome MSuGAL. Liposome size varies from 100 nm to 200 nm. 
100nm 
Figure 4.5: TEM of liposome MSpGAL. Liposome size varies from 50 nm to 150 nm. 
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50nm 
Figure 4.6: TEM of liposome MSaGLU. Liposome size varies from 50 nm to 200 nm. 
Figure 4.7: TEM of liposome MSpGLU. Liposome size varies from 100 nm to 220 nm. 
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4.4.3 LlPOPLEX FORMATION OF LlPOSOMES 
4.4.3.1 Gel Retardation Assays 
In order to determine the optimal ratio for binding between the liposome and the DNA, 
gel retardation assays are commonly performed. These can be seen in Figures 4.8-4.9. 
(a) (b) 
Figure 4.8 : Gel retardation study of (a) MSuGAL liposome: DNA complexes 
and (b) MS~GAL liposome: DNA complexes. 
Incubation mixtures (10 IJI) in 20 mM HEPES, 150 mM NaCI (pH 7.5) 
contained varying amounts of liposome in lanes 1-8 (0,1.0, 1.5, 2.0, 
2.5, 3.0, 3.5 and 4.0 IJg), while the pGL3 DNA was kept constant 
at 0.5 IJg. 
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(a) (b) 
Figure 4.9: Gel retardation study of (a) MSaGLU liposome : DNA complexes 
and (b) MSpGLU liposome : DNA complexes. 
Incubation mixtures (101-11) in 20 mM HEPES, 150 mM NaCI (pH 7.5) 
contained varying amounts of cationic liposome in lanes 1-8 (0,1.0, 
1.5, 2.0, 2.5, 3.0, 3.5 and 4.0 I-Ig), while the pGL3 DNA was kept 
constant at 0.5 I-Ig. 
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No migration of the plasmid DNA was seen at and above the liposome:DNA ratio of 6:1 
(w/w) equivalent to a charge ratio (+/-) of 0.7. This lack of migration is an indication that 
the plasmid DNA is completely bound by the cationic component of the liposome, 
resulting in large complexes that do not migrate into the gel. 
4.4.3.2 Dye Displacement Assays 
These results strongly support the notion that all four lipoplexes which have been 
formulated to contain the synthesized glycolipids readily bring about displacement of the 
intercalated ethidium bromide upon stepwise introduction of liposomes to the plasmid 
DNA. This process is largely driven by the association of DNA phosphodiester negative 
charges forming ion pairs with the cationic headgroups of MS09 (Figures 4.10 and 4.11) 
The fluorescence decreased steadily until the point was attained which seemed to 
correlate with total retardation seen for lipoplexes in gel retardation assays. The 
maximum displacement of ethidium bromide as measured by fluorescence was 
approximately 45% for liposome MSuGAL, 36% for MS~GAL2, 47% for MSuGLU and 
38% for MS~GLU) at the total retardation ratio of liposome:DNA of 6:1 (w/w) and a 
corresponding charge ratio (+/-) of 0.7. As can be seen, MS~GAL and MS~GLU 
liposomes both displayed higher displacement of the dye than MSuGAL and MSuGLU. 
This could be due to the fact that they are both ~-anomers and somehow allow greater 
accessibility to the DNA than their corresponding u-anomers. 
No further addition of liposome was carried out after 45 I-Ig due to the onset of turbidity 
which would have rendered the readings invalid. From the liposome:DNA ratio of 6:1 
(w/w) the graph seems to reach a plateau as liposome:DNA binding had apparently 
reached its optimum, resulting in no further compacting of the double stranded nucleic 
acid taking place. 
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Figure 4.10: Ethidium bromide intercalation assay for galactosylated liposomes 
MSuGAL and MS~GAL at varying liposome:DNA (w/w) binding ratios. 
Cuvettes contained 6 ~g of pBR322 DNA and increasing quantities of 
liposomes at pH 7.5 (section 4.2.4.3) 
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Figure 4.11 : Ethidium bromide intercalation assay for glucosylated liposomes 
MSaGLU1 and MS~GLU2 at varying liposome:DNA (w/w) binding ratios. 
Cuvettes contained 6 I-Ig of pBR322 DNA and increasing quantities of 
liposomes at pH 7.5 (section 4.2.4.3) 
237 
9 
4.4.3.3 Transmission Electron Microscopy of lipoplexes 
The biodistribution of current carrier systems is generally influenced to a large extent by 
their charge and importantly by their size. The sizes obtained for the lipoplexes are of 
great importance especially if these liposomes are to be used for in vivo studies. For 
most gene therapy applications, the target cells will form part of the parenchyma or 
interstitium of an organ, with access to these cells restricted for complexes after 
vascular administration. Most complexes will only enter certain sites, e.g. the liver or 
spleen where suitable gaps or fenestrae are present to allow specific sized complexes 
to pass through (Schatzlein, 2003). In the case of liver cells, complex sizes are 
restricted due to the size of these fenestrae. The pore or fenestrae sizes of liver 
sinusoidal microvessels are between 200 nm and 300 nm in diameter and larger 
lipoplexes or liposomes of about 300 nm in diameter or greater are accumulated in a 
time-dependent manner in the liver due to trapping of the liposomes in the 
reticuloendothelial system (RES) (Oku et a/., 2000). Thus the size of lipoplexes is an 
important property to consider for gene delivery in vivo, since it can limit access to 
target organs and distribution to specific tissues or cells. 
It is assumed that the degree of substitution by sugar residues in a liposome could 
affect the complex 1 lipoplex size. A high degree of substitution will generally increase 
the size of the complex and thus limit transfection efficiency (Palliard, 1999). In our 
liposomes the galactose and glucose components were kept to a minimum. This could 
account for the smaller sizes of lipoplexes seen under EM. In our study the lipoplex 
sizes for all four complexes ranged from 50 nm to an upper limit of 200 nm at higer 
charge ratios (Figures 4.12 to 4.15). At a liposome: DNA ratio of 5: 1 (W/w) , +1- charge 
ratio of 0.6, the diameter of all four lipoplexes ranged from 50 nm to 100 nm, whereas 
at a a higher Iiposome:DNA ratio of 6:1 (W/w),+I_ charge ratio of 0.7, lipoplex diameters 
ranged from 80 to 200 nm. Lipoplex morphology resembled aggregates or clusters 






Figure 4.12 : TEM of complex between liposome MSuGAL and pGL3 DNA at 
(a) liposome:DNA ratio of 5:1 (W/W) , and, 






Figure 4.13 : TEM of complex between liposome MS~GAL and pGL3 DNA at 
(a) liposome:DNA ratio of 5:1 (W/W) , and, 









Figure 4.14: TEM of complex between liposome MSaGLU and pGL3 DNA at 
(a) Iiposome:DNA ratio of 5:1 (W/W) , and, 






Figure 4.15 : TEM of complex between liposome MSpGLU and pGL3 DNA at 
(a) liposome:DNA ratio of 5:1 (W/W) , and, 
(b) Iiposome:DNA ratio of 6:1 (w/w). 
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Reports on the complex size that can be accommodated by the asialoglycoprotein 
receptor have been varied. Some studies have suggested that the hepatocyte 
asialoglycoprotein receptor has an upper size limitation for the uptake of a specific 
ligand of about 10 nm (Schelepper-Schafer et al., 1986) or 21-23 nm (Bijsterbosch and 
van Berkel, 1992) in diameter, depending on the type of artificial ligand used. Another 
proposal is that glycoparticles with diameters greater than 70 nm are not easily 
recognized by the asialoglycoprotein receptor (Rensen et al., 2001). Kawakami et al., 
2002, suggested that a glycoplex size must be 150 nm or less for hepatocyte targeting. 
Our lipoplexes at the optimal transfection ratio (see 4.4.4.3) of liposome:DNA (5:1 w/w) 
were no larger than 100 nm in diameter and this size seemed to be taken up quite 
readily by the receptors on the HepG2 cells as determined by the significant gene 
expression observed at this ratio during transfection studies. Even larger lipoplexes 
(>100 nm) seen at a liposome:DNA ratio of 6:1 (w/w) , afforded good receptor-mediated 
gene expression (4.4.4.3). Hence it may be concluded that the size limit of a lipoplex 
that can be accommodated by the asialoglycoprotein receptor remains an unsettled 
issue. 
For in vivo systems, this size preference is assumed to be related to the existence of 
another receptor for galactosylated proteins in the Kupffer cells of the liver. The Kupffer 
cell receptor is very efficient in taking up and degrading galactosylated molecules of 
larger size in vivo and competes for the uptake of the galactosylated DNA complex with 
the asialoglycoprotein receptor on the surface of hepatocytes. Thus, the diameter of the 
ligand-DNA complex must be relatively small to be effective in transferring genes 
specifically to hepatocytes by receptor-mediated endocytosis via the asialoglycoprotein 
receptor (Perales et al., 1997). 
The endocytotic vesicles with a clathrin coating are reported to have an internal 
diameter of about 100 nm in hepatocytes (Molas et al., 2003). Larger complexes could 
be endocytosed, but a correlation could exist between the structure of the DNA complex 
and the efficiency and specificity for receptor-mediated gene transfer by the 
asialoglycoprotein receptor. Furthermore it is suggested that for in vivo systems uptake 
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of particles of about 100 nm is dependent on the blood pressure within the liver (Pouton 
and Seymour, 2001). It is thought that the belief that 100 nm or smaller vehicles are 
most effective for systemic delivery is only true for inflexible delivery vehicles. Blood 
cells of several microns (up to 7000 nm) in size, have no difficulty in circulating in the 
blood and even in the smallest capillaries, emphasizing the point that flexibility of the 
vehicle is of great importance. Furthermore increased lipoplex size tends to extend their 
circulation time in vivo (Templeton, 2003). 
Since the size and structure of the lipoplex is critical for receptor-mediated gene transfer 
into target tissues in animals, it is important that the condensation process does not 
result in the formation of large aggregated, multi molecular DNA complexes but rather 
into unimolecular complexes of a minimum size. It was observed under EM that when 
the charge on the DNA is totally neutralized (charge ratio of 1: 1) a turbid solution 
consisting of a fine precipitate of DNA complexes is produced that are large aggregates 
of smaller units that are hypothesized to be highly condensed, unimolecular DNA 
complexes (Perales et al. , 1997) .. 
It was concluded that despite the disparity in the sizes reported in the different studies 
due to utilization of different ligands, assays and assay conditions, the size or volume 
of the gene or drug to be enveloped by the receptor will be important for the process to 
be successful and specific (Molas et al., 2003). 
4.4.3.4 Nuclease Digestion Assays 
These studies enabled us to further characterise the strong binding interaction between 
the liposomes and the DNA and to observe what protection is afforded by the cationic 
liposomes to the bound DNA. The effect of the serum nucleases on each of the four 
lipoplexes can be seen in Figures 4.16 to 4.18 respectively. 
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Figure 4.16: Nuclease protection assay of liposome MSuGAL and pBR322 DNA. 
Lane 1 : undigested plasmid pBR322 DNA (1 I-Ig) 
Lane 3: unprotected plasmid DNA (1 I-Ig) digested by serum nucleases 
Lanes 2-8 : Varying amounts of cationic liposomes (1,0, 2, 4, 5, 6, 7 I-Ig) 
with pBR322 DNA (1 I-Ig) and serum (10%). 
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Figure 4.17: Nuclease protection assay of liposome MS~GAL and pBR322 DNA. 
Lane 1 : undigested plasmid pBR322 DNA (1 I-Ig) 
Lane 2 : unprotected plasmid DNA (1 I-Ig) digested by serum nucleases 
Lanes 2-8 : Varying amounts of cationic liposomes (0, 1, 2, 4, 5, 6, 7 I-Ig) 
with pBR322 DNA (1 I-Ig) and serum (10%). 
246 
(a) (b) 
Figure 4.18: Nuclease protection assay of (a) liposome MSaGLU and pBR322 DNA, 
and (b) liposome MSpGLU and pBR322 DNA. 
Lane 1 : undigested plasmid pBR322 DNA (1 I-Ig) 
Lane 2 : unprotected plasmid DNA (1 I-Ig) digested by serum nucleases 
Lanes 2-8 : Varying amounts of cationic liposomes (0, 1, 2, 4, 5, 6, 7 I-Ig) 
with pBR322 DNA (1 I-Ig) and serum (10%). 
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Generally good protection was afforded by the liposomes to the DNA at most 
liposome:DNA ratios. However, the greatest degradation of the DNA was noted for 
lipoplexes with a liposome:DNA ratio of 1:1 (W/W) , especially for The MSaGLU and 
MS~GLU liposomes. This may be attributed to the low liposome:DNA (+/-) charge ratio 
of 0.1 at which stage there may be free unbound DNA molecules present. Indeed at 
such a low ratio it is anticipated that liposome-bound DNA may also be susceptible to 
serum nuclease digestion as condensation may be incomplete. At higher charge ratios it 
can be seen that the DNA was well protected within the lipoplexes, although a small but 
discernable amount of degradation can be seen on the gels. It is noteworthy that this 
degradation occurs to a lesser degree with liposomes containing the ~-glycosides 
suggesting that the DNA in these lipoplexes may benefit from greater protection.This 
observation tallies with the finding that the same ~-glycoside-containing liposomes 
displace more ethidium bromide from DNA than their corresponding a-glycosides 
suggesting, perhaps, greater condensation of the DNA in lipoplexes containing the ~­
glycosides. 
The adsorption of serum proteins can induce a number of effects such as complex 
destabilization, aggregation or retargeting. The stability of lipoplexes or polyplexes 
depends on the strength of the electrostatic interaction, the total charge and the charge 
density of the carrier molecule (Schatzlein, 2003). 
In liver tissue a large proportion of acid DNAses are located in the sinusoidal cells 
(Wattiaux ef al., 2000). This will be an important consideration in future in vivo studies 
since these liposomes seem to afford reasonable protection of the DNA to nucleases. 
248 
4.4.4 CELL CULTURE AND TRANSFECTION STUDIES 
4.4.4.1 Growth and Maintenance of Cell Lines 
The HepG2 and HeLa cells (Figure 2.25 and 2.23), were successfully propagated in 
MEM as described in chapter two. The cells reached confluency after 2-3 days. Both 
cell lines were routinely subdivided into 3:1 or 2:1 splits after trypsinisation for 
experimental purposes. 
4.4.4.2 Growth Inhibition Assays 
High toxicity of liposomes or lipoplexes will limit their application in vivo. Toxicity in vivo 
can arise, in part, due to the opsonisation with serum components and their interaction 
with cells such as macro phages (Monteir et al., 2004). The ultimate goal of the 
development of any novel gene delivery vector will be to ascertain its efficiency in in 
vivo systems. Hence results obtained in these growth inhibition studies are of extreme 
importance. 
In vivo lipoplex-mediated toxicity is closely associated with charge ratio between the 
cationic lipid in the liposome and the DNA, as well as the dose of lipoplex administered. 
Higher charge ratios are toxic to a variety of cell types including cancer cell lines (Dass, 
2002). In our in vitro studies all four liposome preparations showed extremely low 



























Figure 4.19: Growth inhibition studies of liposomes MSuGAI, MSpGAL, MSuGLU and 
MSpGLU:DNA complexes to HepG2 cells in vitro. All liposomes were 
varied (0, 4, 5 ,6 ,7 I-Ig) while the DNA (1 I-Ig) was kept constant in a 
total volume of 0.5 ml MEM. A control sample (no liposome), containing 
only cells was assumed to have 100% survival. Data are presented as 
means ± S.D (n = 4). 
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Figure 4.20: Growth inhibition studies of liposomes MSuGAI, MSPGAL, MSpGLU and 
MSpGLU:DNA complexes to He La cells in vitro. All liposomes were 
varied (0, 4, 5 ,6 ,7 I-Ig) while the DNA (1 I-Ig) was kept constant in a 
total volume of 0.5 ml MEM. A control sample (no liposome), containing 
only cells was assumed to have 100% survival. Data are presented as 
means ± S.D (n = 4). 
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Cells were exposed to the same lipoplex concentrations utilized in transfection studies. 
Maximum cell death recorded for liposome MSaGAL was 16% for HepG2 cells and 17% 
for HeLa cells, while for liposome MS~GAL the maximum cell death recorded was 17% 
for both HepG2 and HeLa cells. Liposome MSaGLU showed a maximum cell death of 
18% for HepG2 cells and 17% for HeLa cells and liposome MS~GLU recorded a 
maximum cell death 16% for HepG2 cells, 17% for HeLa cells. These toxicity levels 
were observed at the highest liposome:DNA ratio of 7:1 (w/w). At optimal transfection 
ratios (5:1) the inhibition level was 8% and 9% for liposomes MSaGAL and MS~GAL 
respectively, and 14% and 7% for liposome MSaGLU and MS~GLU respectively. 
Hence it can be stated that the cytotoxicity levels did not vary much with the different 
liposome formulations and also with the two different cell lines being utilised. As the 
liposome concentrations increased so did the inhibition of cell growth by the lipoplexes. 
4.4.4.3 Transfection Studies 
When galactose is attached to the surface of a transfecting complex, the complex may 
be internalized by hepatocytes via the asialoglycoprotein receptor at a much faster rate 
than that of the untargeted vector (Nishida et a/., 1992). This could be an advantage in 
DNA and drug delivery. The duration of gene expression in transiently transfected cells 
is generally dependent on the proliferation rate of the cells. The results obtained for the 
transient gene expression of our four glycosylated liposome formulations can be seen in 
Figures 4.21 to 4.24. 
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Figure 4.21 : Transfection studies of liposome MSuGAL:DNA complexes with HepG2 
cells in vitro. Competition experiments with HepG2 cells included 300 1-19 
asialofetuin per well. Liposome MSuGAL was varied (0, 4, 5 , 6 , 7 1-19) 
while the DNA (1 1-19) was kept constant in a total volume of 0.5 ml 
MEM. Control 1 contains only cells and control 2 contains naked DNA 

















c::J O:ny:aitirn a3Saf 




CONTROL 1 CONTROL 2 4 5 6 7 
LlPOSOME (I-Ig) 
Figure 4.22: Transfection studies of liposome MSJ3GAL:DNA complexes to HepG2 
cells in vitro. Competition experiments with HepG2 cells included 300 IJg 
asialofetuin per well. Liposome MSJ3GAL was varied (0, 4, 5 , 6 , 7 IJg) 
while the DNA (1 IJg) was kept constant in a total volume of 0.5 ml 
MEM. Control 1 contains only cells and control 2 contains naked DNA 
and no liposome. Data are presented as means ± S.D (n = 4). 
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Figure 4.23: Transfection studies of liposome MSuGLU:DNA complexes to HepG2 
cells in vitro. Competition experiments with HepG2 cells included 300 1-19 
asialofetuin per well. Liposome MSuGLU was varied (0, 4, 5 , 6 , 7 1-19) 
while the DNA (1 1-19) was kept constant in a total volume of 0.5 ml 
MEM. Control 1 contains only cells and control 2 contains naked DNA 
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Figure 4.24: Transfection studies of liposome MSpGLU:DNA complexes to HepG2 
cells in vitro. Competition experiments with HepG2 cells included 300 1-19 
asialofetuin per well. Liposome MSpGLU was varied (0, 4, 5 , 6 , 7 1-19) 
while the DNA (1 1-19) was kept constant in a total volume of 0.5 ml 
MEM. Control 1 contains only cells and control 2 contains naked DNA 
and no liposome. Data are presented as means ± S.D (n = 4). 
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It was reported that the correct structural orientation of the terminal galactose residue in 
a ligand is important for proper binding to the asialoglycoprotein receptor (Hawtery and 
Ariatti, 1999). This was clearly evident in the results obtained with the p-galacto-
derivative showing the best transfection efficiency when compared to its a-anomer. 
There was a 4-fold increase in the targeted transfection efficiency of the liposome 
MSpGAL (21 047 500 RLU/ mg protein) over its a-anomer MSaGAL (5 022 000 RLU/ 
mg protein). The optimal transfection efficiency of liposome MSaGLU (2 371 000 RLU/ 
mg protein) and MSpGLU (2 562 632 RLU/ mg protein) were not significantly different. 
Furthermore it was observed that there is a preference for liposomes bearing the 
galactose moieties rather than those bearing the glucose moieties. This is borne out in 
the large difference in their respective luciferase activities. There was more than an 
eight fold increase in the activity of liposome MSpGAL over both liposomes MSaGLU 
and MSpGLU. Liposome MSaGAL showed a 2-fold increase over liposomes MSaGLU 
and MSpGLU at the optimal transfection ratio of liposome:DNA of 5:1 (W/W) , and +/-
charge ratio of 0.6. It can be seen that optimal transfection was not obtained at the 
Iiposome:DNA ratio of 6:1 (w/w) and (+/-) charge ratio of 0.7, the ratio at which complete 
retardation of the DNA on agarose gel retardation assays was obtained (see 4.4.3.1) 
but at a lower ratio of liposome:DNA of 5:1 (W/W) , (+/-) charge ratio of 0.6. This could be 
due to the fact that the lipoplex size range (50-100 nm in diameter) at the Iiposome:DNA 
ratio 5:1 (w/w) was somewhat smaller than that (80-200 nm) at the higher range. Hence it 
would appear that lipoplex size does play an important role in transfection efficiency and 
in receptor-mediated gene delivery in the system chosen for this study. 
From the transfection results obtained here, it can also be concluded that the 
asialoglycoprotein receptor has the greatest affinity for the MSpGAL (p-anomer), 
followed by MSaGAL (a-anomer), MSpGLU (p-anomer) and finally MSaGLU (0.-
anomer). It is generally assumed that the ASGP-R has the following binding affinity: 
tetraantennary > triantennary > biantennary > monoantennary galactosides (Rensen et 
al., 2001). Our liposome formulations possessed single galactose units extending 
outward from the lipid bilayer of the liposome and still showed extremely high 
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transfection activity when targeted to the HepG2 cells in vitro. However one may 
consider that the monoantennary derivatives synthesized for the present study are in 
fact affixed to a membrane bilayer, and depending on distances between neighbouring 
cholesterylglycosides in the outer leaf of the bilayer, they may mimic a multiantennary 
system resulting in a potentiated interaction between the receptor and the glycosylated 
lipoplex due to favourable spatial conditions. 
It was observed that optimal receptor recognition of synthetic cluster glycosides is also 
determined by appropriate spacing (of at least 15 A) between sugar residues (Rensen 
et a/., 2001). However it has been suggested that the transfection activity with 
glycoplexes is not determined only by the specificity of the lectin expressed at the cell 
surface membrane but also by intracellular trafficking of the glycoplexes, which could be 
mediated by lectins present inside the cells (Fajac et a/., 1999). It is thought that the 
main limitation to sugar-lectin interactions is the low specificity due to the limitation of 
the diversity of the simple sugars, and the large binding site of the lectin that can 
accommodate several simple sugars and therefore is liable to recognize several 
glycoconjugates and show little cell specificity (Palliard, 1999). Our results have clearly 
demonstrated the distinct differences in the transfection activities of the four types of 
glyco-liposomes. It was reported that galactosylated particles can produce a ten fold 
increase in transfection activity in hepatoma cells over glucosylated particles, but show 
no transfection preference in cell lines that lack the asialoglycoprotein receptor (Pun 
and Davis, 2002). 
To test for specific receptor-mediated endocytosis of DNA complexes which include a 
specific ligand, a competition assay is routinely used that employs an excess of ligand. 
The use of excess asialofetuin (300 I-Ig) in the competition assay was extremely 
effective. There was a dramatic decrease in the luciferase activity observed, indicating 
that the principal means of delivery of the plasmid DNA was by internalization by 
receptor-mediated endocytosis via the asialoglycoprotein receptor. In all four liposomal 
formulations the decrease in transfection activity at the optimal transfection ratio was 
greater than 90% [over 95% (20-40 fold decrease) for liposomes MSuGAL (250 476 
RLU/mg protein) and MS~GAL (477 143 RLU/mg protein), and over 92% (14 fold 
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decrease) for liposomes MSGaLU (170 000 RLU/mg protein) and MSpGLU (186 000 
RLU/mg protein)]. In hepatocytes, endocytosis may occur via clathrin coated pits or via 
fluid-phase endocytosis (Synnes et al., 1999). The luciferase activity observed in the 
competition assay with excess asialofetuin could be due to this fluid phase endocytosis 
or 'pinocytosis' process. Excess free asialofetuin up to 4 mg in a 24 well plate, was 
utililised by some researchers in studies using a DNAlgalactosylated polylysine 
complex, but produced only about a 10% decrease in transfection efficiency. This drop 
was attributed to the inhibition of specific recognition of the DNAlgalactosylated 
polylysine complex (Han and Yeom, 2000). 
Others have reported the use of 1 mg of free asialofetuin (1000 fold excess) in a 48 well 
plate, with significant levels of inhibition ranging from a 3 to 9-fold decrease in gene 
expression (Arangoa et al., 2003). Asialofetuin-bound lipoplexes were found to be 
efficient in targeted delivery to the asialoglycoprotein receptor in cultured liver cells. 
Asialofetuin, a natural ligand, is a glycoprotein containing three N-linked glycans with tri-
antennary sugar chains possessing the Galp1~3GalNAc sequence. Hence, it can be 
internalized into hepatoma cells via the asialoglycoprotein receptor (Niidome et al., 
2000). Besides galactose and N-acteylgalactosamine present as terminal 
monosaccharides, mannose units also occur (Hynes et al., 2003). Asialofetuin modified 
with polyethylene glycol has been utilized as a model system for binding to the 
galactose receptor of hepatocytes in vitro and in vivo (Roseng et al., 1992), and 
asialofetuin labeled cationic liposomes were used in receptor-mediated transfer to 
HepG2 cells (Hara et al., 1995). Furthermore asialofetuin lipoplexes and protamine 
sulphate-enhanced asialofetuin lipoplexes showed significant levels of gene expression 
in the liver of mice and in cultured HepG2 cells (Arangoa et al., 2003). 
To demonstrate the inhibition of receptor mediated transfection, free galactose up to 
20 mM was also utilized by some investigators with significant inhibition (Wen et al., 
2004; Hashida et al., 2001; Kawakami et al., 1998), while others utilized up to 100 mM 
N-acetylgalactosamine with marked inhibition of receptor mediation (Rensen et al., 
2001). Previous studies conducted utilizing a 100-fold excess of free asialoorosomucoid 
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over the bound glycoprotein in ternary complexes in competition experiments was also 
shown to be successful in indicating cell-specific targeting and receptor-mediated 
endocytosis in HepG2 cells in vitro (Singh et al., 2001 b; Singh et al., 2003). Receptors 
for free galactose are known to be present in liver parenchymal cells, where glucoside 
or even mannoside residues present on the surface of liposomes, can bring about 
selective uptake of these liposomes (Behari and Nihal, 2000). 
The gene expression levels in HepG2 cells obtained with our four glycosylated 
liposomes were much higher than those obtained for the untargeted cationic liposome 
(MS09) in chapter two, despite the slightly lower percentage of MS09 in the formulation 
of the glycosylated liposomes (44%, M/M), when compared with the unglycosylated 
counterpart (50%, M/M). The B-galactosylated liposome (MSBGAL) produced the 
greatest difference with a 17 fold increase, followed by the a-galactosylated liposome 
(MSaGAL) with a 4 fold increase while both the glucosylated liposomes (MSaGLU and 
MSBGLU) showed a 2 fold increase over the untargeted MS09 liposome at their 
respective optimal gene expression. 
The lipoplexes were also tested for gene transfer efficiency in the HeLa cell line, which 
was used as a control cell line. The HeLa cells, which do not express the galactose-
specific membrane lectin (Bettinger et al., 1999), produced a far lower level of gene 
expression which was comparable to that achieved in the competition assay. The 
highest transfection efficiency, however, was not achieved at the ratio for 
liposome:DNA of 5:1 (w/w) and (+/-) charge ratio of 0.6 as was required for the HepG2 
cell targeting, but was attained at a higher liposome:DNA ratio of 6:1 (w/w) and a (+/-) 
charge ratio of 0.7. This could be due to the fact that the lipoplex size at the 
liposome:DNA ratio 5:1 (w/w) of 50 nm to 100 nm in diameter was smaller than those at 
the higher ratio (80 nm to 200 nm). The differences, however, are marginal and it would 
not appear that binding to the negatively charged cell surface can explain this 
difference, since at the highest ratio of liposome:DNA of 7:1 (w/w) the transfection levels 
are lower. However the transfection levels achieved in the HeLa cells were reduced by 
more than 90% when compared to that achieved for the targeted glycosylated 
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liposomes to the HepG2 cells, at their respective optimal transfection ratios. The 
luciferase activity observed for the HeLa cells could be due to the normal lipofection 
process of the liposomes. The high transfection achieved at a higher charge ratio 
correlated with the complete retardation ratios observed in the gel retardation assays 
(Figures 4.8 to 4.9) and in the maximum displacement of ethidium bromide achieved in 
the dye displacement assays (Figures 4.10 and 4.11 ). 
To determine if these liposomes have the capability and the stability to be utilized in 
future in vivo studies, transfection of the HepG2 cell line was also conducted in the 
presence of 10% serum. There was a 36% drop in transfection for the MS~GAL 
liposomes, a 45% drop in transfection for the MSaGAL liposomes, a 50% drop for the 
MSaGLU liposomes and a 56% drop in transfection efficiency for the MS~GLU 
liposomes. It can be seen that the galactose containing liposomes seem to be more 
stable in the presence of serum than the glucose containing liposomes. The important 
conclusion to emerge is that the MS~GAL liposomes that produced the greatest 
transfection activity showed the least reduction in transfection in the presence of serum. 
Hence it appears to have the potential to be utilized in further studies directed towards 
the development of an in vivo gene transfer system. It has been emphasized that 
stability in serum and thus the proper bioavailability of a vector to its specific receptor 
may be the single greatest limiting factor on the overall gene transfer efficiency in vivo 
(Molas et al., 2003). Albumin, one the serum proteins, is generally the most abundant 
protein that is found to be associated with both neutral and charged liposomes after 
recovery from circulation in vivo. It has been implicated in destabilization of liposomes 
(Semple et al., 1998). 
Liposomes are generally cleared in vivo by the mononuclear phagocyte system (MPS) 
which comprises the liver, spleen and bone marrow. Most of the liposomes 
administered intravenously could be located in the liver (Oku et al. , 2000). Hence if 
these liposomes possess galacto-targeting moieties for targeting to liver cell 
(hepatocyte) receptors, such as the liposomes used in this study, the accumulation and 
hence binding to the liver cells in vivo could increase. Furthermore, the use of a target 
261 
site in vivo that is part of the RES will be of an advantage for the targeted delivery of 
genes, drugs or other macromolecules. This was demonstrated by in vivo studies in 
mice using glycosylated liposomes, where after intravenous injection the glycosylated 
liposomes were rapidly eliminated from the circulating blood and preferentially 
recovered in the liver (Kawakami et a/., 2000). 
However in contrast liposomes without glycosylation were retained for a longer time in 
the circulating blood. Mannosylated , fucosylated and galactosylated liposomes were all 
taken up by the liver via the aSialoglycoprotein receptor in the paranchymal cells, and 
the man nose and fucose receptors in the non-parenchymal cells respectively. 
Galactosylated liposomes, if administered at high doses, can also be taken up by the 
fucose receptors in the non-parenchymal cells, that act as galactose particle receptors 
(Kawakami et a/., 2000). If a target site outside the RES is to be targeted then the 
liposomal formulations would have to be modified so as to avoid being trapped by the 
RES. Fenestrations in the liver play an important role for in vivo delivery, especially in 
allowing the genes access to the parenchyma. Increased hydrostatic pressure has been 
used to widen these pores and to improve delivery (Liu et a/., 1999). 
It has been suggested that even a high level of expression in a small percentage of cells 
could reverse a pathological phenotype, as in the case of hemophilia where an 
expressed protein needs to be secreted (Galun, 2003). Hence, we infer that the HepG2 
cells studied, which express the galactose-specific membrane lectin, were efficiently 
and selectively transfected with the MSaGALlMS~GALlMSaGLU/MS~GLU:DNA 
complexes in a monosaccharide configuration-dependent manner. 
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4.5 CONCLUSION 
We have confirmed in these studies that the galactosyl and glucosylliposomes are both 
effective in transfection via the receptor-mediated endocytotic pathway. They were 
successfully targeted to the asialoglycoprotein receptors on the HepG2 cell surface in 
vitro. Hence it can be seen that the use of targeting liposomes can significantly 
improve the transfection activity. It is said that although cell culture results obtained in 
in vitro systems, cannot be directly translated to in vivo delivery, they can at least 
indicate which lipoplexes or liposome formulations have the potential to be useful for 
applications in animal models or humans (DOzgOne~ et al. , 2001). The 
galactopyranosylcholesterol, especially the 13 anomer-containing liposomes, could have 
the potential to become effective drug or gene carriers. Here, we have also determined 
the ligand recognition characteristic of the asialoglycoprotein receptor in that it has an 
affinity or preference in the order : l3-galactose > a-galactose> l3-glucose > a-glucose, 
although the difference between the a- and l3-glucose anomers was not as great as that 
seen between the a- and l3-galactose anomers. 
Results presented in this chapter suggest that the aSialoglycoprotein receptor does 
indeed display an anomeric preference for the galactose moieties present on the 
liposomal surface in a p-glycosidic link to the cholesterol component. Moreover there 
appears to be a clear epimeric preference with respect to the C-4 configuration, the 
position at which D-glucose and D-galactose differ. It is also gratifying to note that a 
simple glycosidic link between the monosaccharide moiety and the cholesterol anchor 
without a longer spacer is sufficient to elicit the required specificity and recognition. 
Hepatocellular carcinoma represents more than 5% of all cancers in the world with 
estimated deaths exceeding 500 000 per year (Llovet, 2003). Furthermore, the 
incidence of hepatocellular carcinoma is on the rise in a number of countries, partly 
because of an increase in the rate of hepatitis infection. It is expected that as the 
population ages, the proportion of elderly hepatocellular carcinoma patients is likely to 
grow (Dohmen et al., 2004). With recent progress in understanding the molecular 
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changes that underlie cancer development, the prospect of specifically targeting 
malfunctioning molecules and pathways to achieve more effective and rational cancer 
therapy is becoming possible (Sawyers, 2004). Furthermore gene delivery via the 
asialoglycoprotein receptor could be an effective delivery system into the liver in vivo. 
Hence the results obtained in this study bode well for possible future in vivo 
applications. 
Glycoconjugates have found major applications in antiviral therapy, immunoactivation, 
enzyme replacement therapy and gene therapy. It may be concluded that the discovery 
of new mammalian lectins which endocytose their ligands will lead to the rapid 
development of new glycotargeting agents founded on the principles of carbohydrate-
protein interactions (Wadhwa and Rice, 2003). The preparation of DNA:ligand 
complexes remains a significant technical obstacle, and improved methods will likely be 
required to obtain complexes suitable for receptor-mediated gene transfer in vivo. It is 
reported that activated macrophages express the macrophage asialoglycoprotein 
binding protein (M-ASGP-BP) that recognizes terminal galactose or N-
acetylgalactosamine units, and may participate in the interaction between tumoricidal 
macrophages and tumour cells (Matsumoto et al., 1999). Macrophages also infiltrate 
solid malignancies to form the tumour solid mass, dominating in areas of hypoxia and 
necrosis (Greco et al., 2002). Hence, it is hoped that our findings will have further 
implications in future research on liposome-mediated aSialoglycoprotein receptor-
directed gene or drug delivery to hepatocytes or to other cells that possess galactose 
receptors. 
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5. SUMMARY AND CONCLUDING REMARKS 
In order to develop optimum corrective gene transfer to any specific tissue requires the 
tailoring of the transgene expression system into a suitable delivery vehicle. The actual 
selection of the various delivery components depend upon the target tissue and the type 
of disease. Although the efficiency and specificity of non-viral delivery systems have 
previously not been very high, problems relating to transfection methods are being 
gradually resolved. Various transfection mediators for effective and directed gene 
delivery into a variety of cells have been developed. Although liposomes targeted via 
antibodies or ligands are still being developed for testing in clinical trials, liposomes 
passively targeted to tumour tissues have been approved for treatment of Kaposi's 
sarcoma and for clinical trials for other forms of cancer (Duzgune~ and Nir, 1999). 
Liposome-mediated DNA vaccination is a viable prospect. This system can produce 
prolonged gene expression which will eliminate the need for booster injections, and the 
risks associated with live and attenuated vaccines (Chisti, 1999). 
Gene therapy has hence provided a novel approach to the treatment of various 
disorders. As we begin to understand more of the molecular mechanisms involved in 
these diseases we will be able to utilize this knowledge to target specific cells, tissues 
and organs. Our detailed knowledge of the human genome sequence will provide 
promising tools for defining disease-specific targets or genes and their expression 
patterns. The further development of proteomics and achievement of high-throughput 
screenings offer a great potential for the discovery of drugs including DNA drugs for 
gene therapy (Luo, 2004). Hence, with the advent of gene discovery, gene delivery will 
be a major focus, and non-viral delivery methods such as liposomes will prove 
increasingly more effective. 
Infectious diseases, genetic defects and even traumatic injury may someday be treated 
with gene therapy and gene therapy strategies. As more effort is directed towards 
developing vectors and increasing the potential of this technology, the success or failure 
of these systems will depend on the ability to manipulate and control the genetic 
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transfer into specific target cells. Progress towards identifying barriers to gene transfer 
will hopefully lead to more efficient vectors being designed with increased safety and 
lower immunogenicity, ultimately providing gene transfer techniques that could 
revolutionise gene therapy for specific diseases (Pilewski, 2002). 
Advances in molecular and cellular biology have led to the development of a new class 
of biotherapeutic macromolecules such as proteins, (poly)peptides and nucleic acids 
that can be designed to modulate functions of target cells. In order for these 
biotherapeutics to successfully access their targets within the cytoplasm and nucleus, 
efficient gene or drug carriers are required for safe and efficient delivery across cellular 
membrane barriers and into the cytosol of target cells. Hence gene delivery using 
liposomes is undergoing a transition from simple electrostatic systems to more 
complicated engineered designs. 
The investigations which form the basis for this thesis show that the cationic liposomes 
synthesized are a viable and interesting alternative to other non-viral gene delivery 
systems. Results with the cationic cholesterol derivative MS09, in particular, which 
embodies a basic dimethylamino headgroup at the end of a rather long and relatively 
polar spacer separating it from the cholesteryl anchor (Chapter 2), have also revealed 
that the efficiency of these cationic liposomes may be improved by incorporating into the 
liposome the appropriate ligands directed at cognate receptors expressed by model cell 
lines. More specifically it has been demonstrated that the biotin-avidin reaction may be 
applied with success in the construction of a cationic liposome-based DNA delivery 
system containing MS09 that apparently recognizes the transferrin receptor on HeLa 
cells (Chapter 3), although it is clear that not all the assemblies enter the cells by this 
route. In addition, a study of MS09-containing glycosylated liposomes designed to target 
the asialoglycoprotein receptor, which is located on the extracellular face of the plasma 
membrane on the human hepatocyte-derived cell line, HepG2, revealed a strong 
anomeric preference by the receptor for the ~-D-galactopyranosyl moiety while it is 
clear, from the much reduced transfection levels with the glucopyranosyl-containing 
266 
liposomes, that the configuration at the C-4 position in the monosaccharide is critical for 
asialoglycoprotein receptor recognition (Chapter 4). 
The next step would be to apply these cationic liposomes to in vivo models. Most of the 
lipoplexes producing optimum transfection efficiency were relatively small in size, 
ranging from 100-200 nm which is suitable for systemic administration. The 
transfection in mammalian cells has provided us with an indication of the likelihood of 
success when applied to in vivo studies. The stability of the complexes studied in the 
presence of serum suggest that they could be promising candidate vehicles for in vivo 
gene delivery. Herein lies our greatest challenge in the optimisation of the various 
liposomal gene delivery systems to suit the needs for clinical gene delivery. 
One of the broad long term objectives of this type of research is to develop a 
fundamental science base that will lead to the design and synthesis of optimal non-viral 
DNA carriers for gene therapy and disease control. It is further required to improve the 
efficiency of delivering large pieces of DNA containing important human genes and their 
regulatory sequences (> 100 kbp), which at present can only be achieved with synthetic 
vectors (Safinya, 2001). Various cationic lipid / liposome formulations are likely to 
continue to attract scientific and commercial interest for the foreseeable future. It is 
hoped that with further structural and functional studies, a "magic" cationic lipid will 
emerge that will be equally efficient in vitro as it would be in vivo. 
Liposomes have the capacity to tolerate Iyophilisation and later rehydration, which could 
extend the medicinal usage of liposomal formulations. Hence, liposomes need to be 
manufactured in a way that permits retention of structure on rehydration after the 
freeze-drying conditions to which they are subjected (Chisti, 1999). From a 
technological point of view, vesicles are increasingly used in cosmetic industries as 
controlled release agents, e.g. in formulations of lotions, gels, creams and ointments, 
and continue to be explored for their utilization in the food and agricultural industries, 
apart from impacting on the medical field as drug and gene carriers (Chiruvolu et al., 
1994). 
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If gene therapy is to succeed, the corrective plasmid DNA or constructs must be 
delivered to cell targets in a form that will preserve function, penetrate the numerous 
barriers to cell invasion and promote the expression of the therapeutic protein (Birchall 
et al., 1999). Gene transfer approaches will become increasingly more important for the 
treatment of malignant diseases and will hopefully result in effective, specific and safe 
therapies. Gene therapy can be seen as the "light at the end of the tunnel" for many 
affected by a genetic disorder. 
Finally it has been proposed that the promise of better non-viral vectors designed for 
specific gene therapy applications will only be fulfilled with a greater level of 
interdisciplinary integration among different research areas, such as polymer chemistry, 
biophysics, cell biology, molecular biology and medicine amongst others (Molas et aI., 
2003). This could provide important information for the creation of targeted, effective, 
and safe DNA therapeutics in the future. 
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MS02 : N-trityl-p-alanylcholesterylformylhydrazide 
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MS05 : N-trityl-p-alanine NHS ester 
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MS07: N-tritylglycine NHS ester 
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MS08 : Cholesterylformylhydrazide hemisuccinate 
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MS 10 : Glycylcholesterylformylhydrazide 
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MS11 : /3-alanylcholesterylformylhydrazide 
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MSB2 : Aminohexanoylbiotinyl chloesterylformylhydrazide 
